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ABSTRACT 
 
Even with significant advances in the development of biomaterials for drug 
delivery, tissue engineering scaffolds, artificial organs, and other medical devices, one 
obstacle that remains is a limited understanding of material biocompatibility. Ultimately, 
the success or failure of these biomaterials depends on the extent of the wound healing 
and foreign body response following implantation. As macrophage phenotype is dynamic 
throughout the course of these processes, this research targets these cells to engineer 
improved materials for modern healthcare applications, and to better understand the 
material parameters that influence biocompatibility. Evidence shows that polymeric 
systems can influence the function of macrophages, but little progress has been made in 
understanding the ways in which surface chemistries and materials properties can impact 
macrophage differentiation and reprogramming. Controlled M1 macrophage response 
and increased M2 macrophage presence is of particular importance for the integration of 
biomaterials in to the body.  
In wound healing, polymers may also influence collagen production by fibroblast 
cells, which can have an impact on the quality of tissue repair and the timeliness of 
healing. The quality of tissue developed in wound healing is dependent on collagen 
organization. Random collagen deposition is found in young, healthy skin, while well-
oriented collagen is typically associated with scar tissue. Achieving random collagen 
orientation in wound healing by exploiting biomaterial properties would be a vast 
improvement upon the imperfections of the natural wound healing process. This would 
ultimately have importance in the incorporation of implanted medical devices. 
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CHAPTER 1 
INTRODUCTION 
Sections 1.1, 1.2, 1.4 published in Clinical and Translational Medicine, 3, 1-13 (2014) 
Macrophages (MΦs) have long been known to exhibit heterogeneous and plastic 
phenotypes. They show functional diversity with roles in homeostasis, tissue repair, 
immunity and disease. There exists a spectrum of MΦ phenotypes with varied effector 
functions, molecular determinants, cytokine and chemokine profiles, as well as receptor 
expression. In tumor microenvironments, the subset of MΦs known as tumor-associated 
MΦs generates byproducts that enhance tumor growth and angiogenesis, making them 
attractive targets for anti-cancer therapeutics. With respect to wound healing and the 
foreign body response, there is a necessity for balance between pro-inflammatory, wound 
healing, and regulatory MΦs in order to achieve successful implantation of a scaffold for 
tissue engineering. Discussed here are the multitude of ways MΦs are known to be 
important in cancer therapies and implanted biomaterials.  
 
1.1 Heterogeneity of Macrophages 
MΦs are considered to be functionally heterogeneous cells with different 
phenotypes representing distinct sublineages.1,2 The heterogeneity of these cells is 
attributed to their location in the tissue, due to microenvironmental signals that control 
the functional phenotype.1,3–5 In the presence of specific microenviromental signals, MΦs 
are able to switch from one phenotype to another, indicating that these cells have a degree 
of plasticity in addition to heterogeneity.3,6 In general, heterogeneity of MΦs can be 
described as a spectrum of phenotypes.1–3,6–10 One end represents classical MΦs activated 
2  
 
with interferon (IFN)-γ, M(IFN-γ), and at the other end alternative MΦs activated by 
interleukin (IL)-4, M(IL-4).7,8,11–15 This new nomenclature, recently proposed by Murray 
et al., more accurately reflects the individual phenotypes and polarizations of these cells. 
Other variations of MΦs that lie along this spectrum include: M(Ic), activated by immune 
complexes (Ic); M(IL10); those stimulated by glucocorticoids (GC) and transforming 
growth factor (TGF)-β, M(GC+TGF-β); M(GC); M(LPS), activated by 
lipopolysaccharides; and M(LPS+IFN-γ).3,6,8–10 Each of these phenotypes varies in their 
effector functions, molecular determinants, cytokine and chemokine profiles, as well as 
receptor expression.  
Overall, classically activated, formerly referred to as M1, MΦs are known to be 
pro-inflammatory and cytotoxic. MΦs are skewed towards this phenotype when IFNs and 
toll-like receptor (TLR) signaling activate IFN regulatory factor/signal transducers and 
activators of transcription (IRF/STAT) signaling pathways via STAT1.7,10,15–18 This 
transcription factor then causes MΦs to upregulate IRF5, which is essential for 
production of large amounts of pro-inflammatory cytokines,16 including tumor necrosis 
factor (TNF)-α, IL-1β, I-L1, IL-6, IL-8, IL-12, IL-15, IL-18, and IL-23 that elicit both T-
helper (Th)1 and Th17 responses.9,16,18–20 TLR stimulation can also activate nuclear factor 
(NF)-κB, such that p65/p50 heterodimers are formed and lead to the production of 
hypoxia-inducible factor (HIF)-1α.15,21,22 This protein, found in the presence of low 
oxygen concentrations, regulates the NOS2 gene to increase the secretion of inducible 
nitric oxide synthase (iNOS),21 toxic nitric oxide (NO), and reactive oxygen 
intermediates (ROI).19 A chemokine profile for classically activated MΦs may include 
HCC-2 (CCL15), macrophage inflammatory protein (MIP)-3α (CCL20), and B cell 
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attracting chemokine-1 (CXCL13), as well as IFN-γ-inducible chemokines such as, 
monocyte chemotactic protein (MCP)-1 (CCL2), interferon-inducible T cell alpha 
chemoattractant (I-TAC) (CXCL11), interferon gamma-induced protein 10 (IP-10) 
(CXCL10) and monokine induced by gamma interferon (MIG) (CXCL9).7,18,20–22 
Production of these chemokines can be a result of previously mentioned transcription 
factors STAT1 or NF- κB.16,18 These chemokines also coordinate natural killer (NK) and 
Th1 cell responses, integrating classically activated MΦs into the amplification and 
regulation of polarized T cell responses.20,21 Surface molecules expressed by classically 
activated MΦs include elevated amounts of MHC class II receptors; costimulatory 
molecules CD80 and CD86; IL-2Ra, IL-15Ra and IL-7R; and low levels of mannose 
receptor C type 1 (MRC1) and Fcγ RII.17,18,20 Each of these characteristics allow 
classically activated MΦs to be potent effector cells that mediate resistance against 
bacterial, viral, and fungal infections as well as tumor cells.18,19 They are also important 
in the inflammatory stages of wound healing and the foreign body response (FBR) to 
biomaterials.23–25 
Alternatively activated, previously known as M2 MΦs, are said to be pro-
angiogenic, promoting tissue remodeling and repair. This phenotype arises when IL-4 
activates the IRF/STAT signaling pathway via STAT6.7,10,15–18 IL-10, on the other hand, 
activates STAT3-mediated alternative activation and gene expression.7,15–18 This STAT-
mediated activation of MΦs is regulated by the suppressor of cytokine signaling (SOCS) 
family: where IL-4 can upregulate SOCS1, inhibiting the action of STAT1, but IFN-γ and 
TLR stimulation cause SOCS3 to be upregulated to prevent the activity of STAT3.16,26 
The transcription factors STAT3 and STAT6 allow for high-level production of the 
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cytokines IL-10, IL-1 receptor antagonist (IL-1Rα), IL-4Rα, TGF-β, and the type II IL-1 
decoy receptor.16,18,20,21 Other genes activated by STAT6 include mannose receptor 
(Mrc1), resistin-like α (Retnla/Fizz1), and chitinase 3-like 3 (Chi3l3/Ym1). For STAT3, 
some of the genes expressed are Il10, Tgfb1, and Mrc1.16 STAT6 also coordinates with 
peroxisome proliferator-activated receptors PPARγ and PPARδ, as well as Krüppel-like 
factor (KLF)-4, to induce some alternative genes (Arg-1, Mrc1, Fizz1, PPARγ) while 
inhibiting genes associated with classical activation (TNFa, Cox-2, CCL5, iNOS) by 
preventing NF-κB activation.16 However, NF-κB activation and the formation of p50 
homodimers are also important in alternative activation and resolution of 
inflammation.15,21,22 Chemokines induced by IL-4 or IL-13 alternative activation include 
monocyte chemotactic protein (MCP)-4 (CCL13), MCP-2 (CCL8), MCP-1 (CCL2), 
macrophage-derived chemokine (MDC) (CCL22), alternative macrophage activation-
associated chemokine (AMAC)-1 (CCL18) and eotaxin-3 (CCL26).7,18,20–22 CCL22 
specifically attracts Th2 and Treg cells, showing that alternative MΦs are also involved in 
the polarization of T cell responses.21 MΦs activated by IL-10, TGF-β, and GC produce 
the chemokines eotaxin-2 (CCL24), IP-10 (CXCL10), I-TAC (CXCL11), and RANTES 
(CCL5).20,21 Other factors produced include vascular endothelial growth factor (VEGF), 
matrix metalloproteinases (MMPs); and HIF-2α to regulate ARG1 and the arginase 
pathway to produce ornithine and polyamines.18 The exception to alternative activation is 
the phenotype of MΦs induced by Ic; they retain the ability to produce high levels of pro-
inflammatory cytokines.18 Overall, alternatively activated MΦs are efficient phagocytic 
cells with the expression of mannose and galactose receptors; CD163, TLR8, TLR1, and 
IL21a; and MRC1 and scavenger receptor type 1 (SR-A1).17,18,20 They are involved in 
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parasite containment, tumor progression, and function to dampen immune responses.12 In 
the resolution stages of the FBR, alternative MΦs drive the wound healing response, 
often leading to fibrotic encapsulation and failure of implanted devices and scaffolds.23,25  
 
1.2 Macrophages as cancer therapeutic targets 
1.2.1 Tumor-associated macrophages. Tumor-associated MΦs (TAMs) have properties 
consistent with alternatively activated MΦs.27 They produce cytokines like IL-10 and 
TGF-β.21 The polarization of MΦs recruited to a tumor site, or any other tissue, is highly 
dependent on the cytokines present. The production of both IL-10 and TGF-β suppresses 
anti-tumor activities of the immune system allowing tumor cells to avoid destruction by 
immune cells.28 TAMs have been found to be poor producers of NO and ROIs, which are 
typically products of classically activated MΦs.29 In addition, TAMs express low levels 
of cytokines such as IL-12, TNF-α, and IL-6.29 Lastly, TAMs have been found to be poor 
antigen-presenting cells indicating that they do not have the potent effector cell functions 
attributed to classically activated MΦs.19 This information establishes that TAMs 
represent a subset of alternatively activated MΦs, and that many of their byproducts 
enhance tumor growth and angiogenesis. 
 While angiogenesis plays a central role in the progression of tumors from benign 
to malignant, there are many other factors involved. MMPs contribute to tumor invasion 
through matrix remodeling where they are capable of cleaving extracellular matrix 
(ECM) proteins,29 which normally provide a barrier for tumor growth. These MMPs 
along with other proteases such as plasmin and urokinase-type plasminogen activator 
(uPA) are all produced by TAMs.21,29 The continued proliferation and growth aided by 
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TAMs can lead to metastasis of tumor cells. In metastasis, it is suggested that primary 
tumors are able to release factors that increase a metastatic outcome at other sites. These 
sites are referred to as premetastatic niches where the factors secreted by primary tumors 
cause the accumulation of myeloid progenitor cells.30 A recent study has shown that 
TAMs play an important role controlling the survival, migration and growth of metastatic 
cells to these niches.31 TAMs were also found to enhance tumor cell extravasation, 
establishment and subsequent growth in surrounding tissue. The involvement of TAMs in 
tumor angiogenesis, growth, progression and metastasis makes them attractive targets for 
anti-cancer therapeutics. Therapeutic strategies directed at TAMs fall into four 
categories: reduction of effector function, limiting recruitment, prevention of pro-tumor 
MΦ polarization, and MΦ reprogramming;32,33 the benefits and drawbacks of which are 
outlined in Table 1.1.33–42 
Table 1.1. Advantages and disadvantages of anti-cancer therapies targeting macrophage behaviors. 
Approach Advantages Disadvantages 
Anti-angiogenic 
therapy 
Inhibit tumor growth 
and prevent metastasis 
33,34, improves efficacy 
of chemotherapeutics35 
Must be used in combination with 
chemotherapeutics36; systemic effects36,37  
Recruitment 
inhibition 
Prevent macrophages 
from entering tumor, 
becoming TAMs38,39 
Systemic effects38 
Macrophage 
reprogramming 
Macrophages secrete 
tumoricidal molecules 
40,41 
Local delivery necessary to avoid altering 
systemic Th1/Th2 paradigm42 
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1.2.2 Anti-angiogenic therapy. Angiogenesis must occur in tumors for them to grow even 
small amounts.35 This process can be influenced via a multitude of factors that are 
induced in hypoxic regions including VEGF, placental growth factor (PlGF), 
angiopoietins (ANGs), colony stimulating factor (CSF)-1, and CCL2/MCP-1.35 Anti-
angiogenic therapy via the VEGF pathway, the primary angiogenic pathway of MΦs, is 
ineffective, as tumor cells are able to activate other pro-angiogenic pathways.36 However, 
MΦ angiogenic abilities can be indirectly prohibited through the use of other factors. 
When a tumor develops regions of inadequate oxygen supply, HIF1-α subunits are 
stabilized, recruiting bone marrow (BM)-derived cells including MΦs that up regulate 
angiogenesis. The elimination of HIF1-α from tumor environments provides a potential 
anti-angiogenic cancer therapy pathway by inhibiting the recruitment of MΦs and other 
pro-angiogenic cells.43 HIF1-α knockout mice (HIFko) with glioblastoma (GBM) tumors, 
show a decrease in angiogenesis when compared to HIF functional mice with tumors.43  
ANG2 is produced by endothelial cells in hypoxic environments and would 
typically recruit pro-angiogenic cells, however binding of ANG2 with a monoclonal 
antibody inhibited angiogenesis by blocking the interaction of ANG2 with TIE2-
expressing monocytes.44,45 TIE2-expressing monocytes are a subpopulation of TAMs that 
have the greatest role in tumor angiogenesis;44 preventing activation of these cells can 
halt their angiogenic activity and disable further recruitment of pro-angiogenic cells. 
Blocking of ANG2 with a monoclonal antibody inhibits tumor growth; causes regression 
of tumor vasculature by inducing apoptosis in some pro-angiogenic cells; and hinders 
progression of some late stage cancers (Figure 1.1).45 While the anti-angiogenic 
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treatments mentioned here have not been shown to be extremely efficient alone, they may 
be used in combination with other chemotherapeutics to improve the outlook for patients.  
 
 
Figure 1.1. Masson’s trichrome staining of orthotopic, late-stage MMTV-PyMT 
mammary tumors treated according to an extended (9 weeks) treatment schedule. 
Collagen’s blue staining demonstrates abundant fibrotic tissue and scant tumor cells in 
3.19.3-treated tumors (day 78). Left panels show tumor periphery. Scale bars, 600 mm 
(left panels) and 300 mm (right panels). Images are representative of five 3.19.3-treated 
(day 78) and three control IgG-treated (day 48) tumors. Reproduced with permission.45  
1.2.3 Recruitment inhibition. Another option for targeting TAMs is to inhibit the 
recruitment of monocytes to the primary tumor site. CXCL12 is a chemokine that is 
thought to regulate the migration of BM-derived cells, facilitating their transmigration 
through endothelial cell barriers into the tumor microenvironment.46 Also, secretion of 
CXCL12 by stromal cells outside of the tumor microenvironment attracts cancer cells via 
their upregulated CXCR4 receptor.46 Thus, several CXCR4 antagonists are being studied 
as additive cancer therapeutics to reduce tumor infiltration by BM-derived cells and 
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prevent further metastatic spread. One antagonist of interest is CTCE-9908, which is a 
chemokine-based therapy.47–49 In prostate cancer cell lines (PC-3-Neo and PC-3-Bcl-2 
transfected with Bcl-2), treatment with CTCE-9908 reduces VEGFR1and CD11b 
expressing cells.49 Both VEGFR1 and CD11b are expressed on tumor-infiltrating cells 
that promote angiogenesis.15,35,36,50 Phase II clinical trials in hepatocellular carcinoma 
using CTCE-9908 have also been initiated.51  
CCL2 is a chemokine that has been heavily investigated in prostate, ovarian and 
breast cancers because CCL2 regulates the recruitment of monocytes and MΦs to tumors 
and other sites of inflammation.52 In recent glioma therapy studies, a mAB-based CCL2 
blockade reduced the percentage of CD11b+CD45+ TAMs by about 50% and decreased 
the total number of these cells five-fold (Figure 1.2).53 In a previous study, the use of 
anti-CCL2 decreased the overall burden of prostate tumors in vivo by 96% after 5 
weeks.54 Combining this therapy with the already in use, anti-mitotic chemotherapy 
medication, Docetaxel, further improved the results.54 Since then, more work has been 
done to examine the synergy of these two treatments in preventing metastasis of primary 
prostate cancer to bone.55,56  
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Figure 1.2. C57BL/6 mice bearing GL261 glioma received 2 mg/kg/dose (approximately 
40μg/mouse) anti-mouse CCL2 mAb or control IgG twice weekly by i.p. injections 
starting on day 7 after tumor cell inoculation (n=5/group). On day 24, mice were 
euthanized and isolated BILs were pooled from all mice in the same treatment group, and 
evaluated by flow cytometry for surface expression of CD11b and CD45 (A). Absolute 
numbers of CD11b+CD45+ (p=0.0008) (B). Reproduced with permission.53 
 
As CD11b is a MΦ receptor that is important in recruitment to tumor sites, a 
CD11b antibody provides another treatment option for TAM targeted cancer therapy.50 
The use of a monoclonal CD11b antibody both enhances tumor response to radiation and 
reduces infiltration of myeloid cells.50 Based on these examples, the targeting of 
chemokines and chemokine receptors has resulted in an effective enhancement of anti-
cancer therapies by showing both decreased tumor size and prevention of tumor 
metastasis. 
1.2.4 Macrophage reprogramming. MΦ plasticity has led to the idea of utilizing MΦ 
reprogramming to synergistically act with chemotherapeutics. Many of the ways in which 
TAMs contribute to tumor development and survival are specific to the alternatively 
activated phenotype. Thus, being able to prevent TAMs from alternatively differentiating 
or promoting reprogramming of TAMs to classical MΦs will prevent tumor growth.  
Several mechanisms of M2 MΦ polarization have been studied, and these 
pathways may also prove to be viable targets in cancer therapeutics. Jumonji domain 
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containing-3 (Jmjd3) is a histone 3 Lys27 (H3k27) demethylase that has been implicated 
in regulating M2 MΦ polarization.57 A deficiency of Jmjd3 results in trimethylation of 
H3k27 on the gene Irf4, which encodes a key transcription factor M2 activation.57 
Reactive nitrogen species (ROS) production has also been found to play a critical role in 
MΦ differentiation.58 Specifically, inhibition of superoxide (O2-) production prevents M2 
MΦ polarization but does not hinder the M1 phenotype.58 Thus, blocking of the Jmjd3-
Irf4 axis or ROS production may be potentially effective methods for added tumor 
inhibition.  
The differentiation of infiltrating monocytes into TAMs also results from 
cytokines like IL-4, IL-10, and IL-13. The use of IL-3 has been successful at inhibiting 
IL-4 produced by basophils, resulting in MΦs skewed towards a classical polarization.59 
SHIP (src-homology 2-containing inositol 5' phosphatase) is a molecule that negatively 
regulates the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) apoptotic pathway. 
In cancers, the PI3K pathway is overactive, allowing malignant cells to avoid apoptosis, 
essentially becoming immortal. It has been determined that basophils produce SHIP in 
response to IL-3, which can then inhibit IL-4 production necessary for TAM activation 
(Figure 1.3).59 
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Figure 1.3. (A) IL-3 and GM-CSF stimulate the production of more IL-4 from SHIP-/- 
than SHIP+/+ Lin- BM cells. SHIP+/+ and SHIP-/- Lin- BM cells were cultured with M-
CSF, IL-3, or GM-CSF for 24 h and supernatants were subjected to IL-4 ELISAs. Data 
shown are the means ± SEM of duplicate determinations. *, p<0.05 compared with 
unstimulated cells. (B) Model of IL-3-induced M2 skewing and the role that SHIP plays 
in this process. IL-3 stimulates the proliferation and differentiation of both basophil 
precursors and monocyte/macrophage progenitors. IL-3 also stimulates the production of 
IL-4 from basophils and basophil progenitors in a STAT5-dependent manner. SHIP 
within the basophils represses this IL-4 production. The secreted IL-4, in turn, skews, via 
STAT6, the maturing and mature MΦs to an M2 phenotype. Copyright 2009. The 
American Association of Immunologists, Inc.59  
Many tumor-infiltrating monocytes are alternatively activated by cytokines 
released by existing tumor cells. However, the added presence of classical activators such 
as CpG oligodeoxynucleotides (CpG) and an anti-CD40 agonist can increase anti-tumor 
activity of MΦs. CpG causes a pro-inflammatory response in MΦs and the agonistic anti-
CD40 can reverse immune suppression. As a follow up study to those that indicated that 
the synergistic effects of anti-CD40 and CpG increase classical activation,40 a 
combination of anti-CD40, CpG, and the chemotherapeutic agent cyclophosphamide was 
used to study treatment of melanoma in vivo. In this combinatorial study, there was an 
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approximate ten-fold decrease in tumor size and survival was extended by ~12 days.60 
There was also an increase in the percentage of F4/80+Gr1+ inflammatory monocytes.60,61 
Reprogramming of existing TAMs to be classical MΦs is another valid approach 
to improve upon conventional anticancer therapies. IFN-α has long been known to be 
tumoricidal and was the first cytokine to show some benefit in the treatment of some 
cancer types.62 Because of the protein’s short half-life, however, the dose required for 
efficacy becomes toxic to healthy tissue and the tumor is only exposed to short bursts of 
therapy.62 This is why the use of TIE2-expressing monocytes, which are regularly 
recruited to tumor sites, to selectively deliver IFN-α, can inhibit angiogenesis and skew 
MΦ polarization to the classical end of the spectrum.62 This is shown by the presence of 
cells expressing Iba1, a monocyte/macrophage/microglia protein, in and around the tumor 
site. 
Histidine-rich glycoprotein (HRG), a host produced anti-angiogenic and 
immunomodulatory factor to promote TAM reprogramming is another viable target.63 
HRG has been studied to identify mechanisms by which it mediates anti-tumor effects; 
and the results revealed that TAMs activated by HRG down regulated expression of pro-
angiogenic cytokines and upregulated that of angiostatic cytokines. At the same time, 
HRG activated TAMs showed improved quality of existing vasculature causing an 
increase in the effectiveness of other chemotherapeutics.63 Another target for 
reprogramming TAMS is the NF-κB signaling pathway.64 Inhibition of NF-κB signaling 
was found with IκB kinase (IKK)β reduction, stimulating TAMs to become cytotoxic 
through recruitment of NK cells with the production of IL-12.64 These three examples, 
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along with many more, provide proof-of-concept data for the reprogramming of MΦs in 
cancer therapeutics.   
 
1.3 Macrophages in response to implanted biomaterials 
1.3.1 The role of macrophages in the foreign-body response. In both healthy wound 
healing and the FBR, MΦs appear to be important in orchestrating the progression from 
inflammation to recruitment, proliferation and remodeling or fibrous encapsulation. Upon 
implantation of biomaterials and medical devices, injury to the surrounding tissue causes 
dying cells to release high-mobility group protein B1 (HMGB1), histones, and uric acid, 
collectively known as danger associated molecular patterns (DAMPs).65–69 The release of 
DAMPs induces inflammation and activates resident monocytes.67,69 The foreign-body 
response begins with instantaneous surface adsorption of blood proteins, such as albumin, 
fibrinogen, immunoglobulin G (IgG), and various complement proteins.65,70–72 These 
proteins result in activation of complement, opsonization of the biomaterial surface, and 
recruitment of inflammatory cells, including neutrophils and monocytes.70,73–76 Following 
extravasation, monocytes differentiate into tissue MΦs and are classically activated by 
the protein coated biomaterial surface. Activated MΦs secrete many of the cytokines 
mentioned previously, along with the chemoattractants MIP-1α, IL-8 and MCP-1 to 
attract additional monocytes.77–79 Continued recruitment and presence of these pro-
inflammatory cells causes acute inflammation to progress to chronic inflammation. 
When the increased phagocytic activity of classically activated MΦs is impeded 
by the size of the biomaterial, they fuse to form foreign body giant cells (FBGCs).71,72,80 
FBGCs secrete cytokines typically attributed to alternatively activated M2 MΦs, 
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including TGF-β, platelet derived growth factor (PDGF), and IL-10.9,75,78,81 However, 
they also release MMPs, chemoattractant MCP-1, pro-inflammatory RANTES.78,82,83 
MCP-1 continues to attract monocytes, and secretion of MMPs causes ECM breakdown, 
allowing for increased cell infiltration and amplifying DAMP presence to continuously 
activate MΦs.77–79,84 TGF-β, along with IL-4 and IL-23, promote alternative activation of 
MΦs that represent the proliferative phase of wound healing.12,76,85,86 These MΦs are 
profibrotic, which is necessary for tissue repair.76 However, IL-10 stimulated M2-like 
MΦs are required to reduce the inflammatory response of classically activated MΦs and 
FBGCs.9,87 Thus, both chronic inflammation and wound healing can persist until 
granulation tissue or an extensive fibrotic capsule form around the implanted 
biomaterial.71 Fibrous encapsulation typically results from TGF-β activation of resident 
fibroblasts and MΦs to become myofibroblasts that can secrete large amounts of collagen 
I, collagen III, and fibronectin.88–92 The expression of α-smooth muscle actin (α-SMA) 
allows myofibroblasts to contract collagen networks, which can eventually lead to 
excessive scarring and fibrous encapsulation. Although fibroblasts play a key role in 
fibrous encapsulation with the production and contraction of collagen, it is ultimately MΦ 
involvement in the FBR that leads to biofouling of medical devices. Some strategies to 
improve upon the biocompatibility of biomaterials are directed at MΦ involvement in 
inflammation, wound healing and angiogenesis.  
1.3.2 Reducing inflammation. The nonspecific adsorption of proteins and other 
biomolecules to biomaterial surfaces during the initial stages of the FBR has been termed 
“biofouling”.93–97 It is this process that ultimately leads to acute inflammation, which, if 
unresolved, results in chronic inflammation.65,70–72 In general, it is believed that a 
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reduction of biofouling may improve upon subsequent adverse processes of the FBR. 
Both passive and active approaches have been pursued in attaining this goal.96,97 
Passive approaches have typically included preadsorption of less inflammatory 
proteins or cells, or protein-adsorption resistant thin-layer polymeric coatings. 
Preadsorption strategies have been relatively unsuccessful in that other proteins can 
displace preadorbed protein coatings, and cell deposition can lead to issues with cell 
sourcing, host responses to donor cells and long-term stability.98–101 More successful 
approaches in thin-layer polymeric coatings have used polyethylene glycol (PEG), as it 
has proven to be one of the most protein-resistant functionalities.93,95,102,103 In recent 
studies, PEG-b-PLL diblock copolymer, anti-biofouling layers were added to alginate-
PLL100 microparticles.93 1 month after implantation of the alginate-PLL100-PEG454-b-
PLL50 particles in the peritoneal cavity of Balb/c mice, 95 ± 10% of the particles were 
recovered between the intestines and only 36.25 ± 27.87% of capsules showed cellular 
overgrowth.93 This is in comparison to a 2.5 ± 5% recovery and 97.25 ± 5.5% overgrowth 
with alginate-PLL100 particles.93 The mechanism of resistance to protein adsorption of 
PEG surfaces is hypothesized to relate to the ability of the polymer chain to retain 
interfacial water (Figure 1.4),96 and the resistance of PEG to compression due to it’s 
extended coil conformation.96 
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Figure 1.4. Passive anti-inflammatory surface coating for biomaterials. Hydrophilic 
polymeric coatings such as PEG-based hydrogels, retain interfacial water molecules, 
rendering them highly resistant to protein adsorption.96 
 
Active strategies to reducing acute inflammation involve the presentation of 
delivery of anti-inflammatory agents. Use of orally administered anti-inflammatory drugs 
to systemically control chronic tissue inflammation can cause long-term side effects that 
make a locally delivered therapeutics much more desirable.96 Immunomodulatory agents 
may be immobilized on the polymeric coatings, or released in soluble form from the 
coating. Corticosteroids such as, dexamethasone (DEX), when passively released from 
polymeric coatings, show promise in reducing fibrosis following the FBR.94 Encouraging 
attributes of corticosteroids are that they appear to suppress TGF-β and the synthesis of 
collagen by myofibroblasts.71,94 However, they do have a tendency to inhibit 
angiogenesis, which is why Patil et al, concurrently delivered DEX and VEGF from 
PLGA microsphere/PVA hydrogel composites.104 In vivo rat studies revealed that after 4 
weeks, an average of 37 ± 6 inflammation-mediating cells were present per 2.5 x 10-3 
mm2 area of subcutaneous tissue.104 This is compared to the presence of a complete 
fibrotic capsule around the PLGA microsphere/PVA hydrogel composites with no drugs, 
and 24 ± 7 cells with the DEX loaded alone into the materials.104 Although the number of 
inflammation-mediating cells increases from DEX alone to DEX+VEGF, the number of 
blood vessels per 25 x 10-3 mm2 showed an approximate four-fold increase after 4 
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weeks.104 Other anti-inflammatory agents that show promise in passive release are α-
melanocyte-stimulating hormone (α-MSH), curcumin and several anti-inflammatory 
drugs that mitigate NF-κB signaling.96,105 Heparin and stromal cell-derived factor 1α 
(SDF-1α) have successfully reduced acute inflammation as immobilized agents on 
nonfouling polymeric coatings.96,106 
1.3.3 Promoting wound healing. The natural progression of wound healing is from 
inflammation to proliferation and remodeling. In the FBR, the lack of IL-10 stimulated 
M2-like MΦ presence inhibits the transition from acute inflammation to healthy tissue 
repair, resulting in chronic inflammation and fibrotic encapsulation.65 Thus, an increased 
presence of regulatory M2-like MΦs may result in decreased pro-inflammatory 
cytokines, earlier resolution of inflammation, and decreased fibrosis.76  
Varied chemical and physical properties of biomaterials suggest the ability to 
influence MΦ phenotype in these ways. Zwitterionic hydrogels are able to reduce protein 
adsorption to aid in reducing inflammation.107 They also show an increased presence of 
pro-healing MΦs that promote angiogenesis and show no signs of fibrotic encapsulation 
for longer than three months.107 When examining physical properties of biomaterials, it 
suggested that pore size of surgical mesh can influence a predominantly M2 MΦ 
presence.65,97 Restore biologic scaffolds, by DePuy Orthopaedics, derived from porcine 
small intestine submucosa, provide a geometry that increases infiltration of MΦs, but 
does not allow spreading into phagocytic, inflammatory MΦs.24 This causes an increase 
in prolonged, M2 vs. M1 MΦ presence as compared to other biologic scaffolds (Figure 
1.5).24 Sugisis® and MatriStem® biologic meshes, made with porcine small intestinal 
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submucosa and porcine urinary bladder, respectively, also allowed for increased M2 MΦ 
infiltration corresponding with constructive tissue remodeling.23  
 
Figure 1.5. The ratios of M1:M2 percentages are illustrated for each device: small 
intestinal submucosa (SIS; Restore) white bars, carbodiimide crosslinked SIS (CDI-SIS; 
CuffPatch) gray bars, and autologous grafts black bars at each timepoint after 
implantation. The SIS device showed consistent values of less than 1.0 (pre-dominate M2 
response). The CDI-SIS showed values greater than 1.0 at the later timepoints 
(predominant M1 response).24 
 
1.3.4 Stimulating angiogenesis. Neoangiogenesis surrounding biomaterials or medical 
devices is crucial in the ultimate success of many types of implants. Yet, the key 
challenge that remains in tissue engineering is adequate vascularization of tissue 
surrounding drug eluding implants, artificial organs, tissue engineering constructs or 
biosensors.108–110 There are generally two approaches to address this issue, those that are 
cell-based and those that are scaffold-based (Figure 1.6).108,109 Cell-based techniques 
typically focus on using endothelial cells in vitro to provide a starting point for 
vascularization upon implantation in vivo.108,111–113 Other cell-based approaches transfect 
cells to overexpress angiogenic factors.114–116 
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Figure 1.6. Schematic diagrams of different vascularization approaches. (A) Scaffold 
functionalization. Tissue engineering scaffolds may be loaded or chemically couple with 
angiogenic factos, including vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF), and platelet-derived growth factor (PDGF), among other. They 
may also be designed and engineered to have microchannels or porous microgrooves to 
improve oxygen/nutrient perfusion or vascular cell alignment, respectively. (B) Cell-
based techniques. Multi-cellular spheroid cultures are used to generate capillary-like 
sprouts when embedded within a biological matrix. Other cell-based techniques include 
the use of transfected cells to secrete angiogenic factors within a scaffold to induce blood 
vessel formation.108 
 
 Of greater interest here, are the scaffold-based approaches because these 
approaches are more appropriate for applications with medical devices other than tissue 
engineering constructs. Approaches to improved vascularization that consider scaffold 
design have a tendency to go hand-in-hand with those discussed above that are designed 
to increase M2 MΦ presence. Many of those designed for growth factor release are used 
to deliver VEGF, PDGF, bfGF, hepatocyte growth factor (HGF) or ANG-1.117–121 Other 
constructs are designed to improve upon issues of oxygen gradients and flow regimes.108 
This is done by mimicking natural vascular architecture with channeled scaffolds, micro-
patterning, or molecular gradients. In a recent example, microtemplating was used to 
shape poly(2-hydroxyethylmethacrylate-co-methacrylic acid) hydrogels into a scaffold 
with architectures driving heart tissue integration.122 Here, cardiac implantation of 
acellular scaffolds with pore diameters of 30-40 μm showed angiogenesis and reduced 
fibrotic response, all of which correlated with a shift toward a M2 MΦ phenotype.122 
Scaffolds with a hexagonal array of interconnected pores (SHAIPs) have also been 
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developed as cells patches for healing injuries on the surfaces or interfaces of tissues.123 
SHAIPs have uniform pores, but also interconnecting windows. When seeded with 
myoblasts, these scaffolds allowed for high viability and differentiation into multi-
nucleated myotubes, also neovasculature following subcutaneous implantation in vivo.123  
 
1.4 Conclusions 
Based on the information discussed here, it can be concluded that MΦs are an 
appealing and effective target for supplementing current cancer treatments. Thus far there 
is a lack of research leading to an understanding of how to achieve the appropriate 
balance of MΦ phenotypes at tumor and implant sites. In targeting MΦs with cancer 
therapeutics, the intention is to develop localized and target-specific treatment options. 
Several challenges exist and are outlined in Table 1.1. One such challenge lies in 
complete reprogramming to classically activated MΦs, which could yield a systemic loss 
of alternative MΦs resulting in hazardous levels of cytotoxic cytokines and significant 
amounts of tissue damage 9. Classical MΦs are also necessary for basic immunological 
responses to infection, so an exclusively alternative MΦ population may leave patients 
susceptible to routine infections. Lastly, alternative MΦs are extremely important in 
wound healing and a deficiency may leave tissues unrepaired with no chance for 
recovery. Exploiting MΦs to co-opt tumors holds a number of advantages that could 
synergistically interact with existing chemotherapeutics. However, several challenges 
remain in reprogramming MΦs in the tumor microenvironment, including targeted 
delivery to the tumor site and selective delivery to alternatively activated TAM 
populations. Immunomodulation of MΦs may also result in improved success of implants 
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for tissue engineering. In the FBR, the complete absence of M1 MΦs is detrimental in the 
progression of the response. Specifically for successful implantation of a scaffold for 
tissue engineering, M1 MΦs are necessary to instigate the inflammatory response and 
initiate the M2-coordinated wound healing process. Timely resolution of the response 
requires the presence of IL-10high M2 MΦs. Though many of the materials mentioned 
here lead to a timely resolution of the FBR and successful vascularization, these materials 
cannot be used for all tissue engineering applications. Therefore, strategies to modulate 
MΦs in the tumor and biomaterial microenvironment require consideration of the desired 
end result.   
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CHAPTER 2 
ALTERING IN VIVO MACROPAHGE RESPONSES WITH 
MODIFIED POLYMER PROPERTIES 
 
Published in Biomaterials, 56, 187-197 (2015) 
MΦ reprogramming has long been the focus of research in disease therapeutics 
and biomaterial implantation. With different chemical and physical properties of 
materials playing a role in MΦ polarization, it is important to investigate and categorize 
the activation effects of material parameters both in vitro and in vivo. In this study, we 
have investigated the effects of material surface chemistry on in vivo polarization of 
macrophages. The library of materials used here include poly(N-isopropylacrylamide-co-
acrylic acid) (p(NIPAm-co-AAc)) nanoparticles (~600nm) modified with various 
functional groups. This study also focuses on the development of a quantitative 
structure—activity relationship method (QSAR) as a predictive tool for determining the 
macrophage polarization in response to particular biomaterial surface chemistries. Here, 
we successfully use in vivo imaging and histological analysis to identify the macrophage 
response and activation. We demonstrate the ability to induce a spectrum of macrophage 
phenotypes with a change in material functionality as well as identify certain material 
parameters that seem to correlate with each phenotype. This suggests the potential to 
develop materials for a variety of applications and predict the outcome of MΦ activation 
in response to new surface chemistries. 
 
2.1 Introduction 
MΦs are vital and versatile cells of the immune system that exist on a spectrum of 
phenotypes1–6 with the extremes being of particular interest in several therapeutic 
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applications. Classical (M1) MΦs, activated by interferon (IFN)-γ or lipopolysaccharides 
(LPS), represent the pro-inflammatory end of the spectrum; these cells release tumor 
necrosis factor (TNF)-α, monocyte chemotactic protein (MCP)-1, reactive nitrogen 
intermediates (RNIs), interleukin (IL)-1β, IL-1, IL-6, IL-12, and IL-23 that elicit both T-
helper (Th)1 and Th17 responses.2,5,7–11 At the other end of the spectrum are pro-
angiogenic, alternatively activated (M2) MΦs,2,12–14 arising from stimulation by IL-4. 
These cells produce IL-10, IL-1 receptor antagonist (IL-1Rα), transforming growth factor 
(TGF)-β, and the type II IL-1 decoy receptor.7,8,10 MΦs exhibit a certain degree of 
plasticity that allows for phenotypic reprogramming,15,16 and makes them an appealing 
target in the use of biomaterials. 
MΦs play a crucial role in determining the outcome of the foreign body response 
to biomaterials or implanted medical devices.17–19 Monocytes are among the first cells 
recruited to the biomaterial where they differentiate into tissue MΦs and are activated 
towards the M1 phenotype to initiate inflammation. This process is followed by the 
alternative activation of M2 MΦs that maintain homeostasis and promote wound healing. 
20–23 Some studies have found that MΦ phenotype in response to biomaterials is 
dependent on particular material properties.24–29 By reducing the M1 response or 
reprogramming some MΦs to an M2 phenotype, a biomaterial may be used to improve a 
device’s integration into the host tissue. However, for successful implantation, it is also 
important to maintain a balance of the two phenotypes.30 In tumor microenvironments, 
tumor-associated MΦs (TAMs) exhibit an M2-like phenotype and play a role in tumor 
angiogenesis, growth, and metastasis.31–36 M1 MΦs, on the other hand, release molecules 
that are cytotoxic to tumor cells and promote an immune response that would prevent 
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tumor survival and proliferation.11,32,34,36,37 For applications in cancer therapeutics, it 
would be useful for a biomaterial to suppress M2 presence or reprogram MΦs to an M1 
phenotype to aid in targeted treatment of cancer.  
In order to quantitatively understand our findings and use them in a predictive 
manner for future work, quantitative structure-activity relationship (QSAR) models were 
generated from our results. QSAR was originally developed in an effort to relate 
chemical structures to physical properties.38–41 However, this modeling method was 
quickly adapted to understand the relationship of chemical structure and biological 
activity.38,42–44 Here, we use QSAR to determine the impact of surface modifications on 
MΦ phenotype by examining the effect of surface functionalities of materials on cytokine 
profiles and in vivo imaging results. By developing this model with our current library, it 
will allow us to predict the outcome of materials of other functionalities with less 
extensive in vitro and in vivo studies in the future. 
While material properties and functionalities have been used to study the 
plasticity of cells and develop QSAR models in vitro,45–51 a lesser amount of analysis has 
been done on in vivo studies. Here, the library of materials used by Wang et al. was 
injected into SKH1-E mice and monitored for 7 days through in vivo fluorescence 
imaging.45 Histological analysis and ex vivo assays were performed on tissues collected 7 
days post-injection, when the highest-level of MΦ presence is expected. With varied 
amounts of cytokine and effector molecules detected, these experiments demonstrate the 
potential ability of surface modifications to alter MΦ phenotype in vivo. Understanding 
and predicting these outcomes will allow for development of better biomaterials for 
targeted drug delivery, MΦ reprogramming, and implantable medical devices. 
34  
 
2.2 Materials and Methods 
All materials were purchased from Sigma (St. Louis, MO) and used as received, 
unless otherwise indicated. Fresh deionized water (Milli-Q, Barnstead Nanopure, Thermo 
Scientific, Waltham, MA) was used throughout this study. Surface modifiers (Figure 2.1) 
that were coupled to p(NIPAm-co-AAc) particles were: 3-butenylamine (Santa Cruz 
Biotechnology, Dallas, TX); 1,4-dioxan-2-ylmethanamine; glycidamide; 4-amino-3-
penten-2-one; malonamide (Fisher, Pittsburgh, PA); tert-butyl 4-aminobutanoate (VWR, 
Radnor, PA); aminoacetaldehyde dimethyl acetal (Alfa Aesar, Ward Hill, MA); 3-
aminobenzamide oxime; 2,4-dinitro-phenyl-hydrozylamine; 1-amino-4-
oxocyclohexanecarboxylic acid ethylene ketal; 2-aminoethylmethylsulfone 
hydrochloride; 3-amino-1-propanesulfonic acid (Fisher, Pittsburgh, PA); and 
aminomethylphosphonic acid (Alfa Aesar, Ward Hill, MA). 
 
Figure 2.1. The chemical structures of all molecules used for the modification of 
p(NIPAm-co-AAc) particles. Their functional groups are used as labels in the following 
figures for convenience.  
35  
 
2.2.1 p(NIPAm-co-AAc) particle synthesis and modification. The synthesis of the 
particles used in this study and their modifications have been described previously.45 
Briefly, NIPAm (2.4 g), N,N-methylenebis(acrylamide) (0.16 g), and 157 μl AAc (J.T. 
Baker, Center Valley, PA) were dissolved in 100 mL H2O and reacted under N2 for 30 
min at 70°C. Then, 200 mg K2S2O8 dissolved in 10 mL H2O was added to the flask via a 
syringe. After 4 h, the suspension was slowly cooled to room temperature (rt), filtered, 
and dialyzed in H2O for 48 h before being lyophilized (Labconco, Kansas City, MO, 
4.5L). Next, 3 mL of phosphate buffered saline (PBS, diluted from 10X solution, Fisher 
to 0.1 M, pH 7.4), 6 mg of modifier, 0.6 mL of 5% w/v p(NIPAm-co-AAc) particles, and 
60 mg of 1-ethyl-3(-3-dimethylaminopropyl) carbodiimide hydrochloride were vortexed 
and incubated overnight at rt. The particles were dialyzed for 24 h in H2O and 
lyophilized. The particles were reconstituted at 1% w/v.45 
2.2.2 Characterization. To ensure successful modification, NMR spectra were collected 
for each modified particle using a Bruker Avance III Spectrometer. Particles were then 
examined with scanning electron microscopy using a FEI Quanta 250 FE-SEM. Water 
contact angles (WCA) were measured for each p(NIPAm-co-AAc) modified particle 
using the captive bubble technique. The zeta potential of each material was found using a 
Zetasizer Nano Z (Malvern, Westborough, MA). Melting temperatures were determined 
from differential scanning calorimetry measurements taken with a Perkin 1 model 
(PerkinElmer Inc., Waltham, MA). Lastly, alternative activation of complement was 
assessed using the ASTM protocol F2065. The characterization of these materials has 
been previously reported.45 
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2.2.3 Ethics Statement. The research protocol was approved by the local animal ethics 
committees at Iowa State University (Institutional Animal Care and Use Committee) 
prior to initiation of the study. 
2.2.4 Animals. 6-week-old female SKH1-E mice were obtained from Charles River 
Laboratories (Wilmington, MA). The mice were maintained at the animal facilities in the 
College of Veterinary Medicine at Iowa State University, accredited by the American 
Association of Laboratory Animal care, and were housed under standard conditions with 
a 12-hour light/dark cycle. Both water and food were provided ad libitum. 
2.2.5 Injections. Injections were performed in accordance with ISO 10993-6:2007. Prior 
to injection, all materials were sterilized with three washes in 70% ethanol, three washes 
in sterile water, and re-suspended in sterile saline at 5% w/v. The mice were anesthetized 
via isoflurane inhalation at a concentration of 1–4% isoflurane/balance O2 to minimize 
movement. Their backs were scrubbed with 70% isopropyl alcohol and the animals were 
injected with five different modified 5% w/v p(NIPAm-co-AAc) particles in an array 
format on the mouse’s back and a sixth injection of unmodified p(NIPAm-co-AAc) 
particles as a control. All injection volumes were 150 μL and experiments were 
conducted in quintuplicate. Images were taken at 1, 3, and 7 days. 
2.2.6 Imaging. ProSense-680, for imaging cathepsin activity, was synthesized as 
described by Weissleder et al.52 Briefly, 750 mg methoxyl polyethylene glycol 
succinimidyl N-hydroxysuccinimide (NHS) (Nanocs, New York, NY) and 109.5 mg 
poly-L-lysine were reacted overnight in 30 mL of 0.1 M Na2CO3 at pH 8.5.  The polymer 
graft was dialyzed against H2O and lyophilized. Then the polymer graft was dissolved at 
8.4 mg/mL in 0.1 M NaHCO3 at pH 8.3 and 11 mL were reacted with 8.84 mL of 0.1 mM 
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of Cy5.5-NHS in DMSO (Lumiprobe, Hallandale Beach, FL) for 3 h at rt to form 
ProSense-680. Again, this product was dialyzed, lyophilized, and re-suspended in PBS at 
5.3 mg/mL. The imaging agent ProSense-680 was sterilized with a 0.22 μm filter and 
injected into the tail vein (0.15 mL, 32 mg/kg, 5.3 mg/mL) 24 h prior to in vivo 
fluorescence imaging. In vivo fluorescence imaging was performed with a Kodak In Vivo 
Multispectral Imaging System FX Pro (Carestream Health, Rochester, NY). The animals 
were maintained under inhaled anesthesia using 1–4% isoflurane in 100% oxygen at a 
flow rate of 2.5 L/min. A binning of 2 x 2 was used for imaging. Exposure time for each 
image was 2 min. Data were acquired using the manufacturer’s proprietary software. All 
images are presented in fluorescence intensity. Regions of interest (ROIs) were measured 
using ImageJ (NIH, Bethesda, MD). ROI signal intensities were calculated in 
fluorescence intensity/square pixel.  
2.2.7 Histology and tissue homogenization. Mice were euthanized via CO2 asphyxiation 
and the injected biomaterial and surrounding tissue were excised. Two tissue sections for 
each material were fixed in 10% formalin, embedded in paraffin, cut into 5 μm sections, 
and stained using hematoxylin and eosin (H&E), CD206/DAPI (4',6-diamidino-2-
phenylindole), or F4-80/CD40/DAPI for histological analysis. The remaining three tissue 
samples were homogenized by placing the tissue in lysis buffer containing 0.1% Triton 
X-100 and protease inhibitor cocktail (Amresco, Solon, OH), which was used according 
to the manufacturer’s specifications. The tissues were homogenized with a Tissue-Tearor 
(BioSpec, Bartlesville, OK). The homogenized tissues were centrifuged at 13,000 x g for 
10 minutes and the supernatant was collected for the following assays. 
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2.2.8 Quantification of protein. A bicinchoninic acid (BCA) assay (G-Biosciences, Saint 
Louis, MO) was used according to the manufacturer’s specifications to determine the 
total amount of protein present in each homogenized tissue sample. A plate reader 
(BioTek Synergy HT Multidetection Microplate Reader) was used to measure the 
absorbance. 
2.2.9 Measurement of cytokine production. The concentrations of TNF-α and IL-10 in the 
homogenized tissue were determined using commercially available immunoassay kits 
(eBioscience, Inc., San Diego, CA) and performed as described by the manufacturer. The 
absorbance values were measured using a plate reader. 
2.2.10 Griess reagent assay. Nitrite production in the homogenized tissue supernatant 
was measured. Briefly, 1 mM NaNO2 was diluted to 100 μM in Milli-Q water and a 
standard curve was created using two-fold dilutions.  25 µL of sample or 150 µL of 
standard were added to each well with 130 µL of DI water and 20 µL of Griess reagent. 
The plate was incubated for up to 20 minutes and was read at 448 nm with reference of 
690 nm with a plate reader. 
2.2.11 Measurement of arginase activity. 12.5 µL of homogenized tissue supernatants 
were added to individual wells of a 96 well plate along with 12.5 µL 10 mM MnCl2 and 
50 mM Tris (pH 7.5).  The plate was incubated at 55oC for 10 minutes, which allowed for 
activation of the enzyme. 25 µL of 1 M arginine (pH~9.7) was then added to the plate 
before incubating at 37oC for 20 h. Arginase activity was measured through the 
conversion of arginine to urea by adding 200 µL of a 1:2 ratio of solution 1 (1.2 g o-
phthaldialdehyde (Alfa Aesar, Ward Hill, MA), 1 L H2O, and 500 µL HCl (Fisher, 
Pittsburgh, PA)) and solution 2 (0.6 g N-(napthyhl)ethylenediamine dihydrochloride 
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(Acros Organics, Geel, Belgium), 5 g boric acid (Fisher, Pittsburgh, PA ), 800 mL H2O, 
111 mL H2SO4 (Fisher, Pittsburgh, PA), diluted to 1 L with H2O).53 The plate was read at 
520 nm with a reference at 630 nm. 
2.2.12 Statistical analysis. Statistical analysis was performed using XLSTAT® statistical 
software. Statistical significance of the mean comparisons was determined by ANOVA. 
Differences were considered statistically significant for p<0.05. Partial least squares 
(PLS) regression was performed on the material descriptor data set to determine the 
influence of material properties on MΦ response. The material descriptors (Table 2.1) 
were developed based on descriptors defined by Bicerano.54 
Table 2.1. Thirty-six molecular descriptors for the surface modifications used in this 
study. The structure descriptors are defined by Bicerano.54 
ID Structure 
descriptor 
Descriptions 
1  Freely rotating bonds 
2  H-bond donors 
3  H-bond acceptors 
4  Number of sp2 carbon atoms 
5  Number of 1° carbon atoms 
6 1X Connectivity index 1 
7 1Xv Connectivity index 2 
8 0X Atomic index 1 
9 0Xv Atomic index 2 
10 1ξ Intensive connectivity index 1 
11 1ξv Intensive connectivity index 2 
12 0ξ Intensive atomic index 1 
13 0ξv Intensive atomic index 2 
14  Number of non-hydrogen atoms 
15  Number of carbon atoms 
16  Number of hydrogen atoms 
17  Number of oxygen atoms 
18  Number of nitrogen atoms 
19  Number of CH2 
20  𝑁𝑁𝐾𝐾 = 5𝑁𝑁𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 4𝑁𝑁ℎ𝑦𝑦𝑎𝑎𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 − 3𝑁𝑁𝑎𝑎𝑒𝑒ℎ𝑎𝑎𝑦𝑦 − 5𝑁𝑁𝐶𝐶=𝐶𝐶 + 3𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎   
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Table 2.1 continued 
21  𝑁𝑁𝑎𝑎𝑑𝑑 = 19𝑁𝑁𝑁𝑁 + 12𝑁𝑁(𝑠𝑠𝑎𝑎𝑎𝑎𝑎𝑎 𝑔𝑔𝑦𝑦𝑦𝑦𝑠𝑠𝑔𝑔 𝑂𝑂,−𝑆𝑆−) + 52𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎 − 14𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑  
22 
 𝑁𝑁𝑔𝑔𝑦𝑦𝑦𝑦𝑠𝑠𝑔𝑔 = 12𝑁𝑁ℎ𝑦𝑦𝑎𝑎𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦 + 12𝑁𝑁𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 2𝑁𝑁(𝑠𝑠𝑦𝑦𝑠𝑠−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎−(𝑁𝑁𝑁𝑁)−𝑠𝑠𝑠𝑠𝑎𝑎𝑒𝑒𝑎𝑎)
− 𝑁𝑁(𝑎𝑎𝑦𝑦𝑎𝑎𝑦𝑦𝑦𝑦 𝑎𝑎𝑒𝑒ℎ𝑎𝑎𝑦𝑦−𝑂𝑂−) − 𝑁𝑁𝐶𝐶=𝐶𝐶 + 4𝑁𝑁(𝑠𝑠𝑦𝑦𝑠𝑠−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎−(𝐶𝐶=𝑂𝑂)−𝑠𝑠𝑎𝑎𝑦𝑦𝑒𝑒 𝑒𝑒𝑦𝑦 𝑎𝑎 𝑠𝑠𝑎𝑎𝑒𝑒𝑦𝑦𝑦𝑦𝑔𝑔𝑎𝑎𝑠𝑠)+ 7𝑁𝑁(−(𝐶𝐶=𝑂𝑂)−𝑎𝑎𝑠𝑠 𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑎𝑎𝑑𝑑 𝑎𝑎𝑑𝑑𝑎𝑎𝑎𝑎,𝑎𝑎𝑎𝑎𝑒𝑒𝑦𝑦𝑠𝑠𝑎𝑎 ,𝑦𝑦𝑦𝑦 𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎ℎ𝑦𝑦𝑎𝑎𝑎𝑎) + 2𝑁𝑁(𝑦𝑦𝑒𝑒ℎ𝑎𝑎𝑦𝑦−(𝐶𝐶=𝑂𝑂)−) 
23  𝑁𝑁𝑎𝑎𝑒𝑒𝑦𝑦𝑎𝑎𝑎𝑎𝑑𝑑 = 4𝑁𝑁(−𝑆𝑆−) + 12𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎  
24  𝑁𝑁𝑀𝑀𝑀𝑀 = −5𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎 + 3𝑁𝑁𝑎𝑎𝑒𝑒ℎ𝑎𝑎𝑦𝑦 + 5𝑁𝑁𝐶𝐶=𝐶𝐶 − 11𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑  
25  𝑁𝑁𝑀𝑀𝐾𝐾𝑁𝑁 = 3𝑁𝑁(−𝑆𝑆−) + 36𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎 + 8𝑁𝑁𝑎𝑎𝑎𝑎𝑒𝑒𝑦𝑦𝑠𝑠𝑎𝑎 − 4𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑  
26 
NHη 𝑁𝑁𝑁𝑁𝐻𝐻 = −7𝑁𝑁𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 6𝑁𝑁𝑎𝑎𝑒𝑒ℎ𝑎𝑎𝑦𝑦 + 5𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎+ 3𝑁𝑁(𝑠𝑠𝑎𝑎𝑦𝑦−𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎 𝑠𝑠𝑦𝑦𝑠𝑠𝑒𝑒𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎𝑠𝑠𝑎𝑎𝑦𝑦 𝑎𝑎𝑦𝑦𝑦𝑦𝑎𝑎𝑎𝑎𝑒𝑒𝑎𝑎𝑑𝑑 𝑦𝑦𝑎𝑎𝑠𝑠𝑔𝑔𝑠𝑠) + 8𝑁𝑁𝐶𝐶=𝐶𝐶 + 4𝑁𝑁4°𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑦𝑦𝑠𝑠 𝑎𝑎𝑒𝑒𝑦𝑦𝑎𝑎𝑠𝑠+ 2𝑁𝑁3°𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑦𝑦𝑠𝑠 𝑎𝑎𝑒𝑒𝑦𝑦𝑎𝑎𝑠𝑠  
27  𝑁𝑁𝑈𝑈𝑈𝑈 = −2𝑁𝑁𝑂𝑂𝑁𝑁 − 3𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑 + 4𝑁𝑁(𝑠𝑠𝑎𝑎𝑦𝑦−𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎 𝑎𝑎𝑦𝑦𝑦𝑦𝑎𝑎𝑎𝑎𝑒𝑒𝑎𝑎𝑑𝑑 𝑦𝑦𝑎𝑎𝑠𝑠𝑔𝑔𝑠𝑠) 
28  𝑁𝑁𝑎𝑎𝑠𝑠 = 2𝑁𝑁𝐶𝐶𝑁𝑁2 − 7𝑁𝑁𝐶𝐶=𝐶𝐶 + 3𝑁𝑁(𝑠𝑠𝑎𝑎𝑦𝑦−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎 𝑎𝑎𝑦𝑦𝑦𝑦𝑎𝑎𝑎𝑎𝑎𝑎𝑑𝑑 𝑦𝑦𝑎𝑎𝑠𝑠𝑔𝑔𝑠𝑠) − 12𝑁𝑁𝐶𝐶=𝑂𝑂  
29  𝑁𝑁𝑃𝑃𝑆𝑆 = −3𝑁𝑁𝑠𝑠𝑔𝑔3𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑦𝑦𝑠𝑠 𝑎𝑎𝑒𝑒𝑦𝑦𝑎𝑎𝑠𝑠 + 6𝑁𝑁𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑦𝑦𝑠𝑠𝑦𝑦𝑦𝑦 𝑔𝑔𝑦𝑦𝑦𝑦𝑠𝑠𝑔𝑔𝑠𝑠 
30  𝑁𝑁𝑣𝑣𝑎𝑎𝑣𝑣 = 𝑁𝑁𝑎𝑎𝑎𝑎𝑠𝑠𝑦𝑦𝑠𝑠𝑎𝑎𝑦𝑦 + 𝑁𝑁𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑁𝑁𝑂𝑂𝑁𝑁 − 4𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑 + 2𝑁𝑁𝐶𝐶=𝐶𝐶  
31  𝑉𝑉𝑤𝑤 = 3.8618030𝑋𝑋 + 13.7484351𝑋𝑋𝑣𝑣, van der Waals volume 
32 ξNOH 𝜉𝜉𝑁𝑁𝑂𝑂𝑁𝑁 = 𝑁𝑁𝑁𝑁 + 𝑁𝑁𝑂𝑂 − 0.125𝑁𝑁𝑁𝑁𝑁𝑁  
33  Molecular weight 
34  Melting temperature 
35 ζ Zeta potential 
36  Water contact angle 
*  is the number of methyl groups attached to non-aromatic atoms 
is the total number of linkages between amide and non-aromatic atoms 
 
2.3 Results 
2.3.1 Imaging. Prosense® 680 is a protease-activatable fluorescent sensor that, when 
cleaved by proteases, allows for imaging of cathepsin activity. Prosense® 680 was 
injected on days 0, 2 and 6 prior to in vivo imaging on days 1, 3, and 7. Shown in Figure 
2.2A are representative images from each group of mice for all three imaging time points. 
Quantification of the fluorescence intensity is illustrated in Figure 2.2B, which 
demonstrates that cathepsin activity generally increases for up to one week after 
injection. Values for Day 1 range from 442.2 to 1196.8 intensity/square pixel. For Day 3, 
794.1-1876.7 intensity/square pixel, and Day 7 ranges from 918.0 to 2921.1 
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intensity/square pixel. The nitro and phosphonic acid functionalized particles, however, 
do not follow this trend. Nitro shows a peak in cathepsin production on day 3 (1728.8 
intensity/square pixel) that drops again on Day 7 (1179.8 intensity/square pixel). 
Phosphonic acid displays a relatively constant amount of cathepsin production for three 
days of imaging (892.0, 794.1, and 918.0 intensity/square pixel). Statistical analysis was 
performed on these results with connecting letters reports for day 3 and day 7 data given 
in Table 2.2. Because many of the intensity values for day 1 images fell below the limit 
of quantification, statistical analysis could not be performed. Both the limit of detection 
(194.4 intensity/square pixel) and limit of quantification (647.9 intensity/square pixel) 
were calculated. For day 1, ketal (1067.2 intensity/square pixel) and nitro (1196.8 
intensity/square pixel) functionalized particles gave the highest cathepsin signal, while 
acetal (442.2 intensity/square pixel) and ester (468.7 intensity/square pixel) gave the 
lowest. On day 3 the highest cathepsin activity was in the nitro (1728.8 intensity/square 
pixel) and oxime (1876.7 intensity/square pixel) modified p(NIPAm-co-AAc) particle 
implant sites, and the lowest came from phosphonic acid (794.1 intensity/square pixel) 
and ketone 948.6 intensity/square pixel) implants. Day 7 imaging showed high cathepsin 
activity with alkene (2631.3 intensity/square pixel) and amide (2921.1 intensity/square 
pixel) functionalized particles, and low activity with phosphonic acid (918.0 
intensity/square pixel) and ketone (1077.4 intensity/square pixel). 
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Figure 2.2. (A) Representative images from each group of mice on days 1, 3, and 7 along 
with corresponding implant maps. (B) Quantification of the fluorescence intensity for 
days 1, 3, and 7. (*) indicates p<0.05 compared with pNIPAm samples from the same 
day by pairwise comparison. The error bars represent the standard error of the mean and 
the shown limit of quantification is 650 intensity/square pixels. 
 
A 
B 
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Table 2.2. Connecting letters reports for day 3 and day 7 cathepsin activity. Levels not 
connected by the same letter are significant different (p<0.05). 
 
Day 3     
Acetal  B C D 
Alkene A B C  
Amide A B C D 
Epoxide  B C D 
Ester  B C D 
Ether A B C D 
Ketal A B C D 
Ketone   C D 
Nitro A B   
Oxime A    
Phosphonic 
Acid 
   D 
Sulfone  B C D 
Sulfonic Acid A B C  
pNIPAm   C D 
 
Day 7      
Acetal   C D E 
Alkene A B    
Amide A     
Epoxide  B C D E 
Ester    D E 
Ether  B C D E 
Ketal  B C D E 
Ketone    D E 
Nitro   C D E 
Oxime A B C D  
Phosphonic 
Acid 
    E 
Sulfone   C D E 
Sulfonic Acid A B C   
pNIPAm   C D E 
2.3.2 Histology. H&E images revealed varied amounts of MΦs infiltrating the implant 
site based on the modification. Histology images are shown in Figure 2.3. Magnifications 
were chosen to show enough of that tissue section that the implant and surrounding tissue 
might be easily oriented and identified. Ketal, acetal, ketone and nitro functionalized 
particles showed significant amounts of MΦs present in the implant site, while sulfone, 
sulfonic acid, alkene and epoxide groups only had MΦs present around the implant site. 
Immunohistochemistry (IHC) with CD40/F4-80 markers was used to identify M1 MΦs in 
the implant site and a CD206 marker was used to analyze the presence of M2 MΦs. IHC 
images are given in Figure 2.4 and 2.5. Quantification of % CD40/F4-80+ (M1) MΦs and 
% CD206+ (M2) MΦs was done in ImageJ by determining the percent of DAPI stained 
cells that were fluorescently labeled with the corresponding MΦ markers. CD40/F4-80 
staining revealed higher presence of M1 MΦs in sulfonic acid (32%), nitro (20%), and 
unmodified (15%) p(NIPAm-co-AAc) implant sites and a lower presence of M1 MΦs 
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with exposure acetal (2%) and ketone (3%) functionalized particles. The % of CD206+ 
M2 MΦs were not statistically different. Cell quantification data is given in Figure 2.6. 
Statistical analysis was also performed on this data with connecting letter reports given as 
Table 2.3. The IHC images seem to indicate that MΦs are localized to the implant, and 
very few resident monocytes/MΦs are detected in the surrounding tissues. 
 
 
Figure 2.3.  H&E images of (A) acetal (B) alkene (C) amide (D) epoxide (E) ester (F) 
ether (G) ketal (H) ketone (I) nitro (J) oxime (K) phosphonic acid (L) sulfone (M) 
sulfonic acid (N) pNIPAm and (O) unaffected (skin) tissue sections. * indicates implant 
site. Scale bar represents 150 μm. 
* 
* 
* 
* 
* 
* 
A B 
C D 
E F 
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Figure 2.3 continued 
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Figure 2.3 continued 
 
 
Figure 2.4. IHC images of (A) acetal (B) alkene (C) amide (D) epoxide (E) ester (F) 
ether (G) ketal (H) ketone (I) nitro (J) oxime (K) phosphonic acid (L) sulfone (M) 
sulfonic acid (N) pNIPAm and (O) unaffected tissue sections stained with CD206 (M2 
MΦs) and DAPI (nuclei). * indicates implant site. Scale bars: 100 µm. 
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Figure 2.4 continued 
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Figure 2.4 continued 
 
   
 
   
Figure 2.5. IHC images of (A) acetal (B) alkene (C) amide (D) epoxide (E) ester (F) ether 
(G) ketal (H) ketone (I) nitro (J) oxime (K) phosphonic acid (L) sulfone (M) sulfonic acid 
(N) pNIPAm and (O) unaffected tissue sections stained with CD40 (M1 MΦs), F4-80 (pan 
MΦs), and DAPI (nuclei). Left: CD40 and DAPI. * indicate implant site. Middle: F4-80 
and DAPI. Right: CD40, F4-80 and DAPI. Scale bars: 100 µm. 
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Figure 2.5 continued 
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Figure 2.5 continued 
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Figure 2.5 continued 
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Figure 2.6. Quantification of (A) %CD40/F4-80+ MΦs and (B) %CD206+ MΦs in IHC 
images. (*) indicates p<0.05 compared with pNIPAm by pairwise comparison. Error bars 
represent standard deviation. 
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Table 2.3. Connecting letters report for %CD40/F4-80+ (M1) and %CD206+ (M2) MΦs. 
Levels not connected by the same letter are significant different (p<0.05). 
%M1     
Acetal    D 
Alkene   C D 
Amide   C D 
Epoxide   C D 
Ester   C D 
Ether   C D 
Ketal   C D 
Ketone    D 
Nitro  B   
Oxime   C D 
Phosphonic 
Acid 
  C D 
Sulfone   C D 
Sulfonic Acid A    
pNIPAm  B C  
 
%M2  
Acetal A 
Alkene A 
Amide A 
Epoxide A 
Ester A 
Ether A 
Ketal A 
Ketone A 
Nitro A 
Oxime A 
Phosphonic 
Acid 
A 
Sulfone A 
Sulfonic Acid A 
pNIPAm A 
2.3.3 Measurement of cytokine production. Markers of the Th1 response – TNF-α – and 
the Th2 response – IL-10 – were used to determine the ability of the materials to alter 
MΦ phenotype. The results are shown in Figure 2.7A and B with connecting letters 
reports given in Table 2.4. TNF-α/protein (pg/mg) ranges from 0.66 pg/mg to 43.16 
pg/mg for amide and phosphonic acid modified p(NIPAm-co-AAc) particles, 
respectively. For IL-10/protein (pg/mg), the values range from 26.12 pg/mg for sulfonic 
acid to 172.40 pg/mg with oxime-modified p(NIPAm-co-AAc) particles. In comparing 
the data from each of these assays, an IL-10high, TNF-αlow MΦ phenotype results from 
ester (IL-10= 107.94 pg/mg,TNF-α=3.90 pg/mg) and oxime (IL-10=172.40 pg/mg,TNF-
α=2.46 pg/mg) implants, while an IL-10low, TNF-αhigh phenotype is generated with 
exposure to ether (IL-10=75.46 pg/mg,TNF-α=38.78 pg/mg), phosphonic acid (IL-
10=42.30 pg/mg,TNF-α=43.16 pg/mg), sulfone (IL-10=46.05 pg/mg,TNF-α=20.54 
pg/mg) and sulfonic acid (IL-10=26.11 pg/mg,TNF-α=17.28 pg/mg) functionalized 
particles. 
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Figure 2.7. Cytokine expression in response to functionalized p(NIPAm-co-AAc) 
particles ex vivo. (A) TNF-α (B) IL-10 (*) indicates p<0.05 compared with pNIPAm by 
pairwise comparison. Error bars represent the standard error of the mean.   
Table 2.4. Connecting letters report for TNF-α and IL-10 production. Levels not 
connected by the same letter are significant different (p<0.05). 
 
TNF-α       
Acetal    D E  
Alkene    D E F 
Amide     E F 
Epoxide     E F 
Ester     E F 
Ether A      
Ketal    D E  
Ketone      F 
Nitro  B     
Oxime     E F 
Phosphonic 
Acid 
A      
Sulfone  B C    
Sulfonic Acid   C D   
pNIPAm   C D    
IL-10     
Acetal   C D 
Alkene A B C D 
Amide  B C D 
Epoxide  B C D 
Ester A B C D 
Ether A B C D 
Ketal A B C  
Ketone A B C D 
Nitro  B C D 
Oxime A    
Phosphonic 
Acid 
 B C D 
Sulfone  B C D 
Sulfonic Acid    D 
pNIPAm A B   
2.3.4 Arginase:iNOS. Arginase activity was determined by exposing cell lysate to 
arginine and quantifying the urea produced. Increased levels of arginase are associated 
with wound healing and are a marker of M2 MΦs. Nitrites are the stable form of NO and 
were quantified through a Griess reagent assay. The production of NO results from RNIs 
by increased levels of inducible nitric oxide synthase (iNOS) and indicates an M1 
phenotype. The plots for urea and nitrite production are given individually in Figure 2.8 
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A and B, and corresponding connecting letters reports can be found in Table 2.5. In order 
to depict the results from these assays, the amount of urea was divided by the amount of 
nitrite in corresponding samples. This data is represented as arginase:iNOS in Figure 
2.8C. Because both enzymes compete for arginine as a precursor, Arginase:iNOS ratios 
are commonly used as a functional readout in approximating the extent of M1 and M2 
MΦ polarization.55–58 Values here range from 33.35 mg/μmol in nitro to 273.19 mg/μmol 
for amide modified p(NIPAm-co-AAc). By dividing these two values, the data illustrates 
the extent of polarization towards an M2 phenotype (high values) or towards an M1 
phenotype (low values). High values result from the implantation of amide (273.19 
mg/μmol), epoxide (173.99 mg/μmol), and alkene (203.43 mg/μmol) modified particles, 
as well as unmodified (174.73 mg/μmol) p(NIPAm-co-AAc) particles. Low values result 
from ether (39.99 mg/μmol), ketal (58.49 mg/μmol), nitro (33.35 mg/μmol) and oxime 
(64.42 mg/μmol) functionalities. In the tissue samples that were not injected with 
material, there appears to be a much greater population of M1 phenotypic MΦs. 
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Figure 2.8. (A) Urea and (B) nitrite production in response to functionalized p(NIPAm-co-AAc) particles ex vivo. (*) indicates p<0.05 compared with pNIPAm by pairwise 
comparison. (C) Arginase/iNOS ratio. Error bars represent the standard error of the mean.  
Table 2.5. Connecting letters report for urea and nitrite production. Levels not connected by 
the same letter are significant different (p<0.05). 
 
Urea      
Acetal    D E 
Alkene  B C   
Amide A     
Epoxide  B C   
Ester   C D  
Ether    D E 
Ketal   C D  
Ketone    D E 
Nitro   C D  
Oxime    D  
Phosphonic 
Acid 
 B    
Sulfone   C D  
Sulfonic Acid   C D  
pNIPAm     E 
 
Nitrite     
Acetal    D 
Alkene    D 
Amide   C D 
Epoxide    D 
Ester   C D 
Ether  B C D 
Ketal   C D 
Ketone    D 
Nitro A B   
Oxime  B C D 
Phosphonic 
Acid 
 B C  
Sulfone    D 
Sulfonic Acid   C D 
pNIPAm A    
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2.4 Discussion 
 The foreign body response consists of an initial acute phase followed by a chronic 
phase that typically results in granulation and fibrosis.59 The acute phase begins with 
instantaneous protein adsorption after implantation followed by rapid neutrophil 
infiltration that peaks after 1–2 days, and gradually resolves after 7-10 days.59–61 
Neutrophils are followed by monocytes, which extravasate into the tissues and 
differentiate into MΦs 1–2 days after injury.30,59–61 Attempted phagocytosis causes MΦs 
to fuse with each other to form foreign body giant cells (FBGCs) and also secrete factors 
that recruit and activate fibroblasts.30,61 Both MΦs and fibroblasts disperse after 5–9 
days.60 The chronic phase is usually characterized by the presence of monocytes, MΦs, 
FBGCs, and fibroblasts that are activated to become myofibroblasts.30,59 Myofibroblasts 
secrete high amounts of collagen that leads to the formation of a fibrous capsule around 
the biomaterial that typically results in device failure.30 MΦs become numerous one to 
two weeks after injury and diminish at six weeks.60 Both MΦs and neutrophils release 
cathepsins, which degrade the extracellular matrix and facilitate migration through 
inflamed tissue.62,63 Because the focus of this paper is on MΦs, an end point of 7 days 
was chosen, as this is when the number of neutrophils would be diminishing and the MΦ 
population would be maximized. Many forms of cathepsin are recognized as Th2 
enzymes.64–70 Cathepsin activity measured at 7 days was negatively correlated with TNF-
α (R = -0.329) and positively correlated with arginase:iNOS (R = 0.590), demonstrating 
that cathepsin is positively correlated with increased M2 MΦs and negatively correlated 
with M1 MΦs, as expected. This suggests that the cathepsin activity probe used here may 
be suitable for monitoring M2 MΦs. A positive correlation between the fluorescence on 
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day 3 and day 7 (R = 0.629) was observed, suggesting a continual increase in the M2 
population during the week following implantation, which was qualitatively mentioned 
previously. This observation was expected since previous work has shown that M1 MΦs 
are gradually replaced by M2 MΦs as the implant site progresses through the stages of 
wound healing.20,21,30 
Cytokine profiles have been consistently used as a measure of MΦ phenotype. 
This study uses TNF-α, IL-10, and arginase:iNOS as markers for MΦ polarization. IL-10 
and TNF-α are cytokines that are differentially expressed by various MΦ phenotypes. 
High levels of IL-10 are commonly associated with M2 MΦs and tumor progression, and 
high levels of TNF-α are commonly associated with M1 MΦs and tumor suppression. 
Research has also linked chronic low level TNF-α exposure to malignant tumor 
phenotypes.71,72 Using the knowledge that opposing effects can result from different 
concentrations of cytokines, along with tunable responses to the materials developed 
here, treatments may be developed that could allow for personalized medicine. Enzymes 
arginase and iNOS are analyzed herein because subpopulations of MΦs use distinctive 
metabolic pathways of amino acids including arginine. M1 MΦs use iNOS to breakdown 
L-arginine into RNIs and M2 MΦs catalyze L-arginine into ornithine and polyamines 
with the enzyme arginase I.7,11,22,73 RNIs have strong microbicidal effects, while ornithine 
and polyamines are important in collagen metabolism and cell proliferation for tissue 
remodeling and wound healing.11,74–76 Pro-vascularization applications, such as tissue 
engineering, of this study would benefit from low amounts of iNOS and amplified levels 
of arginase. This would result in suppressed immune responses to the materials through 
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inhibition of inflammation and fibrosis as well as improved would healing and repair 
after implantation. 
 Comparing the results of ex vivo TNF-α, IL-10, and arginase:iNOS levels, a 
spectrum between the M1 and M2 phenotypes can be induced through different surface 
modifiers. In measuring cytokine expression, there was no statistical difference between 
unaffected control samples from different mice. The control unmodified p(NIPAm-co-
AAc) particles also showed no statistical difference for different injection patterns. This 
justifies the matrix array of implant sites used to test several different modifications in 
each mouse. There are several functionalized particles that show TNF-αhigh, IL-10low, and 
arginase:iNOSlow profiles such as phosphonic acid, ether, nitro, and sulfonic acid 
indicating a more M1-like presence. On the other hand, amide, alkene, ketone, and 
epoxide induce more M2-like phenotypes with TNF-αlow, IL-10high, and arginase:iNOShigh 
profiles. There are a few functionalizations including ester, ketal and oxime that seem to 
contradict these findings in that they have mixed cytokine profiles of TNF-αlow, IL-10high, 
and arginase:iNOSlow; or intermediate levels of all cytokines as with acetal and sulfone. 
This suggests that these functional groups polarize MΦs such that they lie somewhere in 
the middle of the M1/M2 paradigm. However, the experiments performed here provide 
evidence of the ability to control MΦ phenotype in vivo through the use of various 
surface modifications. 
 IHC of tissue sections allows for the qualitative evaluation of cell phenotype 
surrounding each implant site. These images displayed some correlation with the 
arginase:iNOS results. For example, the response to the nitro functionalized particles has 
a larger amount of CD40/F4-80+ (M1) compared to CD206+ (M2) macrophages, which 
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correlates with it having low arginase:iNOS levels. Opposite trends can be found with 
amide and ketone functionalized particles. Amide particles result in lower CD40/F4-80+ 
macrophages, average % CD206+ and the highest arginase:iNOS ratio. Ketone has very 
low % CD40/F4-80+ macrophages and an average arginase:iNOS ratio. This information 
further validates the finding that day 7 cathepsin activity has a positive correlation with 
arginase:iNOS. Additionally, this information demonstrates that the M1 and M2 
biomarkers measured with IHC were likely due to polarized MΦs present at the implant 
site, rather than resident monocytes/ MΦs. 
 Different material properties have been found to influence particle internalization 
for different MΦ polarizations.45 The focus of the work presented here was to determine 
the effect of these same surface modifiers on MΦ polarization in vivo. PLS analysis was 
performed on arginase:iNOS; TNF-α; IL-10; and cathepsin activity levels measured for 
the different functionalized p(NIPAm-co-AAc) particles. Using QSAR, a prediction of in 
vivo MΦ phenotype was calculated as: 
𝐴𝐴𝐴𝐴𝑔𝑔𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖: 𝑖𝑖𝑁𝑁𝑖𝑖𝑖𝑖 = 186.741 − 5.735𝐻𝐻𝐴𝐴 − 1.737𝑁𝑁𝑠𝑠𝑔𝑔2 − 4.476𝑁𝑁
− 10.586𝑁𝑁𝑂𝑂 + 5.859𝑁𝑁𝐾𝐾 + 3.752𝑁𝑁𝑔𝑔𝑦𝑦𝑦𝑦𝑠𝑠𝑔𝑔 (1a) 
𝐼𝐼𝐼𝐼 − 10 = −15.138 − 59.3921𝜉𝜉 − 39.408𝜉𝜉 + 7.567𝑁𝑁𝐶𝐶 + 8.125𝑁𝑁𝑠𝑠𝑔𝑔2 − 0.484𝑁𝑁𝑎𝑎𝑑𝑑+ 0.988𝑇𝑇𝑎𝑎 (1b) 
𝑇𝑇𝑁𝑁𝑇𝑇 − 𝛼𝛼 = 7.451 + 41.7231𝜉𝜉𝑣𝑣 − 1.576𝑁𝑁𝐶𝐶 − 0.427𝑁𝑁𝑔𝑔𝑦𝑦𝑦𝑦𝑠𝑠𝑔𝑔 − 0.276𝑁𝑁𝑃𝑃𝑆𝑆
− 2.411𝑁𝑁𝑣𝑣𝑎𝑎𝑣𝑣 + 0.199𝑉𝑉𝑣𝑣 − 0.296𝑇𝑇𝑎𝑎 + 0.946𝑊𝑊𝑊𝑊𝐴𝐴 (1c) 
𝑊𝑊𝑖𝑖𝐶𝐶ℎ𝑖𝑖𝑒𝑒𝑖𝑖𝑖𝑖𝑖𝑖3𝑎𝑎𝑎𝑎𝑦𝑦 = 4005.132 − 139.546𝑁𝑁1°𝐶𝐶 + 24.2481𝑋𝑋 + 11.588𝑁𝑁 + 11.171𝑁𝑁𝐶𝐶
− 43.015𝑊𝑊𝑊𝑊𝐴𝐴 − 570.4591𝜉𝜉𝑣𝑣−1008.4110𝜉𝜉 (1d) 
𝑊𝑊𝑖𝑖𝐶𝐶ℎ𝑖𝑖𝑒𝑒𝑖𝑖𝑖𝑖𝑖𝑖7𝑎𝑎𝑎𝑎𝑦𝑦 = 4778.395 − 267.952𝑁𝑁1°𝐶𝐶 − 36.1950𝑋𝑋𝑣𝑣 − 162.124𝑁𝑁𝑂𝑂+ 23.281𝑁𝑁𝑁𝑁 + 132.238𝑁𝑁𝐶𝐶𝑁𝑁2 + 37.012𝑁𝑁𝑔𝑔𝑦𝑦𝑦𝑦𝑠𝑠𝑔𝑔 − 70.770𝑊𝑊𝑊𝑊𝐴𝐴 (1e) 
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The results for the goodness of the fit for the above equations are as follows: 1a) the 
predicted Y-variation, Q2Y = 0.719 and the explained Y-variation, R2Y = 0.923; 1b) Q2Y 
=0.861 and R2Y = 0.936; 1c) Q2Y =0.768 and R2Y = 0.968; 1d) Q2Y =0.723 and R2Y = 
0.826; and 1e) Q2Y =0.647 and R2Y = 0.852. Eriksson has stated that Q2Y > 0.5 is 
generally regarded as good an Q2Y > 0.9 is excellent.40 For in vitro experiments, R2 
should be ≥ 0.81 for a good fit while an R2 > 0.64 is suggested for in vivo data.77 Another 
criteria for these fits is that the difference between R2Y and Q2Y should be less than 
0.3.40 Failing to meet the last criteria indicates the presence of outliers. Our proposed 
equations meet all of these requirements. Plots of observed versus predicted values from 
these models are shown in Figure 2.9. The correlation coefficients for arginase:iNOS, IL-
10, TNF-α, and cathepsin with the material parameters in Table 2.1, along with in 
vitro45,78 and ex vivo results are shown in Figures 2.10-2.13. Material parameters 
demonstrating poor correlations with the measured values were excluded from the fit. 
Measured values were dependent on eight or fewer material parameters. 
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Figure 2.9. Plots of experimentally determined (observed) versus predicted values for (A) TNF-α 
secretion, (B) IL-10 secretion, (C) Arginase/iNOS and (D) 7 day cathepsin activity. Error bars 
represent the standard deviations of the observed and predicted values. The results for the statistics 
of the model were the following: (A) Q2Y = 0.768 and R2Y = 0.968 (B) Q2Y = 0.861 and R2Y = 
0.936. (C) Q2Y = 0.719 and R2Y = 0.923 and (D) Q2Y = 0.647 and R2Y = 0.852.   
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Figure 2.10. Correlation coefficients of material parameters and measured values of 
TNF-α. 
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Figure 2.11. Correlation coefficients of material parameters and measured values of IL-
10. 
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Figure 2.12. Correlation coefficients of material parameters and measured values of 
arginase:iNOS. 
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Figure 2.13. Correlation coefficients of material parameters and measured values of 
cathepsin activity. 
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 There are several parameters that appear to affect MΦ phenotype in vivo. The 
parameters that appear most frequently in equation 1(a-e) are number of carbon atoms, 
the number of functional groups (i.e. NK and Ngroup), and WCA. Some of the parameters 
are linked to specific MΦ phenotypes, implying that polarization of MΦs can be achieved 
through exploiting material parameters. The presence of M1-like MΦs is affected by 
increased intensive connectivity index 2 (R = 0.776 for TNF-α), decreased melting 
temperature (R = -0.386 for TNF-α), and increased WCA (R = 0.269 for TNF-α). M2-like 
MΦ presence is affected by decreased WCA (R = -0.621 for day 3 cathepsin and -0.501 
for day 7 cathepsin), increased melting temperature (R = 0.511 for IL-10), increased 
number of carbon atoms (R = 0.494 for IL-10 and 0.367 for day 3 cathepsin), increased 
number of non-hydrogen atoms (R = -0.612 for arginase:iNOS and 0.443 for day 3 
cathepsin), decreased intensive atomic index 1 (R = -0.442 for IL-10 and -0.537 for Day 
3 cathepsin), decreased number of 1˚ carbon atoms (R = -0.432 for day 3 cathepsin and -
0.467 for day 7 cathepsin), and increased number of sp2 carbon atoms (R = 0.494 for IL-
10 and -0.246 for arginase:iNOS). Of specific importance here are the opposite trends 
found for M1 and M2 MΦs with respect to melting temperature and WCA. Increasing 
presence of M1-like MΦs with increasing hydrophobicity was expected as increased 
adsorption of some proteins is typically the result of increased hydrophobicity (WCA = 
40°-70°).79–81 Protein adsorption plays a role in adherence of MΦs to biomaterial 
surfaces, M1 MΦ activation, and FBGC formation.30,82,83 However, some work shows the 
opposite correlation in that increased hydrophobicity (WCA = 80°-90°) yields anti-
inflammatory responses.84–86 This can be explained with the bell curve for cell attachment 
vs. WCA presented by Hollinger,87 which is made up of three regions of interest. Water 
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contact angles of 0 - 45° represent the conditionally non-adhesive region, 45 - 75° the 
adhesive region, and the non-adhesive region above 75°.87 This curve would suggest that 
materials in the conditionally non-adhesive or non-adhesive regions are ideal for 
achieving anti-inflammatory MΦ responses. Because the WCAs of the materials studied 
here fall between 35° and 50°, the positive correlation associated with M1-like MΦs and 
the negative correlation associated with M2-like MΦs was expected based on these 
previously identified trends. There has been very little work to examine the impact of 
material melting temperature on MΦ phenotype, but there have been some findings to 
suggest that softer materials with lower melting temperatures increase phagocytosis by 
MΦs.45,88 This would also support our findings in that lower melting temperatures appear 
to stimulate M1 MΦs, which are typically efficient phagocytic cells.45,46,89 
 With respect to M1-like MΦs, there was a positive correlation between TNF-α 
and intensive connectivity indices 1 and 2, (R = 0.785 and R = 0.776). A slight positive 
correlation (R = 0.269) exists between TNF-α and WCA. Connectivity indicies 1 and 2, 
along with atomic indicies 1 and 2 have negative correlations (R = -0.652, -0.638, -0.551, 
and -0.609) with arginase:iNOS. The number of non-hydrogen atoms, number of carbon 
atoms, and the number of oxygen atoms all also have negative correlations with 
arginase:iNOS (R = -0.612, -0.516 and -0.523), which is not surprising as these 
contribute to the hydrophobicity/hydrophilicity of particles and WCA also has a slightly 
negative correlation of R = -0.224. Finally, cathepsin activity has negative correlations 
with WCA (R = -0.501), number of primary carbons (R = -0.467), and number of oxygen 
atoms (R = -0.378).  
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 For M2-like MΦs, a positive correlation was found between IL-10 and number of 
carbons (R = 0.630). Another interesting correlation is between IL-10 and the number of 
sp2 carbons (R = 0.494). The arginase:iNOS results correlate positively with zeta 
potential (R=0.572). Cathepsin activity also correlates with zeta potential (R=0.589), 
which is expected based on the earlier observation that cathepsin activity is a measure of 
M2-like MΦs. Zeta potential has been studied as a predictive measure of 
biocompatibility.90 Some studies seem to contrast the findings of this work as they have 
found increasing zeta potential to provoke strong inflammatory responses. However, 
these studies did not examine MΦ phenotype to quantify the response, but only measured 
the overall presence of MΦs at the implant sites.90,91 Interestingly, there does not seem to 
be any correlation between previous in vitro work45 and the ex vivo TNF-α and IL-10 
measured here, validating the necessity of in vivo experiments. 
 
2.5 Conclusions 
With this work, useful insight was gained about in vivo MΦ response to various 
material functionalities. The induction of multiple MΦ phenotypes confirms the ability to 
control MΦ activation in vivo and suggests the importance of chemical properties in the 
biocompatibility of materials. The results obtained suggest that changing properties such 
as melting temperature and WCA can result in opposite MΦ phenotypes. Correlation of 
material parameters and MΦ phenotype with QSAR implies progress in the identification 
of materials for a vertical impact on cancer therapies and tissue engineering. While 
interesting information was gained from QSAR development in this research, future work 
will include an expansion of the materials to refine the predictive model. Also, validation 
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of the model with new materials will be performed. Overall, this in vivo study was 
successful at drawing conclusions about the biomaterial parameters that will allow for 
tuning MΦ polarization responses to biomaterials. 
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CHAPTER 3  
POLY-L-ARGININE BASED MATERIALS AS INSTRUCTIVE 
SUBSTRATES FOR FIBROBLAST SYNTHESIS OF COLLAGEN 
Published in Biomaterials, 63, 47-57 (2015) 
The interactions of cells and surrounding tissues with biomaterials used in tissue 
engineering, wound healing, and artificial organs ultimately determine their fate in vivo. 
We have demonstrated the ability to tune fibroblast responses with the use of varied 
material chemistries. In particular, we examined cell morphology, cytokine production, 
and collagen fiber deposition angles in response to a library of arginine-based polymeric 
materials. The data presented here shows a large range of vascular endothelial growth 
factor (VEGF) secretion (0.637 ng/106 cells/day to 3.25 ng/106 cells/day), cell migration 
(~15 minutes < persistence time < 120 minutes, 0.11 μm/minute < speed < 0.23 
μm/minute), and cell morphology (0.039 < form factor (FF) < 0.107). Collagen 
orientation, quantified by shape descriptor (D) values that ranges from 0 to 1, 
representing completely random (D = 0) to aligned (D = 1) fibers, exhibited large 
variation both in vitro and in vivo (0.167 < D < 0.36 and 0.17 < D < 0.52, respectively). 
These findings demonstrate the ability to exert a certain level of control over cellular 
responses with biomaterials and the potential to attain a desired cellular response such as, 
increased VEGF production or isotropic collagen deposition upon exposure to these 
materials in wound healing and tissue engineering applications.  
 
3.1 Introduction 
The extracellular microenvironment affects cells and is instrumental in controlling 
cellular behavior and responses.1 Implanted biomaterials, tissue engineering constructs, 
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and artificial organs all interact to some extent with surrounding tissues and cells. 
Ultimately, their in vivo fate depends on the outcome of this interaction. The impact of 
biomaterials on cells has been widely studied;2–5 however, the ability to tune the response 
of fibroblasts for applications in wound healing and tissue engineering, in particular the 
substrate’s ability to alter the distribution of collagen fiber orientation through changing 
chemical functional group alone, has not been explored.  
Wound healing is a complex process involving the interaction of various cell 
lineages and tissue types.6,7 While healing is often rapid and efficient, the resultant tissue 
is not always aesthetically appealing or functionally suitable.6 Scar tissue is visually 
unpleasant and is mechanically weakened, sometimes dysfunctional. At maximum, 
remodeled tissue only reaches 80% of the strength of unwounded skin.7 Reorganization 
of collagen by fibroblasts is directly responsible for this decrease in strength.8 In healthy 
tissue, collagen is found to have isotropic fiber orientation, while scar tissue contains 
smaller bundles of collagen aligned parallel to one another.8 This variation is especially 
problematic for tissue-engineered scaffolds and artificial organs because fibrotic tissue 
impedes nutrient transport.4 
Achieving random collagen deposition that more closely resembles young, 
healthy skin would be a vast improvement upon the imperfections of the natural wound 
healing process and the integration of tissue engineered scaffolds. One approach would 
be to develop a wound-healing polymer that can influence the way in which fibroblasts 
synthesize and deposit collagen. Numerous wound dressings, other than standard 
bandages and gauzes, have aimed to provide an optimum environment for cells involved 
in wound healing.9 These conditions include a warm, moist environment with oxygen 
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circulation and low bacterial access.9 Many newly developed dressings decrease pain 
levels and healing time; they can also serve an antibacterial, absorbent, adherent, or 
occlusive function. Preeminent dressings also elicit the appropriate cell-material 
interactions crucial for the immunomodulation and improved would healing processes.9 
Unfortunately, none of the commercially available wound dressings target the remodeling 
phase of wound healing, in particular how fibroblasts respond to the biomaterials, to 
reduce scarring.9 
Here, we present a potential platform for engineering fibroblast responses to 
improve upon the wound healing process. This work directly targets and affects 
fibroblasts in the remodeling phase. The library of materials used here is based on the 
amino acid arginine. Arginine-rich peptides have been extensively explored as 
intracellular delivery vehicles as their guanidine functionality allows them to interact 
with the phosphate groups in cell membranes.10,11 We have developed a library based on 
arginine on the premise that interactions between the arginine moieties and the cell 
membrane may result in altered cell morphology, cytokine production, and collagen fiber 
deposition distribution by fibroblasts. 
 
3.2 Materials and Methods 
3.2.1 PLR modification. Fifteen different molecules (Figure 3.1A) (Sigma, St. Louis, 
MO), herein called amidine derivatives, were used to modify poly-L-arginine (PLR) with 
an 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Oakwood Chemical, West 
Columbia, SC) coupling reaction. A generalized reaction scheme is given in Figure 3.1B. 
Briefly, 4 mL of a 2.5 mg/mL solution of PLR in phosphate buffered saline (PBS) were 
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placed in glass scintillation vials with 100 molar equivalents of amidine derivative. 200 
mg of EDC was added to the vial and the reaction was allowed to stir for 4 hours at room 
temperature.  The polymers were then dialyzed in DI H2O for 24 hours to remove EDC 
and unreacted amidine derivatives, and subsequently lyophilized (4.5 L, Labconco, 
Kansas City, MO). The modified PLR was re-suspended in PBS at 0.1% and stored at -
20°C. 
 
 
Figure 3.1. Synthesis of a new library of poly-L-arginine (PLR) derivatives. (A) Chemical 
structures of molecules used to modify PLR.  The amidine derivatives shown here are numbered 
for easier identification in experiments and discussion throughout the paper. (B) A generalized 
reaction scheme for the modification of PLR 
 
3.2.2 Materials Characterization. In order to ensure that the reaction proceeded, NMR 
was used to characterize the reaction products (Figure 3.2). The modified PLR samples 
were dissolved in D2O and freeze-dried three times to replace all OH groups with OD 
A 
B 
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groups before 2mg of polymer were dissolved a final time in 600μL of D2O. The 1H 
spectra were recorded on a Bruker Avance III Spectrometer at 70°C, a sweep width of 
6602.1Hz, a 90° pulse, and an acquisition time of 2.48 s. 128 repetitive scans with 64k 
points were acquired and the data were processed in MNova with 128k points, zero 
filling, and exponential line broadening of 1.0Hz.12 16 repetitive scans were acquired at 
room temperature for the 1H spectra of the amidine derivatives with all other parameters 
the same as above. In comparing spectra, additional peaks were found near 1.8, 3.5, and 
3.8 ppm for each modified PLR. Primary amines typically appear in the region of 1 – 3 
ppm, depending on H-bonding. The 1.8 ppm shift is assigned to the primary amine 
formed during the amidine reacting with the carboxylic acid. Because peaks were not 
present at these chemical shifts in the spectra of the amidine derivative reacted with PLR, 
it was determined that they were a result of the formation of amide bonds in EDC 
coupling reactions. Protons associated with imidazole show shifts in the range of 7 – 8.4 
ppm, which were not observed the 1H NMR spectra. 
  
Figure 3.2. NMR spectra collected of amidine derivatives, modified PLRs, and control 
PLR. (A-O) Dashed lines indicate additional peaks found in the modified PLR spectra, 
representing the formation of an amide bond by EDC coupling. 
 
A 
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Figure 3.2 continued 
 
3.2.3 Water contact angle. The hydrophobicity of each modified PLR sample was 
measured by determining the water contact angle of each sample. The captive air bubble 
method was used as all the samples were very hydrophilic. The coated coverslips were 
attached to microscope slides and placed upside down on top of a container of water. An 
air bubble (100 μL) was then distributed under the coverslip and imaged with a digital 
camera (Canon EOS Rebel T3i, Canon, Melville, NY).  This process was repeated to 
N 
O 
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obtain five replicates before the angle between the glass and the bubble were measured 
using ImageJ (NIH, Bethesda, MD) software and subtracted from 180° to determine the 
final water contact angle.  Water contact angles and corresponding standard deviations 
are shown for each modified PLR sample in Table 3.1A. Details of multiple comparisons 
for this data are given in Tables 3.1B.The angle of 24o for a control glass coverslip 
closely matched other literature values for silicon dioxide.13 With the highest angle 
measuring at 69°, this data indicates that all samples are reasonably hydrophilic. Although 
none of the samples are as hydrophilic as the control, modifications 4, 5, 7, 9 and PLL 
were the most hydrophilic with water contact angles between 34o and 38o which is in the 
conditionally non-adhesive region, as defined by Vogler and Saltzman.14 Modifications 3, 
11, and 12 were the most hydrophobic with angles greater than 55o, falling in the 
adhesive region. The remaining modifications were moderately hydrophilic with angles 
ranging from 41o -53o.  
3.2.4 Cell culture. The mouse embryo fibroblast cell line NIH/3T3 (American Type Cell 
Collection, ATCC, Manassas, VA) was cultured in complete media (CM, Dulbecco’s 
modified Eagle’s medium (DMEM, Mediatech Inc., Manassas, VA) supplemented with 
10% bovine calf serum (BCS, Mediatech Inc.), 100 U/mL penicillin, and 100 μg/mL 
streptomycin) at 37°C in 5% CO2. Approximately every three days, the cells were 
passaged to ensure proper cell growth through 0.025% trypsin-EDTA detachment and 
subculturing at 5.4 × 103 cells/cm2.  
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Table 3.1. (A) WCA measurements with values are reported as the mean value ± 
standard deviation. (B) Connecting letters report for modified PLR WCAs. Samples not 
connected by same letter are significantly different p<0.05. 
 
A.  
1 41.55 ± 4.51 
2 47.21 ± 3.28 
3 56.40 ±4.25 
4 34.95±4.10 
5 38.02±2.90 
6 53.83±3.22 
7 37.20±2.07 
8 53.42±1.12 
9 38.84±2.34 
10 41.38±2.09 
11 62.64±2.91 
12 69.03±3.56 
13 41.28±3.87 
14 49.79±3.77 
15 41.09±1.51 
PLL 46.12±3.68 
PLR 35.03±3.58 
Glass  Coverslip 24.46±3.68  
 
B.  
1      F G  
2    D E F   
3  B C      
4       G  
5       G  
6   C D     
7       G  
8   C D E    
9       G  
10      F G  
11 A B       
12 A        
13      F G  
14   C D E    
15      F G  
PLL     E F   
PLR       G  
Glass Coverslip        H 
3.2.5 Cell viability. Cytotoxicity of all materials synthesized was determined using MTT 
assays. This assay operates by converting a yellow tetrazole (MTT, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Research Products International 
Corp., Mt. Prospect, IL) to a purple formazan in the mitochondria of living cells. During 
passaging, NIH/3T3 cells were seeded at 250,000 cells/cm2 in 24-well plates (KSE 
Scientific, Durham, NC). Prior to this, the wells were coated with 0.05% solutions of the 
modified PLR samples by incubating 200µL/well at 37°C for one hour and washing twice 
with sterile PBS. After 24 hours, the supernatant was removed from each well to be 
assayed.  500 µL of media were then added to each well along with 50 µL of an MTT 
solution (5mg/mL in DI water). After incubation for 2 h at 37°C, 425 µL of media were 
removed from each well and 500µL of dimethyl sulfoxide (DMSO, Fisher, Waltham, 
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MA) were added to dissolve the purple formazan crystals. The absorbance was read at 
540 nm with a reference at 690 nm with a BioTek Synergy HT Multidetection Microplate 
Reader (BioTek, Winooski, VT). Positive controls of cells in the absence of any PLR 
were used to normalize all samples. Negative controls containing media and PLR were 
also done. All experiments were done in quadruplicate. Results were expressed as the 
mean value ± standard error of the mean normalized to the positive control. 
3.2.6 Measurement of VEGF production. Secretion levels of VEGF in cell culture 
supernatant were measured using ELISA assays. 96 well ELISA plates (eBioscience Inc., 
San Diego, CA) were coated with 100 μl/well of polyclonal goat anti-VEGF164 antibody 
(R&D Systems; AF 493 NA, Minneapolis, MN) at 0.6 μg/mL diluted in PBS and 
incubated for 12 -16 hours at room temperature (rt). Subsequently, the wells were washed 
with PBS and blocked for 1 h at rt with 200 μl of assay diluent (eBioscience Inc.). After 
washing, serial dilutions of VEGF164 standards (R&D Systems; 493-MV) and supernatant 
samples were prepared in assay diluent and incubated at rt for 12-16 hours. Plates were 
washed and incubated for 12-16 hours at 4°C with biotinylated polyclonal goat anti-
VEGF164 antibody at 0.4 μg/mL (R&D Systems; BAF 493). After washing the plates, 
streptavidin/horseradish peroxidase (ThermoScientific, Prod# N504, 1:1000, Waltham, 
MA) was added to the wells and incubated for 30 minutes at rt. A substrate solution 
(tetramethylbenzidine (TMB), ThermoScientific, Prod#34029) was added to each well 
and developed for 5 minutes. The reaction was stopped with 2M H2SO4. Absorbance was 
measured at 450 nm, with a reference at 650 nm. All experiments were performed in 
quadruplicate. Results were expressed as the mean value ± standard error of the mean. 
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3.2.7 Cell migration. NIH/3T3 cells were seeded on coated dishes at 8,400 cells/cm2 and 
incubated overnight at 37°C in 5% CO2 to permit cell adhesion. Fresh medium with 12 
mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma) was added 
at the beginning of each experiment to buffer the solution in the absence of a CO2 
environment. In a control experiment, cells were incubated on the surface of unmodified 
PLR, PLL, and uncoated petri dishes. 
3.2.7.1 Cell tracking and migration analysis. Cell migration experiments were performed 
using time-lapse microscopy. Briefly, petri dishes were placed on the heating stage at 
37°C and imaged every 5 minutes for 6 hours with a 10x objective using an inverted 
microscope (Zeiss Axio Vert.A1, Jena, Germany) and digital camera (Canon EOS Rebel 
T3i). The motion of individual cells was tracked by marking cell centroids using ImageJ 
software. A minimum of 50 cells were tracked for each surface modification or control.  
Cell locomotion can be characterized by cell speed and persistence time. These 
parameters are calculated by fitting the mean-squared displacement to the persistent 
random walk model: 
  (1) 
where 𝑡𝑡 is time, 𝑆𝑆 is the root mean square speed of the cell population, and 𝑃𝑃 is the 
persistence of cell movement.15 Persistence describes the time period over which cell 
movement continues in the same direction. Values of mean squared displacement 〈𝐷𝐷2〉 
were calculated using the overlapping interval method. Pooled averages of displacements 
for cell paths in all replicate experiments were used for fitting with equation 1.16,17 
Matlab (MathWorks, Natick, MA) was used to calculate the pooled average of 
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displacements from loaded coordinates. The displacements were fit with a Levenberg-
Marquardt algorithm using Matlab.18 
3.2.8 Cell staining for fluorescent imaging. NIH/3T3 cells were cultured on glass 
coverslips that had been cleaned for 2 h in 200 mL ethanol, 50 g NaOH, and 300 mL DI 
water before being rinsed vigorously for 10 min with DI water. The glass coverslips were 
then placed in treated 35 × 10 mm2 Petri dishes (Corning, Tewksbury, MA). Using 600 
μL of 0.05% modified PLR in PBS, the coverslip was covered and incubated at 37°C for 
1 h. Unmodified PLR, PLL, and uncoated coverslips were used as controls. The 
coverslips were rinsed twice with 1 mL of PBS and seeded with 25,000 cells/cm2 in 2 mL 
of CM and incubated at 37°C in 5% CO2 for 48 h. After 48 hours, the coverslips were 
rinsed twice with PBS and fixed using methanol at -20°C for 7 minutes. After rinsing 
twice with ice cold PBS, the samples were blocked with 1% BSA and 0.3% Tween-20 in 
PBS and incubated at rt for 1 h. The cells were stained with 1:100 α-tubulin rabbit mAb 
Alexa Fluor® 488 Conjugate (5063, Cell Signaling Technology, Danvers, MA), and 
incubated at 4°C overnight in the dark. After washing 3 times with PBS for 5 minutes, the 
coverslips were incubated in 0.1 μg/mL DAPI for 2 minutes and rinsed with PBS. Then, 
the samples were mounted on microscope slides with 50 μL of glycerin jelly, sealed with 
clear nail polish, and imaged with an EVOS® FLoid® Imaging Station (Life 
Technologies, Grand Island, NY) using the blue channel (excitation/emission 390/446 
nm) and the green channel (482/532 nm). 
3.2.9 Morphology analysis. CellProfiler (Broad Institute, www.cellprofiler.org, 
Cambridge, MA) was used to analyze the morphology of the adherent cells. A more 
detailed description on the software can be found at www.cellprofiler.org. This software 
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was used to analyze the shape and morphology of the NIH/3T3 cells on surfaces coated 
with each modified PLR and control. The shape was analyzed using a form factor, FF: 
𝐹𝐹𝐹𝐹 =  4 ∗ 𝜋𝜋 ∗ 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎/𝑝𝑝𝑎𝑎𝑎𝑎𝑝𝑝𝑝𝑝𝑎𝑎𝑡𝑡𝑎𝑎𝑎𝑎2         (2)                                                                                  
The pipeline for this analysis included four modules: IdentifyPrimaryObjects, 
IdentifySecondaryObjects, IdentifyTertiaryObjects and MeasureObjectSizeShape.  
Adjustments were made to the threshold correction factor in the first two modules for 
each image set. 
3.2.10 Ethics Statement. The research protocol was approved by the local animal ethics 
committees at Iowa State University (Institutional Animal Care and Use Committee) 
prior to initiation of the study. 
3.2.11 Animals. 6-week-old female SKH1-E mice were obtained from Charles River 
Laboratories (Wilmington, MA). The mice were maintained at the animal facilities in the 
College of Veterinary Medicine at Iowa State University, accredited by the American 
Association of Laboratory Animal care, and were housed under standard conditions with 
a 12-hour light/dark cycle. Both water and food were provided ad libitum.  
3.2.12 Injections. Injections were performed in accordance with ISO 10993-6:2001. Prior 
to injection, 105-150 μm glass beads (Polysciences, Warrington, PA) were autoclaved for 
sterilization.  They were then coated with each of the fifteen modified PLRs, PLL, and 
unmodified PLR via electrostatic interactions between the negatively charged glass beads 
and the positively charged PLRs 19. Unmodified glass beads were also tested. The mice 
were anesthetized via isoflurane inhalation at a concentration of 1–4% isoflurane/balance 
O2 to minimize movement. Their backs were scrubbed with 70% isopropyl alcohol and 
the animals were injected with five different modified 10%-v/v glass beads in an array 
92  
 
format on the mouse’s back and a sixth sample of unmodified PLR coated glass beads as 
a control. All injection volumes were 100 μL and experiments were conducted in 
quintuplicate.  
3.2.13 Histology. Mice were euthanized via CO2 asphyxiation and the injected 
biomaterial and surrounding tissue were excised. One or two tissue sections were fixed in 
10% formalin, embedded in paraffin, cut into 5mm sections, and either stained using 
Mason’s Trichrome for histological analysis or used for SHG.  
3.2.14 SHG. 3.2.14.1 Sample preparation. Samples for SHG were initially prepared in 
the same way as those for fluorescence imaging at a seeding density of 60,000 cells/cm2. 
After fixing the cells with ice-cold methanol for 7 min and washing twice with cold PBS, 
the coverslips were mounted on a glass microscope slide with glycerin jelly (10 g gelatin, 
60 mL DI water, 70 mL glycerin).  
3.2.14.2 Collagen gel preparation. Collagen type I (BD Biosciences, Franklin Lakes, NJ) 
at concentration 9.87 mg/mL was mixed on ice with 10x PBS, 1 M NaOH, and DI H2O to 
obtain final concentration of 4 mg/mL. Microscope glass slides were covered with 600 
μL of 0.05% PLR in PBS. Collagen gel solution was pipetted on microscope glass slides 
and were gelled at 37˚C for 30 min. Microscope slides were mounted with glass 
coverslips.  
3.2.14.3 Microscopy equipment and SHG experiments. The laser system is a mode-locked 
Ti:Sapphire laser (100 fs pulse width, 1 kHz repetition rate, Libra, Coherent, Santa Clara, 
CA) that produces an 800 nm fundamental. The average power at the samples was 
controlled using a combination of a half-wave plate and a Glan-Thompson polarizer 
(Thorlabs, Newton, NJ) and kept between 1-10 mW, as experimentally determined to be 
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below the damage threshold of the cells. SHG signal was collected in the transmission 
mode. For this setup, an inverted microscope stand (AmScope, Irvine, CA) and 20X 
Nikon Plan Fluorite objective (0.50 NA, 2.1 mm) were used to focus the beam and the 
SHG light was collected with a 40x Nikon water immersion objective (0.8 NA, 3.5 mm). 
The transmitted SHG signal was reflected by a dichroic mirror (Thorlabs) and separated 
from the fundamental beam with a short pass filter < 450nm (Thorlabs) and a 808 nm 
notch filter (NF-808.0-E-25.0M, Melles Griot), before detection by an intensified CCD 
camera (iCCD, iStar 334T, Andor, Belfast, UK).  
Polarization analysis of SHG signal from samples was accomplished using a 
Glan-Thompson polarizer and a half-wave plate mounted on a motor driven rotational 
stage (Thorlabs). These optics were inserted before the focusing objective. The Glan-
Thompson polarizer was used to achieve linear polarization, which was rotated with a 
half-wave plate 20. An additional polarizer was inserted into the optical path in front of 
the iCCD to ensure the polarization state of the transmitted SHG signal. Images were 
acquired every 10° from 0° to 350°.  
3.2.14.4 Theoretical background and image processing. A model describing SHG in 
collagen based on cylindrical symmetry, which reduces independent second-order 
susceptibility tensor elements to four tensors, was used to fit the acquired images.21–25 In 
our setup, the laser beam is normally incident on a sample x-z plane. Considering these 
assumptions and our configuration, the SHG intensity can be written as a function of 
polarization angle of the incident laser beam: 
𝐼𝐼𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑐𝑐 ∙  ��𝑠𝑠𝑝𝑝𝑠𝑠2(𝜃𝜃𝑒𝑒 −  𝜃𝜃𝑜𝑜) + �𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧� 𝑐𝑐𝑐𝑐𝑠𝑠2(𝜃𝜃𝑒𝑒 − 𝜃𝜃𝑜𝑜) �2 + �𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧�2 sin2�2(𝜃𝜃𝑒𝑒 −  𝜃𝜃𝑜𝑜)�� (3)  
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where 𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧
𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧
  and  𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧
𝜒𝜒𝑧𝑧𝑧𝑧𝑧𝑧
 are second-order susceptibility tensor element ratios, 𝜃𝜃𝑒𝑒  and 𝜃𝜃𝑜𝑜 are 
incident polarization angle and collagen fiber angle, respectively.  
SHG images of the 15 samples and 3 controls (PLL, unmodified PLR, and 
uncoated coverslips) were obtained using the software package provided with the iCCD 
camera (Solis, Andor). Final images were acquired by averaging at least 15 images for 
each polarization angle. A portion of the image processing was done using ImageJ 
software. A small background, likely due to the ambient light noise, was subtracted from 
all images. After background subtraction, images were filtered using a median noise filter 
(3×3) to attenuate the salt-and-pepper noise in SHG images. Matlab was used to 
determine the deposited collagen orientation angle and tensor susceptibilities for every 
region of interest (ROI) by fitting equation 2 with the Levenberg-Marquardt algorithm 18. 
Images were binned to obtain 4×4 pixel areas (i.e. 4×4 ROIs) and Matlab was used to 
determine the mean signal intensity per pixel and per ROI. Photon counts below 5 counts 
per pixel were excluded from analysis, which was found to be below the limit of 
detection for this setup. The Matlab script also provides the susceptibility tensor element 
ratios as a heat map image to present the spatial distribution of these parameters and 
orientation angle maps. 
Collagen fiber orientation was analyzed using SHG radar graphs in which SHG 
intensity was plotted as a function of incident polarization angle. SHG polarimetry 
profiles can be used for determining degree of organization of the collagen fibers secreted 
by fibroblast cells on different polymer substrates.26 Fourier transformation was used for 
extracting shape characteristics of SHG radar graphs. Fourier space representation of   
can be expressed as follows: 
95  
 
          (4) 
Where and are normalized amplitude of the shape and .  is defined as 
normalization amplitude roughness (NAR). For  collagen orientation is uniaxial, 
while for collagen fibers with orientation is completely random.27 
3.2.15 Statistical analysis. The statistical significance of the mean comparisons was 
determined by ANOVA using the JMP Pro statistical software package. Pair-wise 
comparisons were analyzed with Turkey HSD. Differences were considered statistically 
significant for P < 0.05. Partial least squares (PLS) regression was performed on the 
material descriptor data set to determine the influence of material properties on collagen 
orientation. The material descriptors (Table 3.2) were developed based on descriptors 
defined by Bicerano.28 
Table 3.2. Twenty-three molecular descriptors for the modified PLRs used in this study. 
ID Structure 
descriptor 
Descriptions 
1 r Freely rotating bonds 
2  H-bond donors 
3  H-bond acceptors 
4  Number of sp2 carbon atoms 
5  Number of 1° carbon atoms 
14  Number of non-hydrogen atoms 
15  Number of carbon atoms 
16  Number of hydrogen atoms 
17  Number of oxygen atoms 
18  Number of nitrogen atoms 
19  Number of CH2 
20  𝑁𝑁𝐾𝐾 = 5𝑁𝑁𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑒𝑒 + 4𝑁𝑁ℎ𝑦𝑦𝑎𝑎𝑦𝑦𝑜𝑜𝑦𝑦𝑦𝑦𝑦𝑦 − 3𝑁𝑁𝑒𝑒𝑒𝑒ℎ𝑒𝑒𝑦𝑦 − 5𝑁𝑁𝐶𝐶=𝐶𝐶 + 3𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑜𝑜𝑠𝑠𝑒𝑒 
21  𝑁𝑁𝑎𝑎𝑑𝑑 = 19𝑁𝑁𝑁𝑁 + 12𝑁𝑁(𝑠𝑠𝑎𝑎𝑎𝑎𝑒𝑒 𝑔𝑔𝑦𝑦𝑜𝑜𝑠𝑠𝑔𝑔 𝑂𝑂,−𝑆𝑆−) + 52𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑜𝑜𝑠𝑠𝑒𝑒 − 14𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑    
1
( )
=
= −∑
M
i j
u u
u
D A A ( 1, 2,..., 1)= −u N
i
uA
i
uA i j D
1=D
0=D
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Table 3.2 continued 
22 
 𝑁𝑁𝑔𝑔𝑦𝑦𝑜𝑜𝑠𝑠𝑔𝑔 = 12𝑁𝑁ℎ𝑦𝑦𝑎𝑎𝑦𝑦𝑜𝑜𝑦𝑦𝑦𝑦𝑦𝑦 + 12𝑁𝑁𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑒𝑒 + 2𝑁𝑁(𝑠𝑠𝑜𝑜𝑠𝑠−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑒𝑒−(𝑁𝑁𝑆𝑆)−𝑠𝑠𝑠𝑠𝑎𝑎𝑒𝑒𝑒𝑒)
− 𝑁𝑁(𝑎𝑎𝑦𝑦𝑎𝑎𝑦𝑦𝑦𝑦 𝑒𝑒𝑒𝑒ℎ𝑒𝑒𝑦𝑦−𝑂𝑂−) − 𝑁𝑁𝐶𝐶=𝐶𝐶 + 4𝑁𝑁(𝑠𝑠𝑜𝑜𝑠𝑠−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑒𝑒−(𝐶𝐶=𝑂𝑂)−𝑠𝑠𝑒𝑒𝑦𝑦𝑒𝑒 𝑒𝑒𝑜𝑜 𝑎𝑎 𝑠𝑠𝑎𝑎𝑒𝑒𝑦𝑦𝑜𝑜𝑔𝑔𝑒𝑒𝑠𝑠)+ 7𝑁𝑁(−(𝐶𝐶=𝑂𝑂)−𝑎𝑎𝑠𝑠 𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑜𝑜𝑦𝑦𝑦𝑦𝑦𝑦𝑎𝑎𝑑𝑑 𝑎𝑎𝑑𝑑𝑎𝑎𝑎𝑎,𝑎𝑎𝑒𝑒𝑒𝑒𝑜𝑜𝑠𝑠𝑒𝑒,𝑜𝑜𝑦𝑦 𝑎𝑎𝑦𝑦𝑎𝑎𝑒𝑒ℎ𝑦𝑦𝑎𝑎𝑒𝑒) + 2𝑁𝑁(𝑜𝑜𝑒𝑒ℎ𝑒𝑒𝑦𝑦−(𝐶𝐶=𝑂𝑂)−) 
24  𝑁𝑁𝑀𝑀𝑀𝑀 = −5𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑜𝑜𝑠𝑠𝑒𝑒 + 3𝑁𝑁𝑒𝑒𝑒𝑒ℎ𝑒𝑒𝑦𝑦 + 5𝑁𝑁𝐶𝐶=𝐶𝐶 − 11𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑 
26 
NHη 𝑁𝑁𝑆𝑆𝐻𝐻 = −7𝑁𝑁𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑒𝑒 + 6𝑁𝑁𝑒𝑒𝑒𝑒ℎ𝑒𝑒𝑦𝑦 + 5𝑁𝑁𝑠𝑠𝑠𝑠𝑦𝑦𝑠𝑠𝑜𝑜𝑠𝑠𝑒𝑒+ 3𝑁𝑁(𝑠𝑠𝑎𝑎𝑦𝑦−𝑎𝑎𝑒𝑒𝑎𝑎𝑐𝑐𝑒𝑒𝑦𝑦𝑒𝑒𝑎𝑎 𝑠𝑠𝑜𝑜𝑠𝑠𝑒𝑒𝑒𝑒𝑦𝑦𝑎𝑎𝑎𝑎𝑠𝑠𝑎𝑎𝑦𝑦 𝑎𝑎𝑦𝑦𝑜𝑜𝑎𝑎𝑎𝑎𝑒𝑒𝑎𝑎𝑑𝑑 𝑦𝑦𝑎𝑎𝑠𝑠𝑔𝑔𝑠𝑠) + 8𝑁𝑁𝐶𝐶=𝐶𝐶 + 4𝑁𝑁4°𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑜𝑜𝑠𝑠 𝑎𝑎𝑒𝑒𝑜𝑜𝑎𝑎𝑠𝑠+ 2𝑁𝑁3°𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑜𝑜𝑠𝑠 𝑎𝑎𝑒𝑒𝑜𝑜𝑎𝑎𝑠𝑠  
27  𝑁𝑁𝑈𝑈𝑈𝑈 = −2𝑁𝑁𝑂𝑂𝑆𝑆 − 3𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑 + 4𝑁𝑁(𝑠𝑠𝑎𝑎𝑦𝑦−𝑎𝑎𝑒𝑒𝑎𝑎𝑐𝑐𝑒𝑒𝑦𝑦𝑒𝑒𝑎𝑎 𝑎𝑎𝑦𝑦𝑜𝑜𝑎𝑎𝑎𝑎𝑒𝑒𝑎𝑎𝑑𝑑 𝑦𝑦𝑎𝑎𝑠𝑠𝑔𝑔𝑠𝑠) 
28  𝑁𝑁𝑎𝑎𝑠𝑠 = 2𝑁𝑁𝐶𝐶𝑆𝑆2 − 7𝑁𝑁𝐶𝐶=𝐶𝐶 + 3𝑁𝑁(𝑠𝑠𝑎𝑎𝑦𝑦−𝑎𝑎𝑒𝑒𝑎𝑎𝑒𝑒𝑦𝑦𝑒𝑒𝑎𝑎 𝑎𝑎𝑦𝑦𝑜𝑜𝑎𝑎𝑎𝑎𝑎𝑎𝑑𝑑 𝑦𝑦𝑎𝑎𝑠𝑠𝑔𝑔𝑠𝑠) − 12𝑁𝑁𝐶𝐶=𝑂𝑂 
29  𝑁𝑁𝑃𝑃𝑆𝑆 = −3𝑁𝑁𝑠𝑠𝑔𝑔3𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑜𝑜𝑠𝑠 𝑎𝑎𝑒𝑒𝑜𝑜𝑎𝑎𝑠𝑠 + 6𝑁𝑁𝑑𝑑𝑎𝑎𝑦𝑦𝑐𝑐𝑜𝑜𝑠𝑠𝑦𝑦𝑦𝑦 𝑔𝑔𝑦𝑦𝑜𝑜𝑠𝑠𝑔𝑔𝑠𝑠 
30  𝑁𝑁𝑣𝑣𝑎𝑎𝑣𝑣 = 𝑁𝑁𝑎𝑎𝑒𝑒𝑠𝑠𝑜𝑜𝑠𝑠𝑎𝑎𝑦𝑦 + 𝑁𝑁𝑎𝑎𝑦𝑦𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑁𝑁𝑂𝑂𝑆𝑆 − 4𝑁𝑁𝑑𝑑𝑦𝑦𝑑𝑑 + 2𝑁𝑁𝐶𝐶=𝐶𝐶  
32 ξNOH 𝜉𝜉𝑁𝑁𝑂𝑂𝑆𝑆 = 𝑁𝑁𝑁𝑁 + 𝑁𝑁𝑂𝑂 − 0.125𝑁𝑁𝑆𝑆𝑁𝑁  
33 
 Molecular weight 
36  Water contact angle 
 
 
3.3 Results 
3.3.1 Polymer synthesis and characterization. A library of 15 modified poly-L-arginines 
(PLRs) were synthesized through carbodiimide chemistry and were characterized through 
NMR (Figure 3.2). Figure 3.1A shows the structures of the amidine derivatives that were 
covalently attached to PLR. They were determined to be hydrophilic through water 
contact angle (WCA) measurements (Table 3.1A). Some correlations have been found 
between wettability and protein adsorption strength leading to differences in cell 
migration and morphology.14,29 This is to be expected as cells migrate using lamellipodia 
or filopodia, which are developed by actin polymerization and stabilized by adherence of 
transmembrane receptors to the extracellular matrix (ECM) in vivo.30 In the presence of 
biomaterials, cells may not effectively migrate if the substrate is not chemically or 
physically similar to the ECM and does not allow for binding of transmembrane 
receptors. Morphology of cells on substrates is also dependent on transmembrane 
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receptors and the ability of cells to rearrange attachment sites. If cells cannot detach from 
a surface, they will remain spread out and unable to migrate, as is the case on materials 
with higher surface energy, increased wettability, lower amine content, and increased 
material stiffness.31,32 
3.3.2 Cell viability. Materials must be cytocompatible to be useful in tissue engineering 
and wound healing applications. Cell viabilities were normalized to cells cultured on 
tissue culture polystyrene (TCPS). Cells were at least 70% viable on the different 
substrates (Figure 3.3), indicating that the materials synthesized here are not cytotoxic. 
Details of multiple comparisons for this data are given in Table 3.3. 
 
Figure 3.3. Viability of NIH/3T3 cells is not affected by modified PLR samples. Cells 
were adhered to modified PLR substrates. The control samples are PLR and PLL.  All 
experiments were done in quadruplicate. Results are expressed as the mean value ± 
standard deviation. 
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Table 3.3. Statistical analysis of MTT data. Connecting letters report. Samples not 
connected by same letter are significantly different p<0.05. 
MTT         
1    D 
2 A B C  
3 A    
4 A    
5 A B   
6 A B   
7 A B   
8 A B   
9 A    
10 A    
11 A B   
12 A B   
13 A    
14 A B   
15   C D 
PLR A B   
PLL  B C D 
 
3.3.3 VEGF secretion. VEGF is a key component in angiogenesis, epithelization, and 
collagen deposition, which are integral in the wound healing process.33 VEGF has 
prominent applications in localized angiogenesis for therapeutic purposes; for example, 
promoting neovascularization in ischemic regions.34 Ennet et al. reported VEGF 
concentrations up to 10 ng/mL at the implant site and significant upregulation of local 
angiogenesis in vivo.35 The VEGF concentration required to initiate normal 
neovascularization ranges from approximately 5 to 70 ng/106 cells/day.36 These 
concentrations were produced by primary myofibroblasts.    
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VEGF production by fibroblasts in response to modified surfaces and controls 
were evaluated (Figure 3.4A). All three controls (PLR, PLL and TCPS) showed similar 
levels of VEGF expression (~ 0.55 ng/106 cells). Surfaces with modifications 4, 6 and 15 
significantly increased VEGF secretion compared to all controls (p<0.001). Modification 
6 elevated VEGF release ~ 3 fold, compared to controls, while 4 and 15 showed ~ 2 fold 
increase. Modification 3 upregulated VEGF expression compared to PLR and PC. The 
remaining modifications did not significantly affect VEGF expression; however, 
differences were observed when comparing modifications to one another (Table 3.4). For 
example, culturing cells on 1, 2, 5 and 7 led to an increase of VEGF compared to 10, 11, 
and 13 (p<0.05).  
3.3.4 Migration. The ability of cells to attach and migrate through the ECM plays a 
crucial role in homeostasis, tissue development, and wound healing.29,37 Cell adhesion 
receptors link to adhesion ligands, providing traction and signaling for locomotion.38 Cell 
migration on solid substrates occurs through amoeboid movement involving a sequence 
of cell protrusions and retractions using actin filaments.39 For implanted biomaterials 
rapid healing is vital for a successful outcome. Increasing cell migration speed can 
significantly promote the healing process following implantation,32 necessitating an 
understanding of the way cells interact with synthetic surfaces when designing materials 
for wound healing and tissue engineering applications.40  
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Figure 3.4. The effect of PLR substrates on persistence time and speed, VEGF secretion, 
and morphology of NIH/3T3 cells. (a) VEGF expressions are normalized to the number 
of viable cells. Error bars represent the 95% confidence interval based on the standard 
deviation. (*) indicates p<0.05 compared with PC by pairwise comparison and (**) 
p<0.05 compared with other samples by pairwise comparison. (b) Mean speeds and 
persistence times are reported for cells (n≥50) migrating on PLR modified substrates. 
Error bars represent the 95% confidence interval based on the standard error of the mean. 
(c) Representative images of fibroblasts morphology in response to different surfaces of 
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modified PLRs. Images are arranged to show the spectrum of FF values and morphology 
found.  Green is α-tubulin rabbit mAb Alexa Fluor® 488 Conjugate and blue is DAPI.  
The scale bar represents 100μm. (d) Quantitative measurements of fibroblast morphology 
cultured on PLR substrates. Histograms of FF values for each sample (red) plotted with 
that of cells cultured on a glass coverslip (black).  The y-axis represents the percent of 
cells (n>750) on each sample that were determined to have each FF value.   
 
Table 3.4. Statistical analysis of VEGF expression by fibroblast cells. Connecting letters 
report. Samples not connected by same letter are significantly different p<0.05. 
VEGF               
1    D E F  
2    D E   
3   C D    
4  B C     
5    D E   
6 A       
7    D E   
8     E F G 
9      F G 
10       G 
11       G 
12     E F G 
13       G 
14     E F G 
15  B      
PLR     E F G 
PLL    D E F G 
Glass 
Coverslip     E F G 
 
We examined the effect of the PLRs on fibroblast migration behavior. The 
persistence of directionality and cell migration speed results are shown in Figure 3.4B. 
Modifications 3, 10, and 13 significantly increased directionality of cell migration 
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compared to TCPS, and maximum migration rates were found for TCPS coated with 
modification 3. Fibroblasts also migrated faster on modifications 8 and 5. Modifications 
4, 7, 9, 12, 14, 15, and PLL only slightly affected migration rate, while decreasing 
persistence. Modification 2 inhibited the migration of fibroblasts without any change in 
persistence compared to TCPS. The degree of migration of cells on other modifications 1, 
6, 11, 13, and PLR was approximately the same, with 13 having higher persistence of 
directionality. Overall, the persistence varied from ~ 15 to 120 minutes and the speed 
ranged from 0.11 to 0.23 μm/minute. Cells cultured on TCPS were in the middle of these 
regions with a P of 60 minutes and an S of 0.18 μm/minute. This compares well with 
other literature values of ~ 0.2 μm/minute for NIH/3T3 cells,41 ~ 0.17 μm/minute for 
primary fibroblasts,42 and directional persistence of ~ 40 minutes for secondary 
fibroblasts.43 
3.3.5 Cell morphology. Most cell types require adhesion to a surface for viability and 
growth.37 Thus, adhesion typically precedes cell spreading, migration, and ultimately cell 
function.14 Cell morphology is thought to impact biomaterial integration and wound 
healing, as normal cell morphology is typically indicative of proper cell adhesion leading 
to cell function and biocompatibility.29 For this reason, cell morphology was 
characterized in response to PLR substrates. A spectrum of cell morphologies that 
qualitatively fit into three categories can be seen in Figure 3.4C. Cells cultured on 
modifications 1, 6, 13, 14, 15, and PLL, were similar to the cells cultured on glass 
coverslips, mostly rounded with very little cytoplasm was visible in the images. Very few 
elongated cells were observed on these surfaces. Cells cultured on a second group of 
modifications, 8, 11, 5, 9, 3, and 4 exhibited an elongated and linear morphology. When 
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cultured on modifications 2, 7, 10, 12, and PLR, the majority of cells were spread out in 
an unrestricted manor, adopting more triangular or rectangular shapes. Quantitative 
analysis of the cell morphology is shown in Table 3.5, where a form factor (FF) value of 
1 indicates a perfectly circular object and 0 corresponds to linear or star shaped 
morphologies. These values were used to arrange the images and histograms in Figure 
3.4C and D in a spectrum based on their shape. Histograms (Figure 3.4D) illustrate the 
percent of cells portraying each FF value. Based on the mode of the form factor, 
modifications 2, 4, 7, 10, 12, and PLR showed a large decrease when compared to the 
glass coverslip indicating that the cells cultured on these samples were more spread out, 
not circular, with a larger perimeter. There was only a moderate shift in this value from 
the control for modifications 3, 5, 6, 8, 9, 11, and 15, which had form factors between 
0.07 and 0.09. Lastly, 1, 13, 14, and PLL produced values very similar to that of the 
control. 
3.3.6 SHG. Self-assembly of collagen plays an essential role in tissue repair and growth,26 
making the orientation angle of deposited collagen a key parameter in determining the in 
vivo fate of tissue engineered constructs. It has been shown that the amount of collagen 
produced by fibroblasts depends on surface chemistry of the material in vitro.44 Collagen 
deposited on biomaterial surfaces and its orientation can dictate the successful outcome 
of implanted devices. A thin and well-oriented collagen capsule around the implant has 
low vascular density and can hinder the function of encapsulated cells for tissue 
engineering applications or artificial organs.45 SHG is a nonlinear optical technique in 
which isotropic or centrosymmetric molecules do not generate signal, meaning that cell 
culture media will not interfere with the images. This technique is perfectly suited to 
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studying collagen, which has a triple helical structure, rendering it non-centrosymmetric. 
Furthermore, since SHG is a second-order phenomenon, orientation angles of molecules 
can be measured.22  
 
Table 3.5. Mode FF values for each sample along with the variance and skewness of the 
corresponding histograms. 
FF Mode Variance Skewness 
1 0.1016 0.0121 4.041 
2 0.0387 0.1110 5.442 
3 0.0713 0.0262 3.223 
4 0.0580 0.0125 4.6540 
5 0.0769 0.0088 5.242 
6 0.0895 0.0121 4.325 
7 0.0472 0.0195 3.700 
8 0.0865 0.0136 4.126 
9 0.0731 0.0077 5.132 
10 0.0546 0.0160 4.665 
11 0.0851 0.0084 5.816 
12 0.0542 0.0264 3.195 
13 0.1062 0.0093 5.031 
14 0.0971 0.0092 5.177 
15 0.0899 0.0109 4.849 
PLL 0.1072 0.0085 4.478 
PLR 0.0570 0.0180 3.584 
Glass 
Coverslip 0.0967 0.0246 2.986 
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Representative SHG images of collagen deposited by fibroblasts in vitro on the 
modified PLR surfaces can be seen in Figure 3.5A. Polarimetry profiles of collagen 
orientation angles are shown in Figure 3.5B. These plots represent the integrated intensity 
of images taken every 10° from 0 to 360°. A shape descriptor, D, was used to quantify 
the shape of the polarimetry profile and is shown in Figure 3.5C. D ranges from 0 being 
perfectly circular, or an isotropic collagen distribution, to 1 being aligned collagen. 
Modifications 2, 3, 4, 7, 12, 14, and PLR exhibit oval polarimetry plots (0.17 < D < 
0.22). Modifications 1, 10, and 11 show slightly higher order in collagen orientation, with 
the D values very closely resembling the cells cultured on glass coverslips (Figure 3.5C 
(0.27 < D < 0.32)). Modification 6 had extremely round polarimetry profiles with the 
lowest D values among all samples (0.17 ± 0.01). On the other hand, modifications 5, 8, 
and 13 showed the highest degree of collagen orientation with D values of 0.30, 0.36 and 
0.33, respectively. In examining the profiles in Figure 3.5B, modification 5 appears to 
have four-fold symmetry. Several other materials appear to be oriented at 135° (8 & 10).  
In vivo characterization of the orientation of the collagen adjacent to the materials 
28 days after implantation was also performed. SKH1-E, an immunocompetent wound 
healing mouse model was injected with 105-150 μm glass beads coated with PLR 
modified with the molecules in Figure 3.1. Controls of unmodified PLR, PLL, and 
uncoated particles were also injected. Animals were sacrificed at 28 days after material 
implantation, and the tissue surrounding the implant was excised, fixed, and either 
stained with Masson’s trichrome or imaged with SHG. 
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Figure 3.5. SHG emanates from collagen secreted by fibroblasts cultured on modified 
PLR substrates, which cause fibroblasts to secrete collagen fibers with different 
orientation angles. (A) Representative SHG images of collagen secreted by fibroblast 
samples on different surfaces of modified PLRs. SHG intensity is expressed in blue 
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pseudocolor. The scale bar represents 25μm. (B) Representative SHG polarimetry 
profiles for fibroblast cells on different modified PLR surfaces. Y scale corresponds to 
SHG intensity in arbitrary units and the azimuthal angles correspond to polarization 
angles. Arrows are a guide to the eye for the major axes of the collagen fiber orientation. 
(C) Shape descriptor values for collagen secreted by fibroblasts on modified PLR 
surfaces. Error bars represent standard deviation.  
 
Representative images and polarimetry profiles are shown in Figure 3.6A and B. 
Modifications 3, 6, 7, 10, 14, and PLL have collagen orientation similar to that of the 
unaffected skin (0.28 ± 0.07). Modifications 4, 5, 9, 11, and 12 elicit higher collagen 
orientation compared to the unaffected skin section but similar to the uncoated glass 
beads (0.37 ± 0.02). From the polarimetry profiles it can be noticed that modification 13 
has the highest collagen orientation degree (0.52 ± 0.07) and was significantly higher 
compared to the controls (p<0.05). All D values for in vivo data are given in Figure 3.6C.  
Standard histological evaluation around the implants was used to evaluate the 
tissue response after implantation. Representative Masson’s trichrome images are shown 
in Figures 3.6D and E, with the remaining images in Figure 3.7. The implanted beads 
were dislodged during the processing, however, collagen fibrils can be seen surrounding 
voids that remain from the implanted materials. New blood vessels are observed in Figure 
3.6E, which is modification 14.  
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Figure 3.6. SHG emanates from collagen secreted in vivo by cells adjacent to the implant 
sites containing modified PLR substrates coated on glass beads. (A) Representative SHG 
images of collagen secreted in vivo near the surfaces of glass beads with modified PLR 
coatings. SHG intensity is expressed in blue pseudocolor. The scale bar represents 25μm. 
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(B) Representative SHG polarimetry profiles of collagen secretion at modified PLR glass 
bead implant sites. Y scale corresponds to SHG intensity in arbitrary units and the 
azimuthal angles correspond to polarization angles. Arrows are a guide to the eye for the 
major axes of the collagen fiber orientation. (C) Shape descriptor values for collagen 
secreted adjacent to implant sites for modified PLR coated glass beads. Error bars 
represent standard deviation. (D) and (E) representative Masson’s trichrome staining 
images of tissue sections containing implanted glass beads coated with modified PLR 1 
and 14, respectively. Arrowhead indicates the presence of blood vessels. The scale bar 
represents 150 μm.  
 
 
 
Figure 3.7. Masson’s Trichrome staining images of tissue sections containing implanted 
coated glass beads. Coatings include modified PLR (A) 1, (B) 2, (C) 3, (D) 4, (E) 5, (F) 
6, (G) 7, (H) 8, (I) 9, (J) 10, (K) 11, (L) 12, (M) 13, (N) 14, (O) 15; and (P) unmodified 
PLR, (Q) PLL, (R) uncoated glass beads as well as (S) adjacent unaffected tissue. Scale 
bar represents 150 µm. 
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Figure 3.7 continued 
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Figure 3.7 continued 
 
Very little correlation was observed between the in vitro and in vivo results 
(R2=0.304). However, modifications 2, 3, 6, and 7 exhibit a low degree of collagen 
orientation for both in vitro and in vivo studies. The same trend was noticed for 
modification 5, which has four-fold symmetry and high D values for both cases. It was 
also determined that the orientation of collagen gels deposited on modified PLR surfaces 
have no dependence on surface chemistry (Figure 3.8). Taken together this illustrates the 
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ability for polymers to control the orientation of deposited collagen, a result that has 
never previously been seen. 
 
Figure 3.8. Shape Descriptor values for collagen gels on each modified PLR sample. 
Error bars represent the standard deviation.   
 
 
3.4 Discussion and conclusions 
The impact of different physiochemical properties on cell adhesion, migration, 
and proliferation is of great interest for biomedical applications. As mentioned above, 
many different parameters are important in engineering fibroblast function for wound 
healing and medical device implantation, such as the orientation of collagen deposition 
and VEGF production. Thin and well oriented collagen is associated with scar tissue and 
can hinder proper function of implanted devices due to low vascular density.8,26 This is 
also why angiogenesis is instrumental in a successful wound healing or incorporation 
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process.33 Discussed below are some of the ways hydrophobicity and chemical structure 
impact each of these factors, as well as how these cellular functions correlate with one 
another. 
As previously mentioned, the attachment of cells to a surface is necessary for 
proliferation and functionality.37 In the body, this surface is the ECM. In cell culture, 
almost any surface could provide the mechanical stability necessary for cellular 
attachment, ergo differences in cell behavior in response to materials must be due to the 
physiochemical properties.37 A plethora of work has examined how chemical groups and 
physical properties of substrates affect cell behavior.1,31,46–48 Some work has shown 
hydrophobicity to be important in cell proliferation rate, adhesion, and collagen synthesis, 
with peaks in all three around WCAs of 70°.14,49 In this work, hydrophobicity appears to 
impact cell morphology similarly. FF, a measure of morphology also indicates 
adhesion,46 where lower values correspond to spread out morphologies that are better 
adhered to the surfaces. It was found that FF reached a minimum at WCAs between 34° 
and 48°, and again for more hydrophobic surfaces. There was low adhesion for some 
WCAs between 41° and 53° (Figure 3.9). Taken together, this means that very different 
cell adhesion can result from materials with similar WCAs. Hydrophilicity is not the only 
factor influencing cell adhesion since polymers with similar WCAs exhibited similar cell 
morphologies. Other studies have found that positively charged functional groups 
contribute to better cell attachment.46  
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Figure 3.9. Empirically derived correlations between FF and water contact angles. 
During the final stage of the foreign body response to implanted biomaterials 
collagen is deposited to form a fibrous capsule with unidirectional collagen fibers.45,50 
Our results demonstrate that functional groups are able to affect collagen fiber orientation, 
as deposited by fibroblasts. Previously, collagen alignment was attributed to collagen 
molecule interaction with hydrophobic/hydrophilic surfaces,51 to traction forces 
generated by cell movement,52 or to the orientation of the cell layer.53 Our results do not 
show a dependence of collagen orientation on the hydrophobicity of the surface, which 
might be due to the narrow range of hydrophilicity of our samples. Modifications with 
further spread out morphologies have a low degree of collagen orientation. For example, 
PLL and modification 6 exhibited compact cell morphologies with extremely isotropic 
collagen orientation angles, while modifications 8 and 5 deposit collagen with the highest 
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degree of order in our experimental set and show moderate cell spreading. This 
observation may result from initial cell adhesion dictating collagen fiber orientation,53 
suggesting that optimal substrate material interactions with the cell can lead to more 
isotropic collagen orientation.  
 There does not seem to be a complete trend between the speed or persistence of 
cells and the form factor or anisotropy of collagen fibers for the various modified PLRs. 
There are, however, several regions in Figure 3.4B that mildly correlate with the WCAs. 
For example, 1, 2, 13, and PLR all show lower WCAs on the volcano plot (Figure 3.9), 
and have the slowest speeds. In contrast, 3 and 8 are considerably more hydrophobic with 
greater speeds in comparison to other samples. This suggests that the hydrophobicity of a 
material does have a specific impact on the migration of cells, but not one that can be 
easily identifiable trend based on chemical moieties.    
 Another parameter that can be controlled by substrate-cell interactions is VEGF 
secretion. A range between 0.637 ng/106 cells and 3.25 ng/106 cells was found. Using 
materials to control VEGF secretion, rather than or in addition to controlled release, 
remains a largely unexplored avenue. This work clearly demonstrates the ability of 
material interactions with fibroblasts to induce such an effect. Interestingly, modifications 
15 and 6 secrete 2 and 3 times the amount of VEGF compared to the control sample and 
induce very isotropic collagen fiber orientations.  
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Figure 3.10. Correlation coefficients of material parameters and in vivo measured 
collagen D values. 
 
Statistical analysis was performed on in vivo collagen D values in order determine 
the presence of any existing correlations with in vitro results or other material parameters. 
Correlation coefficients and material parameters measured are given in Figure 3.10 and 
Table 3.2, respectively. There are several correlations with the in vivo D values that are 
made apparent with the results of this analysis. The in vivo D values have relatively 
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strong correlations with VEGF secretion (R = -0.451), FF values (R = 0.420), and in vitro 
D values (R = 0.541). As for material parameters, both number of carbons and NPS have 
positive correlations (R = 0.459 and 0.436, respectively) with in vivo D values. These 
correlations are not surprising as the number of carbon atoms, the number of sp3 carbon 
atoms, and the number of carbonyl atoms are all important in determining the 
hydrophobicity of the material. As previously discussed, the hydrophobicity of materials 
plays an important role in cell adhesion leading to varied collagen deposition. 
The data presented here shows important progress in the ability to tune cellular 
responses through biomaterials. This feature was exemplified through the large variation 
of VEGF secretion, collagen fiber orientation, cell migration, and cell morphology. These 
findings demonstrate extremely promising avenues for future work in tissue engineering 
and wound healing. Additionally, this work illustrates the need for additional studies in 
structure/function relationships to build predictive models for rational biomaterial design. 
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CHAPTER 4 
 
THE EFFECT OF CHEMICALLY MODIFIED ALGIANTES ON 
MACROPHAGE PHENOTYPE AND BIOMOLECULE TRANSPORT 
 
Published in the Journal of Biomedical Materials Research Part A, in press (2016) 
MΦ reprogramming has received significant attention in applications such as cancer 
therapeutics and tissue engineering where the host immune response to biomaterials is crucial in 
determining the success or failure of an implanted device. Polymeric systems can potentially be 
used to redirect infiltrating M1 MΦs towards a pro-angiogenic phenotype. This work exploits the 
concept of MΦ reprogramming in the engineering of materials for improving the longevity of 
tissue engineering scaffolds. We have investigated the effect of 13 different chemical 
modifications of alginate on MΦ phenotype. Markers of the M1 response – tumor necrosis 
factor-α (TNF-α) and inducible nitric oxide synthase – and the M2 response – arginase – were 
measured and used to determine the ability of the materials to alter MΦ phenotype. It was found 
that some modifications were able to reduce the pro-inflammatory response of M1 MΦs, others 
appeared to amplify the M2 phenotype, and the results for two materials suggested they were 
able to reprogram a MΦ population from M1 to M2. These findings were supplemented by 
studies done to examine the permselectivity of the materials. Diffusion of TNF-α was completely 
prevented through some of these materials, while up to 84% was found to diffuse through others. 
The diffusion of insulin through the materials was statistically consistent. These results suggest 
that the modification of these materials might alter mass transport in beneficial ways. The ability 
to control polarization of MΦ phenotypes with immunoprotective materials has the potential to 
augment the success of tissue engineering scaffolds. 
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4.1 Introduction 
Type 1 diabetes results from an autoimmune destruction of insulin producing beta cells in 
the pancreas, which leads to an inability to control blood sugar levels.1,2 The 2014 National 
Diabetes Statistics Report states that, as of 2012, 29.1 million Americans, or 9.3% of the 
population, have diabetes.3 The Juvenile Diabetes Research Foundation has reported that as 
many as 3 million Americans have type 1 diabetes.4 Type 1 diabetics currently rely on glucose 
monitoring and exogenous insulin administration to manage their blood sugar.1,2,5 Hypoglycemia 
can result in acute complications including seizures, unconsciousness, brain damage, or death, 
while high blood sugar can cause chronic problems such as fatigue or organ and joint damage.2 
While insulin has served as a viable treatment option, developing implicit closed-loop systems 
may facilitate improved glycemic control and reduced risk for comorbid conditions.1  
Microencapsulation of islets of Langerhans for artificial pancreas transplantation has 
been a focus of research pertaining to diabetes therapeutics for over three decades.6 Among the 
many advantages of this technique are the potential for xenotransplantation, which reduces the 
burden on human donors, and circumvention of an immunosuppressive regimen that is currently 
necessary with transplantations through the Edmonton protocol.7 Even with the advancements 
and clinical trial successes of the last decade, a few obstacles must to be resolved before there 
will be wider spread application of this technology.7–10 Recipients are exhibiting variable graft 
survival with continual reduction of implant function over the five years post-transplant.8,11–13 
Parameters that may be addressed in order to improve upon functional outcome include particle 
size or type, implant site, islet mass, material composition, selective permeability, and insulin 
release kinetics.7,9,10,14–17 A few of these parameters are discussed below and are the focus of this 
work. 
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Alginate, the most commonly used material in islet microencapsulation,9,18–20 is an 
extremely appealing polymer for many applications in biomedical engineering. It is a naturally 
occurring polymer making it relatively inexpensive, has low toxicity and good biocompatibility, 
and is easily gelled under mild conditions with divalent cations, allowing minimal graft 
intolerance to the process of islet encapsulation.21 The structure of alginate is similar to that of 
the extracellular matrix in living tissues, thus increasing biocompatibility.21 Alginate matrices 
provide a relatively inert and moist microenvironment for improved islet survival.21,22 Few 
hydrogels are capable of crosslinking more quickly in mild environments, which allows for rapid 
microcapsule formation and low exposure time of islets to adverse environments.10 
Microcapsules also have high gel porosity. However, this porosity can easily be controlled 
through layer-by-layer deposition of alternating cationic and anionic polymers, which allows for 
controlled diffusion of macromolecules and selective permeability.22–24  
The biocompatibility of alginate remains variable and insufficiently understood.  Many 
aspects of alginate have been studied in an attempt to ascertain and improve upon the 
biocompatibility of this material. Mannuronic acid and guluronic acid content;19,25–27 poly-L-
lysine (PLL), poly-L-orthinine, and polyethylene glycol coatings;18,25,28 molecular weight and 
solution viscosity29–32; purity level;7,25,33,34 variation in crosslinking divalent cation;28 cation-free 
crosslinkers35 as well as size and shape of microcapsules36 are all variations of properties that 
have been thoroughly examined. However, little work has been done to chemically modify the 
surface functionalities of alginate and study the impact this has on cell function and 
permselectivity.37,38  
With the restriction that microcapsules for islet transplantation must be 
immunoprotective, there are some permeability requirements that must be met. The capsules 
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must prevent immune cell-donor cell interactions and protect against the influx of high-
molecular weight effector molecules.39 As both large and small molecules (i.e. transferrin and 
lipid carriers or insulin) must be able diffuse in to and out of the capsule, it can be difficult to 
protect against the immune system.9,20 Thus far, the approach has been to minimize the immune 
response by purifying alginates to remove some pathogen-associated molecular patterns 
(PAMPs).40 Others propose that with the use of xenografts, human cytokines may not have the 
same cytotoxic effects on the encapsulated islets, decreasing the necessity to eliminate cytokine 
diffusion.41 In either case, there is added benefit to eliminating the presence of toxic molecules as 
well as interfering with the diffusion kinetics in to the microcapsule, which some designs have 
been able to accomplish.39,42,43 Some groups have studied the diffusion kinetics of small 
molecules in alginate beads by determining diffusion coefficients, distribution constants, and 
other diffusion characteristics.44,45 Yet, a significant amount of work remains to be done in 
examining the effect that alginate modification has on these parameters.   
Altering the permselectivity and understanding the diffusion kinetics of polymers could 
have benefits in improving the artificial pancreas. These adjustments would prevent or limit the 
transport of cytotoxic molecules while permitting the diffusion of insulin and nutrients. 
However, another option would be to use the material to alter the cytotoxic molecules produced 
by surrounding MΦs.46 MΦs exist in a spectrum of phenotypes with the extremes serving 
specific roles in wound healing and the foreign body response. Monocytes are one of the first 
cells recruited to biomaterial implant sites. They are activated towards the M1, pro-
inflammatory, phenotype by activated lymphocytes (interferon (IFN)-γ) or microbial stimuli 
(lipopolysaccharides (LPS)). This causes them to initiate inflammation, releasing cytotoxic 
molecules like tumor necrosis factor (TNF)-α and reactive nitrogen intermediates (RNIs).47–51 
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M2, pro-angiogenic, MΦs, activated by interleukin (IL)-4 or IL-13 maintain homeostasis and 
promote wound healing with the release of IL-10, vascular endothelial growth factor, and 
transforming growth factor-β.47–51 It has been shown that MΦ phenotype may be influenced by 
physical and chemical microenvironmental stimuli.52–57 Thus, using surface chemistry to alter the 
activation of MΦs at the implant site to favor the M2 polarization may increase the survival of 
encapsulated islets and the success of the implant through increased blood vessel development 
and advantageous tissue repair.  
This work aims to improve upon the effectiveness of islet microencapsulation by 
addressing a few of the issues described above. Ideally, the materials explored here will allow for 
tailoring of the permeability of the microcapsules to improve insulin release kinetics and increase 
immunoisolation. The diffusion of a model protein, cytokine, and insulin are studied here in 
order to better understand the kinetic effects of alginate modification. The use of modified 
alginates in this work is also focused on MΦ reprogramming, working towards a material for 
islet encapsulation that will negate the need to attend to the issues of particle size, implant site, 
and islet mass. 
 
4.2 Materials and Methods 
4.2.1 Materials. All experiments had at least three replicates and error bars that indicate the 
standard deviation. Unmodified alginate served as the positive control for all experiments. All 
materials were purchased from Sigma (St. Louis, MO) and used as received, unless otherwise 
indicated. Fresh deionized (DI) water (Milli-Q Nanopure, Thermo Scientific, Waltham, MA) was 
used throughout this study. 
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Surface modifiers (Figure 4.1) coupled to medium viscosity (~600-900 cps, ~250,000 
MW) alginate (MP Biomedicals, Santa Ana, CA) were selected to represent a variety of common 
chemical functional groups. This included: 3-butenylamine (Santa Cruz Biotechnology, Dallas, 
TX); 1,4-dioxan-2-ylmethanamine; glycidamide; 4-amino-3-penten-2-one; malonamide (Fisher, 
Waltham, MA); tert-butyl 4-aminobutanoate (VWR, Radnor, PA); aminoacetaldehyde dimethyl 
acetal (Alfa Aesar, Ward Hill, MA); 3-aminobenzamide oxime; 2,4-dinitro-phenyl-
hydrozylamine; 1-Amino-4-oxocyclohexanecarboxylic acid ethylene ketal; 2-
aminoethylmethylsulfone hydrochloride; 3-amino-1-propanesulfonic acid (Fisher); and 
aminomethylphosphonic acid (Alfa Aesar).  
 
Figure 4.1. The chemical structures of molecules used in the modification of medium viscosity 
alginate. The functional groups listed here are used as labels in the following figures for 
convenience. 
 
4.2.2 Alginate monomer content. ASTM F2259,58 a standard test method for determining the 
chemical composition and sequence in alginate by proton nuclear magnetic resonance (1H-NMR) 
spectroscopy, was followed for the quantification of mannuronic acid and guluronic acid content 
in the alginate used herein. Briefly, the samples were acid hydrolyzed in HCl to depolymerize 
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the sample, and then freeze-dried twice to reduce water content. Triethylenetetraminehexaccetic 
acid (TTHA, Alfa Aesar) was added to chelate the divalent cations that interact with alginate. 
DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) was used to calibrate the acquisition. With the 
parameters outlined in the standard, the spectrum was acquired with a Bruker Avance III-600 
Solution NMR Spectrometer. Numeric integration of the relevant 1H-NMR signals was 
performed in MNova. The guluronic acid content and the mannuronic acid content were 
determined from these integrated signal intensities. The number average block lengths were 
calculated as in Grasdalen et al. 1981.59 
4.2.3 Alginate modification. The thirteen different surface modifiers were individually coupled to 
alginate via an 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Oakwood Chemical, 
West Columbia, SC) and N-hydroxysuccinimide (NHS, Thermo Scientific, Waltham, MA) 
coupling reaction (Figure 4.2). Briefly, 150 mL of a 1 mg/mL solution of alginate in conjugation 
buffer (100 mM 2-(N-morpholino)ethanesulfonic acid (MES, Alfa Aesar), 500 mM NaCl 
(Fisher), at pH 6.0) were placed in glass bottles with 100 molar equivalents of surface modifier. 
120 mg of EDC and 180 mg of NHS were added to the vial and the reaction was allowed to stir 
for 4 h at room temperature. To quench the reaction, 150 μL of hydroxylamine hydrochloride 
(RICCA Chemical Company, Arlington, TX) were added to each vial. The polymers were then 
dialyzed in DI water for 48 h, replacing the water after 24 h, to remove EDC and unreacted 
surface modifiers, and subsequently lyophilized (4.5 L, Labconco, Kansas city, MO). The 
modified alginates was re-suspended in DI water at 1.25% and stored at 4°C. 
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Figure 4.2. Reaction scheme for the modification of alginate with amine containing molecules 
by EDC/NHS carbodiimide chemistry. 
 
4.2.4 NMR. In order to ensure that the reaction proceeded, NMR was used to characterize the 
reaction products. The modified alginate samples were dissolved in D2O and lyophilized three 
times to replace all protons with deuterium before ~12.5mg of polymer were dissolved a final 
time in 600μL of D2O. The 1H spectra were recorded on a Bruker Avance III Spectrometer at 
70°C, a sweep width of 6602.1 Hz, a 90° pulse, and an acquisition time of 2.48 s. 128 repetitive 
scans with 64k points were acquired and the data were processed in MNova with 128k points, 
zero filling, and exponential line broadening of 1.0 Hz.60 Sixteen repetitive scans were acquired 
at room temperature for the 1H spectra of the surface modifiers with all other parameters the 
same as above. Representative combined spectra of unmodified alginate, modified alginate and 
monomer are given in Figure 4.3. 
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Figure 4.3. Representative comparisons of NMR spectra collected of surface modifiers, 
modified alginates, and unmodified alginate (A-C). 
 
A 
B 
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Figure 4.3 continued 
4.2.5 Elemental analysis. Elemental analysis results for %C, %H, and %N were acquired using a 
PE 2100 Series II combustion analyzer (Perkin Elmer Inc., Waltham, MA). Measurements were 
performed in triplicate with an acetanilide calibration standard, combustion and reduction 
temperatures of 925 oC and 640 oC, respectively, and a resulting accuracy of +/- 0.3% for each 
element. All standards and reagents are from Perkin Elmer and/or Elementar America's Inc. 
4.2.6 Water contact angle. The captive air bubble method was used since all the samples were 
very hydrophilic. Microscope slides were first coated with PLL in order to have a positively 
charged surface that the alginate would more readily adhere to in an even coating. Microscope 
slides were then coated with each modified and unmodified alginate by crosslinking with SrCl2 
(Alfa Aesar) before the slide was inverted over a container of water. An air bubble (100 μl) was 
then distributed under the microscope slide and imaged with a digital camera (Canon EOS Rebel 
T3i, Canon, Melville, NY). This process was repeated to obtain five replicates. The angle 
C 
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between the glass and the bubble were measured using ImageJ (NIH, Bethesda, MD) software 
and subtracted from 180° to determine the final water contact angle.  
4.2.7 pKa. 1.0 M HCl was used to reduce the pH of the 1.5 mg/mL solutions of each modified 
and unmodified alginate to ~1.8. Varied concentrations of NaOH were added to the solutions to 
obtain titration curves and determine the pKa’s of the alginates.  
4.2.8 DSC. Differential scanning calorimetry (DSC) measurements were made on Perkin Elmer 
Pyris 1 model (PerkinElmer Inc., Waltham, MA). 5-10 mg of lyophilized samples were sealed 
into standard aluminum DSC pans. Melting temperatures for each sample were determined using 
a ramp rate of 20°C/min and scanning from 0°C to 300°C.     
4.2.9 Compression modulus. Manual compression tests were performed on modified and 
unmodified alginate pegs that were roughly 10x10x4 mm3. A peg was placed between two 
microscope slides and various weights were added to the top microscope slide. An image was 
taken after each weight was added.  The changing distance between the two slides was measured 
in ImageJ. 
4.2.10 Particle synthesis. Alginate microparticles were prepared by electrostatic droplet 
generation. Briefly, a medium viscosity alginate solution was prepared at 1.25% in DI water. 
Fine, spherical droplets were formed by extrusion of the polymer through a 26 gauge stainless 
steel needle (Hamilton Co., Reno, NV) using a NE-300 Just Infusion syringe pump (Kats 
Scientific, Grand Prairie, TX) and a 10 mL plastic syringe. A voltage of 2 kV was applied with a 
positively charged needle and a grounded crosslinking solution. Alginate particles were 
crosslinked in 0.2 M SrCl2. The potential difference was controlled by a high-voltage dc unit 
(Model 30R, 3B Scientific, Tucker, GA). The distance between the needle tip and the surface of 
the crosslinking solution was 4 cm and the flow rate of polymer solution was 6 mL/min. These 
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parameters were determined for empty microparticles before being employed in encapsulation of 
cells for testing glucose-responsiveness or modified polystyrene particles for diffusion tests. 
Samples of microparticles were measured with a Zeiss microscope (Axio Vert.A1, Jena, 
Germany). The average diameter and standard deviations were then calculated from the 
measured data. Fluorescein (FC) conjugated PLL and alginate labeled with rhodamine were used 
for layer-by-layer deposition in order to ensure the effectiveness of the protocol for later 
experimental use Figure 4.4. 
 
Figure 4.4. Alginate microparticles (A) unmodified (B) layered with fluorescein labeled PLL (C) 
layered with unmodified PLL and rhodamine labeled alginate (D) layered with fluorescein 
labeled PLL and rhodamine labeled alginate.  
 
4.2.11 Cell culture. RAW 264.7 cells (American Type Cell Collection, ATCC, Manassas, VA) 
were cultured in complete media (CM, Dulbecco’s modified Eagle’s medium (DMEM, 
Mediatech, Inc., Manassas, VA) supplemented with 10% fetal bovine serum (FBS, Mediatech, 
Inc.), 100 U/mL penicillin, and 100 μg/mL streptomycin) at 37°C in 5% CO2. Approximately 
every three days, the cells were passaged to ensure proper cell growth using a cell scraper to 
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detach cells and subculturing at 6.7 × 103 cells/cm2. INS-1 cells (AddexBio, San Diego, CA) 
were cultured in RPMI-1640 media (Mediatech, Inc.) supplemented with 10% FBS, 100 U/mL 
penicillin, 100 μg/mL streptomycin, 10 mM HEPES (Life Technologies, Grand Island, NY), 1 
mM sodium pyruvate (Life Technologies), and 0.05mM 2-mercaptoethanol (Life Technologies) 
at 37°C in 5% CO2. The cells were passaged every seven days through 0.025% trypsin-EDTA 
(Mediatech, Inc.) detachment and subcultured at 6.7 × 104 cells/cm2. 
4.2.12 Cell viability of adherent cells. During passaging of RAW 264.7 cells, 24-well plates 
(KSE Scientific, Durham, NC) were coated with 0.05% solutions of PLL samples by incubating 
200 µL/well at 37°C for one hour and washing twice with sterile PBS. For the coatings, ~100 µL 
of each modified alginate were used to coat the bottom of a well, any excess alginate was 
removed, and 500 µL of 0.2 M SrCl2 were added to crosslink the coating. The crosslinking 
solution was left in the wells for approximately 5 minutes before it was aspirated. The plate was 
then seeded at 125,000 cells/cm2 in 500 µL of media per well with 25 ng/ml IL-4 (eBioscience 
Inc., San Diego, CA) or 5 μg/ml LPS and incubated for 48h before proceeding with an MTT 
viability assay. A control set of experiments was not activated and is referred to as naïve cells. 50 
µL of an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Research 
Products International Corp., Mt Prospect, IL) solution (5 mg/mL in DI water) were added to 
each well before the plate was incubated for 2 h at 37°C. After incubation, 1mL of dimethyl 
sulfoxide (DMSO, Fisher) was added to each well to dissolve the purple fomazan crystals. The 
absorbance was read at 540 nm with a reference at 690 nm with a BioTek Synergy HT 
Multidetection Microplate Reader (BioTek, Winooski, VT). Positive controls of cells in the 
absence of any alginate were used to normalize all samples. Negative controls containing media 
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and modified alginates were also done. All experiments were done in quadruplicate. Results 
were expressed as the mean normalized to the positive control. 
4.2.13 Cell viability of encapsulated cells. RAW 264.7 cells were seeded directly on PLL coated 
plate well with 25 ng/ml IL-4 (eBioscience Inc.) or 5 μg/ml LPS and allowed to attach for 24 h. 
Alginate coatings were made as previously described. These coatings, along with those in the 
previous section, were made with the modified alginate in order to insure contact between the 
MΦs and the material. This allows for investigation of the material’s ability to alter MΦ 
phenotype. After 48 h, the supernatant was removed from each well to be assayed.  500 µL of 
media were then added to each well along with 50 µL of 5 mg/ml MTT. After the 2 h incubation, 
425 µL of media were removed from each well and 500 µL of DMSO were added. Data 
collection and data reduction remained the same as above.  
4.2.14 TNF-α ELISA. Secretion of TNF-α from the encapsulated cell experiments was 
determined using commercially available enzyme linked immunosorbant assay (ELISA) kits 
(eBioscience, Inc., San Diego, CA) and performed as described by the manufacturer.     
4.2.15 Urea assay. After the 48 h incubation with encapsulated cells, wells were washed with 
400 µL of PBS. 100 µL of cell lysis buffer (150 µL protease inhibitor cocktail (Amresco, Solon, 
OH) and 15 µL Triton X-100 (Acros Organics) filled to 15 mL with DI water) were added to 
each well and the plates were placed on ice for 10 min. 25 µL of the lysate were transferred from 
each well to a 96 well plate along with 25 µL of a 10 mM MnCl2 (Fisher) and 50 mM Tris 
solution (Fisher).  The plate was incubated at 55oC for 10 minutes. 50 µL of 1 M arginine (pH 
9.7) was then added to each well before incubating at 37oC for 20 h. Arginase activity was 
measured through the conversion of arginine to urea by adding 200 µL of a 1:2 ratio of solution 
1 (1.2 g o-phthaldialdehyde (Alfa Aesar, Ward Hill, MA), 1 L H2O, and 500 µL HCl (Fisher, 
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Pittsburgh, PA)) and solution 2 (0.6 g N-(napthyhl)ethylenediamine dihydrochloride (Acros 
Organics), 5 g boric acid (Fisher, Pittsburgh, PA ), 800 mL H2O, 111 mL sulfuric acid (Fisher, 
Pittsburgh, PA), diluted to 1 L with H2O).61 The plate was read at 520 nm with a reference at 630 
nm. 
4.2.16 Griess reagent assay. Nitrite production in supernatant from encapsulated cell 
experiments was measured. Briefly, 1 mM NaNO2 was diluted to 100 μM in DI water and a 
standard curve was created using two-fold dilutions.  150 µL of sample or standard were added 
to each well along with 130 µL of DI water and 20 µL of Griess reagent. The plate was 
incubated for up to 20 minutes and is read at 448 nm with reference of 690 nm.  
4.2.17 Cell staining for fluorescent imaging. Raw 264.7 MΦs were cultured on glass coverslips 
that had been cleaned for 2 h in 200 mL ethanol, 50 g NaOH, and 300 mL DI water before being 
rinsed vigorously for 10 min with DI water. The coverslips were placed in 35 × 10 mm Petri 
dishes (Corning, Tewksbury, MA) and coated with PLL as described above. Petri dishes were 
seeded at 100,000 cells/cm2. After 24 h, the Petri dishes were coated with modified or 
unmodified alginate using the same protocol as for the adherent and encapsulated cell 
experiments. 48 h after coating, the media was removed and 2 mL of a 55 mM sodium citrate, 30 
mM EDTA, 150 mM NaCl solution were added to the petri dishes, and they were placed on a 
plate shaker (Sea Star® Digital Orbital Shaker) at 120 rpm for 10 min to dissolve the alginate 
coatings. Next, the coverslips were fixed using methanol at -20°C for 7 minutes. After rinsing 
twice with ice cold PBS, the samples were blocked with 1% BSA (bovine serum albumin) and 
0.05% Tween-20 in PBS and incubated at rt for 30 min. The coverslips were incubated with 
primary antibodies for CD11c (ab33483, Abcam, Cambridge, UK) and CD206 (ab64693, 
Abcam, Cambridge, UK) at 4°C overnight. After washing 3 times with 1X phosphate buffered 
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saline 0.05% Tween-20 (PBST) for 5 min, the coverslips were incubated secondary antibodies 
(ab173003, Abcam, Cambridge, UK and sc-3925, Santa Cruz Biotechnology, Dallas, TX) for 1 h 
at rt in the dark. They were washed 3 times with PBS for 5 min in the dark, then incubated with 
0.1 μg/mL DAPI (4’,6-diamidino-2-phenylindole, U0031, Abnova, Walnut, CA) for 5 minutes 
and rinsed with PBS. Then, the samples were mounted on microscope slides with 30 μL of 
glycerin jelly, sealed with clear nail polish, and imaged with an EVOS® FLoid® Imaging 
Station (Life Technologies, Grand Island, NY) using the red channel (excitation/emission 
586/646 nm) blue channel (390/446 nm) and the green channel (482/532 nm). 
4.2.18 Glucose challenge. During passaging, INS-1 cells were encapsulated in unmodified 
alginate at 1 x 106 cells/mL of alginate using the same parameters as described above for 
electrostatic droplet generation. Particles were then layered by alternating PLL and modified 
alginates, so that electrostatic interactions of the cationic and anionic layers, respectively, would 
allow for uniform coating of the particles. The final layer structure of the particles was 
unmodified alginate-PLL-modified alginate-PLL-modified alginate. This number of layers was 
determined by diffusion experiments performed in this lab to be a number that would give a 
detectable difference between samples. Incubating a 0.05% solution of the material with the 
particles for 5 minutes formed each layer. Samples were washed twice with PBS before 
continuing to the next layer. For this experiment, cells were first encapsulated in unmodified 
alginate because the modification of the alginate was expected to change the ability of the 
modified materials to crosslink, which in turn affects the pore size of the material. In this 
application, the goal was to determine what impact of materials properties such as, charge, 
hydrophobicity and size have on biomolecule transport. They were then distributed in to a 24 
well plate at 500,000 cells per well or 1 mL of a 50% particle solution. After 24 h, the 
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supernatant was aspirated from each well, and a glucose challenge was performed.62  500 µL of 
Krebs-Ringer-Bicarbonate-HEPES buffer (KRBH, 134 mN NaCl, 4.7 mM KCl (Fisher), 1.2 mM 
KH2PO4 (Fisher), 1.2 mM MgSO4.7H20 (Fisher), 1 mM CaCl2.H2O (Acros Organics), 0.5% 
bovine serum albumin, 10 mM HEPES (Fisher)) was added to each well to wash the particles. 
After aspirating the wash buffer, 1mL of low glucose KRBH (2.8 mM glucose (Fisher)), was 
added to each well and incubated for 1 h. This pre-incubation solution was aspirated, the 
particles were washed twice with 500 µL of KRBH, and then incubated for 1 h with high glucose 
KRBH (16.5 mM glucose). This supernatant was collected for further analysis. The particles 
were then washed twice with 500 µL of KRBH before a 1 h incubation with low glucose KRBH. 
Supernatant was again collected for later assays and the particles were transferred in DI water to 
5 mL tubes for DNA quantification. 
4.2.19 Insulin ELISA. Insulin secretion by INS-1 cells with exposure to both high and low 
glucose was measured by performing insulin ELISAs on the supernatants collected in the 
experiment above. This was done using commercially available immunoassay kits (ALPCO, 
Salem, NH) and performed as described by the manufacturer.     
4.2.20 DNA quantification. The amount of DNA in each sample of the glucose challenge was 
quantified using a CyQuant kit (Life Technologies). The DI water that the particles were stored 
in was aspirated and the tubes were filled to 2.5 mL with a 55 mM sodium citrate, 30 mM 
EDTA, and 150 mM NaCl solution. The tubes were sonicated for 20 minutes and stored at -80°C 
overnight. Samples were thawed and sonicated again for 10 minutes before 400 µL of an RNase 
solution (30 µL RNase (BP2539100, Fisher Bioreagents) (20 mg/mL) in 10 mL DI water) were 
added to each tube and incubated at room temperature for 1 h. The standard curve included DNA 
concentrations of 200, 150, 100, 67, 50, 25 and 5 ng/mL using the DNA standard provided in 
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half DI water and half lysis solution (1 mL lysis buffer included in the kit, 100 µL dye included 
in the kit, and 9 mL DI water). 25µL of each sample along with 175 µL of lysis solution were 
placed in individual wells of a black, 96-well plate and at room temperature for 5 minutes in the 
dark before reading (excitation 480, emission 520).  
4.2.21 Polystyrene particle labeling. 10mg of amino polystyrene (PS) particles (Spherotech, Inc, 
Lake Forest, IL) were modified with 2 mg of bovine IgG (55267, MP Biomedicals, Santa Ana, 
CA), human IgG (I4506, Sigma, St. Louis, MO), or mouse IgG (Thermo Scientific) in PBS using 
20 mg of EDC. 
4.2.22 BSA diffusion. Diffusion of unwanted proteins into the modified alginate particles was 
measured using the model protein bovine serum albumin (BSA, CHEM-IMPEX INT’L INC., 
Wood Dale, IL). Bovine IgG labeled PS particles were suspended at 1.2 mg/mL in unmodified 
alginate and used to make particles by electrostatic droplet generation as described above. The 
resulting particles were layered as previously described. ~200 of these particles were incubated 
with 2 mL of 0.125 mg/mL Cy5.5 (Lumiprobe) labeled BSA. Absorbance readings of the 
supernatant were collected at 1, 2, 3, 4, 6, 8, 10, 24, 32, and 48 h followed by readings every 24 h 
for 9 days.  
4.2.23 Insulin diffusion. The amount of insulin able to diffuse in to the particles was measured by 
exposing human IgG labeled PS particles in layered alginate particles to Cy5.5 labeled human 
insulin. Readings of the supernatant were collected at the same times as with the BSA diffusion 
for 6 days.  
4.2.24 TNF-α diffusion. Diffusion of the cytotoxic molecule TNF-α, was measured by 
encapsulating mouse IgG labeled PS particles in layered alginate particles. ~200 particles were 
incubated with 2 mL of supernatent collected from LPS activated RAW 264.7 cells. After four 
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days, the supernatant was collected and compared to the original serum by TNF-α ELISA to 
determine the amount of TNF-α that had diffused in to the particles.  
 
4.3 Results 
4.3.1 Modification and characterization. The chemical composition of the unmodified, medium 
viscosity alginate was determined from the integrated intensities as indicated in the ASTM 
standard. The mannuronic acid content was determined to be 56% ± 1%. In addition, the number 
average block lengths were found to be NG>1= 6.7 ± 0.7, NG= 2.3 ± 0.1 and NM= 2.9 ± 0.1. After 
modification of alginate with the molecules shown in Figure 4.1, the materials synthesized were 
characterized for their hydrophobicity, pKa, melting temperature, and compression modulus, 
which are shown in Table 4.1. Ranging from 40° to 61° the WCAs of the modified alginates 
suggest that all materials are relatively hydrophilic. Some modified alginates had two pKa’s 
while others only showed one. The single pKa’s fell between 7.18 and 7.51. For materials that 
exhibited two pKa’s, the first was around pH 5 and the second between 8.38 and 8.55. The pKa’s 
of unmodified alginate are typically found to be 3.38 and 3.65, the pka’s of mannuronic and 
guluronic acid, respectively.63,64 Melting points were found using DSC. All materials melt 
around 130°C with a range of 118°C -145°C. These values seem to correlate well with the DSC 
thermograms of unmodified alginate in previous work.65–68 The compressive modulus of 
modified alginates ranges from 8.75 kPa to 15.15 kPa, which compare to literature values of 
~10kPa for unmodified alginate.69,70 Elemental analysis suggested modification with all modified 
samples being statistically different in %N from unmodified alginate, no statistical difference in 
%H between modified and unmodified samples, and only some samples, showing different %C 
from unmodified alginate (Table 4.2). 
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Table 4.1. Characterization of modified alginates. Water contact angles, pKa’s, melting points, 
compression moduli, and insulin partition coefficients were measured. Errors associated with 
WCAs represent standard deviation between the five replicates measured. All melting point 
measurements have an error of ± 5°C. Compression moduli are given ± standard deviation. 
Errors of the insulin partition coefficients are given as the standard deviation. 
Modification WCA (º) pKa1 pKa2 
Melting 
Point (°C) 
Compression 
modulus (kPa) 
Partition 
coefficient 
Acetal 51.896 ± 1.805 5.18 8.52 125.75 10.934 ± 0.144 0.646 ± 0.066 
Alkene 39.957 ± 1.005 7.43 -- 128.03 10.556 ± 0.255 0.659 ± 0.063 
Amide 57.72 ± 0.995 5.15 8.42 133.82 11.215 ± 0.501 0.612 ± 0.057 
Epoxide 51.958 ± 1.114 7.18 -- 145.34 10.206 ± 0.255 0.666 ± 0.061 
Ester 49.705 ± 1.022 7.30 -- 131.25 13.096 ± 0.338 0.643 ± 0.054 
Ether 53.622 ± 1.19 7.46 -- 128.87 10.799 ± 0.706 0.656 ± 0.060 
Ketal 52.45 ± 0.878 4.95 8.43 118.34 11.794 ± 0.75 0.631 ± 0.068 
Ketone 47.785 ± 0.693 7.24 -- 133.74 11.492 ± 0.652 0.668 ± 0.075 
Nitro 58.818 ± 1.046 7.33 -- 131.08 14.525 ± 1.144 0.620 ± 0.074 
Oxime 61.044 ± 1.071 7.51 -- 137.89 15.115 ± 0.56 0.637 ± 0.067 
Phosphonic 
acid 59.81 ± 2.258 5.10 8.44 132.21 8.75 ± 0.788 0.630 ± 0.056 
Sulfone 58.16 ± 1.801 5.04 8.38 131.28 10.646 ± 0.316 0.613 ± 0.061 
Sulfonic acid 59.179 ± 1.917 5.03 8.55 133.44 9.964 ± 0.273 0.627 ± 0.059 
Unmodified 
alginate 54.091 ± 2.001 7.42 -- 131.08 15.149 ± 0.871 0.631 ± 0.058 
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Table 4.2. Elemental analysis results for modified and unmodified alginates. %C, %H, and %N 
are given ± standard deviations. (*) indicates p<0.05 compared with unmodified alginate by pairwise comparison. 
Modification %C %H %N 
Acetal 32.19 ± 0.13 4.40 ± 0.09 1.07 ± 0.08* 
Alkene 25.61 ± 0.62* 3.81 ± 0.11 1.56 ± 0.06* 
Amide 31.65 ± 0.21 4.56 ± 0.13 1.59 ± 0.06* 
Epoxide 26.57 ± 0.26* 3.97 ± 0.17 1.69 ± 0.05* 
Ester 31.45 ± 0.10* 4.53 ± 0.09 1.63 ± 0.01* 
Ether 30.80 ± 0.38* 4.26 ± 0.20 0.59 ± 0.06* 
Ketal 28.70 ± 0.40* 3.96 ± 0.12 0.95 ± 0.05* 
Ketone 26.55 ± 0.26* 3.91 ± 0.21 1.69 ± 0.13* 
Nitro 33.0 ± 0.40 4.39 ± 0.23 0.71 ± 0.03* 
Oxime 29.19 ± 0.29* 4.16 ± 0.08 1.22 ± 0.03* 
Phosphonic 
acid 32.26 ± 0.10 4.12 ± 0.10 0.43 ± 0.01* 
Sulfone 29.05 ± 0.06* 4.25± 0.06 1.39 ± 0.17* 
Sulfonic acid 32.43 ± 0.92 4.69 ± 0.29 1.68 ± 0.00* 
Unmodified 
alginate 32.73 ± 0.20 4.26 ± 0.13 0.04 ± 0.01 
 
4.3.2 Particle fabrication. Microparticles fabricated by electrostatic droplet generation were 
measured with a Zeiss microscope. The average diameter of the particles was 685.15 ± 14.20 
μm. A representative image of unmodified alginate particles is given in Figure 4.5.  
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Figure 4.5. Representative image of unmodified alginate particles synthesized by electrostatic 
droplet generation. The average size of the particles was measured to be 685.15 ± 14.20 μm. 
Scale bar = 600 μm. 
 
4.3.3 Cell viability. Materials used for islet microencapsulation must be cytocompatible in order 
to allow for survival of both the islet cells and those cells surrounding the particles at the implant 
site. Cytotoxicity of the modified alginates was measured using an MTT assay with MΦs, and 
the viability of cells exposed to modified alginate was expressed as a percentage of cell viability 
on PLL coated tissue culture plastic. Both cells encapsulated under and adherent on top of 
modified alginate coatings exhibited upwards of 70% viability suggesting minimal cytotoxicity 
(Figure 4.6 A and B).  
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Figure 4.6. Cell viability of LPS activated, IL4 activated, and naïve RAW 264.7 macrophages 
(A) adherent to and (B) encapsulated under modified and unmodified alginate layers. Error bars 
represent standard deviation. 
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4.3.4 TNF-α ELISA. Production of the cytotoxic cytokine TNF-α by cells exposed to modified 
alginates was measured and reported in Figure 4.7A. Connecting letters reports for each 
macrophage activation of been included in Table 4.3. Several modifications of alginate were able 
to significantly decrease the amount of TNF-α produced in comparison to unmodified alginate 
for all MΦ phenotypes. These modified alginates include ester, ketone, nitro, oxime, phosphonic 
acid, sulfone, and sulfonic acid. For acetal and ketal, the amount of TNF-α was only reduced for 
IL-4 activated and naïve MΦs. Ether and amide modified alginates caused a decrease in TNF-α 
expression for LPS and IL-4 activated MΦs but not naïve cells. Modifications alkene and 
epoxide only showed a decrease for IL4 MΦs, and naïve MΦs had increased TNF-α expression 
when exposed to epoxide-modified alginate. TNF-α production by IL-4 activated MΦs ranged 
from 0.6 to 9.6 ng/106 cells with 18.9 ng/106 cells produced under unmodified alginate. Naïve 
MΦs produced a range of TNF-α that spanned 3.8 to 55.4 ng/106 cells. TNF-α produced by LPS 
activated cells spanned a similar range of 3.7 to 38.1 ng/106 cells, however on a sample-to-
sample basis, the amount of cytokine produced was most often highest for LPS activated MΦs. 
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Figure 4.7. (A) TNF-α expressed by LPS activated, IL-4 activated, and naïve RAW 264.7 
macrophages encapsulated under modified and unmodified alginate layers. Error bars represent 
standard deviation. (*) indicates p<0.05 compared with unmodified alginate for the same 
activation by pairwise comparison. All IL-4 samples are statistically different than IL-4 activated 
cells with unmodified alginate. (B) Arginase:iNOS ratios for all macrophage phenotypes 
encapsulated under modified and unmodified alginate layers. Error bars represent standard error 
of the mean.  
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Table 4.3-4.5. Connecting letters reports for TNF-α production by each macrophage phenotype. 
Levels not connected by the same letter are significantly different (p<0.05). 
 
4.3. TNF-α (LPS)     
Acetal A    
Alkene A B   
Amide   C D 
Epoxide A    
Ester   C  
Ether   C D 
Ketal A    
Ketone   C D 
Nitro   C D 
Oxime   C D 
Phosphonic Acid    D 
Sulfone   C D 
Sulfonic Acid    D 
Unmodified alginate A B   
  
4.4. TNF-α (NA)       
Acetal     E F 
Alkene   C    
Amide  B     
Epoxide A      
Ester    D E F 
Ether A      
Ketal    D   
Ketone      F 
Nitro    D E  
Oxime     E F 
Phosphonic Acid     E F 
Sulfone     E F 
Sulfonic Acid      F 
Unmodified alginate A B C    
 
 
 
4.5. TNF-α (IL4)         
Acetal        H 
Alkene      F G  
Amide  B       
Epoxide     E F G  
Ester   C D E    
Ether      F G  
Ketal  B C D     
Ketone    D E F G  
Nitro  B C      
Oxime    D E F   
Phosphonic Acid    D E F   
Sulfone    D E F   
Sulfonic Acid       G H 
Unmodified alginate A        
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4.3.5 Arginase/iNOS: Arginase activity was determined for encapsulated MΦs by exposing cell 
lysate to arginine and quantifying the urea produced. Increased levels of arginase are associated 
with wound healing and are a marker of M2 MΦs. Nitrites are the stable form of NO and were 
quantified through a Griess reagent assay. The production of NO results from RNIs by increased 
levels of inducible nitric oxide synthase (iNOS) and indicates an M1 phenotype. In order to 
report the results from these assays, the amount of urea was divided by the amount of nitrite in 
corresponding samples. This data is given as arginase:iNOS in Figure 4.7B. Absolute values for 
urea and nitrite production are provided in Figure 4.8 with corresponding connecting letters 
reports given in Tables 4.6-4.11. Values here range from 4.71 mg/μmol with acetal to 17.93 
mg/μmol with phosphonic acid for naïve MΦs. LPS activated MΦs exhibited a range of 4.35 
mg/μmol with ester and oxime functionalities to 14.86 with ketal. Finally, a range of 6.00-15.48 
mg/μmol was measured for IL4 activated MΦs. By dividing these two values, the data illustrates 
the extent of polarization towards an M2 phenotype (high values) or towards an M1 phenotype 
(low values). High values result from alkene, epoxide and phosphonic acid. Low values result 
from acetal and unmodified alginates.  
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Figure 4.8. Absolute values for urea (A) and nitrite (B) production for all macrophage 
phenotypes encapsulated under modified and unmodified alginate layers. Error bars represent 
standard deviation. (*) indicates p<0.05 compared with unmodified alginate for the same 
activation by pairwise comparison. 
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Table 4.6-4.8. Connecting letters reports for urea production by each macrophage phenotype. 
Levels not connected by the same letter are significantly different (p<0.05). 
 
4.6. Urea  (LPS)      
Acetal  B C D  
Alkene    D E 
Amide  B C   
Epoxide A     
Ester     E 
Ether    D E 
Ketal A     
Ketone  B C D E 
Nitro A     
Oxime     E 
Phosphonic Acid  B    
Sulfone  B    
Sulfonic Acid  B C   
Unmodified alginate   C D E 
  
4.7. Urea  (IL4)     
Acetal    D 
Alkene    D 
Amide A    
Epoxide    D 
Ester A B   
Ether A    
Ketal    D 
Ketone    D 
Nitro    D 
Oxime  B   
Phosphonic Acid   C  
Sulfone    D 
Sulfonic Acid A    
Unmodified alginate    D 
 
4.8. Urea  (NA)          
Acetal       G H I 
Alkene   C D E     
Amide    D E F    
Epoxide     E F G   
Ester  B C       
Ether   C D      
Ketal     E F G H  
Ketone     E F G H  
Nitro        H I 
Oxime   C       
Phosphonic Acid A         
Sulfone         I 
Sulfonic Acid  B        
Unmodified alginate      F G H I 
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Table 4.9-4.11. Connecting letters reports for nitrite production by each macrophage phenotype. 
Levels not connected by the same letter are significantly different (p<0.05). 
 
4.9. Nitrite (LPS)     
Acetal A B C  
Alkene A B   
Amide A B C  
Epoxide A B C  
Ester A B   
Ether A B   
Ketal A B C  
Ketone A    
Nitro   C D 
Oxime A B C  
Phosphonic Acid    D 
Sulfone  B C  
Sulfonic Acid  B C  
Unmodified alginate    D 
  
 
4.10. Nitrite  (IL4) 
Acetal    D E    
Alkene        H 
Amide A        
Epoxide       G H 
Ester   C      
Ether A B       
Ketal      F G  
Ketone      F G  
Nitro      F G  
Oxime    D     
Phosphonic Acid     E F   
Sulfone       G  
Sulfonic Acid  B C      
Unmodified alginate       G  
 
4.11. Nitrite  (NA)         
Acetal     E    
Alkene      F G  
Amide   C D     
Epoxide       G H 
Ester  B       
Ether  B C      
Ketal      F G  
Ketone       G H 
Nitro        H 
Oxime A        
Phosphonic Acid     E    
Sulfone       G H 
Sulfonic Acid    D     
Unmodified alginate      F   
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4.3.6 Cell staining for fluorescent imaging. Immunocytochemistry (ICC) fluorescent 
staining was used to identify the MΦ phenotypes resulting from culturing under modified 
alginate surfaces. A CD11c marker was used to identify M1 MΦs and a CD206 marker 
was used to indicate an M2 MΦ phenotype. Representative images are shown in Figure 
4.9, with additional images given in Figure 4.10. The images shown in Figure 4.9 were 
chosen as they give examples of materials that seem to qualitatively indicate both no 
impact on MΦ phenotype (ether, Figure 4.9A) and MΦ reprogramming (amide, Figure 
4.9B). Figure 4.9C also shows control images for each activation in order to demonstrate 
the ability of this staining procedure to identify each phenotype by the aforementioned 
markers.  
4.3.6 Insulin production. After encapsulating INS-1 cells in unmodified alginate and 
layering the microparticles with modified alginates and PLL, the cells were subjected to a 
glucose challenge. Insulin produced and released from the particles in response to this 
glucose challenge was measured by performing insulin ELISAs on the supernatant 
collected. In order to better quantify the insulin production, CyQuant assays were 
performed on the encapsulated cells to determine the amount of DNA, and effectively, 
the number of cells present in each sample. The amount of insulin produced was divided 
by the amount of DNA and reported in Figure 4.11. Connecting letters reports for insulin 
produced in response to both 16.5mM and 2.8mM glucose solutions are provided in 
Table 4.12 and 4.13. Values were fairly consistent for all modifications: 10-20 pg 
insulin/ng DNA for high glucose solutions and 2-9 pg insulin/ng DNA for low glucose 
solutions. Exceptions for high glucose solutions include amide (24.18 pg insulin/ng 
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DNA) and sulfone (7.66 pg insulin/ng DNA); for low glucose solutions, ketal allows 
11.72 pg insulin/ng DNA through the particles. 
 
 
Figure 4.9. Representative fluorescent staining images. Various macrophage phenotypes 
cultured with (A) ether and (B) amide modified alginates. (C) Control staining images for 
each macrophage phenotype cultured on glass cover slips. Scale bars represent 50µm. 
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Figure 4.10. Immunocytochemistry fluorescent staining images. (A) IL4 activated 
macrophages (B) LPS activated macrophages (C) non-activated macrophages. Cells were 
stained with fluorescently labeled CD206 (red) and CD11c (green) markers as well as 
DAPI (blue).  
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Figure 4.10 continued 
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Figure 4.10 continued 
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Figure 4.11. Insulin release data for INS-1 cells encapsulated in unmodified alginate 
particles layered with modified alginate and PLL. Error bars represent standard deviation. 
 
Table 4.12 and 4.13. Connecting letters reports for insulin in response to high and low 
glucose concentrations. Levels not connected by the same letter are significant different 
(p<0.05).
 
4.12. 16.5mM 
glucose 
    
Acetal  B C D 
Alkene A B C  
Amide A    
Epoxide A B   
Ester A B C  
Ether  B C D 
Ketal A B C D 
Ketone  B C D 
Nitro  B C D 
Oxime A B C D 
Phosphonic 
Acid 
  C D 
Sulfone    D 
Sulfonic Acid  B C D 
Unmodified 
alginate 
 B C D 
 
4.13. 2.8mM  
glucose 
    
Acetal  B C D 
Alkene  B C D 
Amide    D 
Epoxide    D 
Ester  B C D 
Ether   C D 
Ketal A    
Ketone  B C D 
Nitro  B C D 
Oxime A B   
Phosphonic 
Acid 
  C D 
Sulfone  B C D 
Sulfonic Acid  B C D 
Unmodified 
alginate 
A B C  
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4.3.7 BSA diffusion. Cy 5.5 labeled BSA was not detectible inside of the modified 
alginate particles, thus BSA diffusion data is not presented here. The lack of BSA 
diffusion suggested that large, unwanted proteins may not be capable of entering the 
particles to hinder the function of encapsulated islets. 
4.3.8 Insulin diffusion. Diffusion of insulin into the particles was measured as a function 
of time over a period of six days. Diffusion profiles were very similar for all 
modifications, negating the significance of diffusion coefficients. Partition coefficients 
(Table 4.1) were calculated for the modified particles by normalizing the results to a 
control solution with no particles. Coefficients fell between 0.612 and 0.668 with no 
statistical significance. This further validates the data given above.  
4.3.9 TNF-α diffusion. The amount of TNF-α able to diffuse into the particles after four 
days was measured using a TNF-α ELISA (Figure 4.12). The connecting letters report for 
TNF-α diffusion is provided in Table 4.14. Four days was determined to be the length of 
time it takes for insulin and BSA to reach steady state. There was significant variety in 
the amount of TNF-α able to enter the modified particles. Both ester and ketone modified 
particles were able to completely prevent any detectible TNF-α diffusion. Acetal, alkene, 
epoxide, ketal, and phosphonic acid particles allowed less than 20% loading. Between 20 
and 40% loading was obtained with ether, oxime, and sulfone, while 50-90% was 
observed with amide, nitro, sulfonic acid and unmodified alginate particles. It is plausible 
that the lack of TNF measured in this latter group was due to not only loading of TNF 
into the particles, but also adsorption to the surface of the particles. Either case is 
undesirable in this application. TNF diffusing into the particles would be toxic to the 
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encapsulated islets and adsorbed TNF would still elicit an unfavorable immune response 
to the injected particles and could result in device failure. 
 
 
Figure 4.12.  Loading percentage of TNF-α into layered alginate particles containing 
mouse IgG labeled polystyrene particles. Error bars represent standard deviation.  
 
Table 4.14. Connecting letters reports for TNF-α diffusion. Levels not connected by the 
same letter are significant different (p<0.05) 
TNF-α     
Acetal A B   
Alkene A B   
Amide    D 
Epoxide A B   
Ester A    
Ether A B C  
Ketal A B   
Ketone A    
Nitro   C D 
Oxime A B C  
Phosphonic 
Acid 
A B   
Sulfone  B C  
Sulfonic Acid    D 
Unmodified 
alginate 
  C D 
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4.4 Discussion 
Alginate has been extensively studied for immunoisolative transplantation and 
other biomedical applications in an attempt to better understand the effect chemical and 
physical properties have on the materials biocompatibility.8,19,21,27,28,32,71–73  However, 
little research has been done to examine the impact of alginate functionality on implant 
survival.19,74 Similarly, the relationship between alginate properties and MΦ polarization 
has not been well studied. Others have only studied the effect of MΦ presence has on 
implant survival.46,75 With it being well known that material properties can impact MΦ 
phenotype,54,56,57,76–79 this present study aims to discover material functionalities that 
result in the desired anti-inflammatory, pro-angiogenic MΦ response. An additional goal 
for these materials is to limit TNF-α diffusion while having little to no effect on the 
transport of either glucose or insulin. 
Our results demonstrate that several modified alginates were able to reduce the 
pro-inflammatory response of MΦs. LPS and IL-4 activated as well as naïve MΦs had 
decreased TNF-α production in response to ester, ketone, nitro, oxime, phosphonic acid, 
sulfone, and sulfonic acid modified alginates. Ketone, phosphonic acid, sulfone and 
sulfonic acid modified alginates also showed increased arginase:iNOS ratios for all MΦ 
phenotypes when compared to unmodified alginate. This suggests that these 
modifications may improve the biocompatibility of alginate, making them useful in 
applications where a decreased pro-inflammatory response is crucial. One such 
application may be with medical device implantation. TNF-α expression by M1 (LPS 
activated) MΦs was down regulated to the level expressed by M2 (IL4 activated) MΦs 
with modifications nitro and amide, which both have increased arginase:iNOS ratios for 
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M1 MΦs. Nitro also has an increased arginase:iNOS ratio for naïve MΦs. These findings 
may be suggestive of MΦ reprogramming, which is extremely important in tissue 
engineering applications, particularly encapsulated islet transplantation, where increased 
angiogenesis by M2 MΦs is vital.47 Modifications alkene, amide, ester, ether and oxime 
seem to amplify the M2 phenotype in cells already activated by IL4, but of those only 
ester and oxime exhibit favorable cytokine profiles for other phenotypes. With this in 
mind, it may be useful to combine ester or oxime modifications with nitro or amide to 
achieve both MΦ reprogramming and intensified M2 polarization.  
 Reprogramming MΦs though coating with these materials is one possible 
explanation for the change in TNF- α secretion through the gel, with altering mass 
transport properties being a second. To distinguish between these two options, diffusion 
experiments were performed to detangle which materials reprogrammed MΦs and which 
altered transport. Based on the results of all diffusion experiments conducted in this 
work, we are able to achieve varied immunoisolation between modifications. Percent 
loading of TNF-α ranges from 0 to 84%. While amide, nitro, and sulfonic acid have high 
loading percentages with TNF-α diffusion, these modifications result in very low TNF-α 
expression through alginate layers by all MΦ phenotypes. Taken together, these results 
validate the idea that MΦ reprogramming is achieved with some modifications while 
permselectivity is modified through other chemical moieties. Modifications ester and 
ketone both seem to completely prevent diffusion of TNF-α into the particles. This is 
especially promising as the ester functional group was one that appeared to augment M2 
activation. Several other modifications that caused decreased TNF-α production by all 
MΦ phenotypes had fairly low TNF-α loading percentages, including oxime, phophonic 
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acid, and sulfone modified alginates. Acetal, alkene, epoxide, and ketal functionalities 
also allowed less than 20% loading of TNF-α. Insulin release from layered particles 
encapsulating INS-1 cells ranges from 7.7 to 24.2 pg insulin/ng DNA. The highest release 
was from amide-modified particles, again indicating the amide-modified alginate as a 
promising material. The amount of insulin released from alkene, epoxide and ester 
particles follows closely behind that of amide, again indicating that ester may be another 
favorable modification.  
While no significant correlations were found between the physical properties and 
overall function of the materials studied here, this can have important implications. For 
example, chemical modification of alginate will cause a decrease in the crosslinking 
density of the resulting hydrogel. This was shown with measurement of the compressive 
modulus (Table 4.1). It would be expected that a decreased crosslinking density would 
allow for greater TNF-α diffusion through modified materials, particularly with 
phosphonic acid, which has the lowest compressive modulus. However, the percent 
loading into the phosphonic coated particles was only 7% while that of the unmodified 
particles was 53%. This indicates that the likely culprit affecting the transport properties 
is the functional groups. It is also important to note that TNF-α diffusion ranges from 0-
84%, while none of the measured material properties show as much variation. Taken 
together, this information leads to the conclusion that aspects of the chemical 
functionalities, rather than the resulting material properties may be important in the 
biocompatibility of materials. Overall, the findings of this work are promising for future 
work with chemically modified alginate for microencapsulation of islet cells and 
applications in tissue engineering. 
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4.5 Conclusions 
 In this present study important progress was made in the improvement of alginate 
as a successful biomaterial. The induction of multiple MΦ phenotypes and MΦ 
reprogramming by some modified alginates confirms the ability of a material to control 
MΦ activation, or even reprogram the phenotype. Of additional importance is the fact 
that chemical modifications can give drastic differences in diffusion and transport of 
biomolecules allowing for controlled immunoisolation.  These results also corroborate 
the importance of chemical properties in the biocompatibility of materials, as it is likely 
the interaction between the surface moieties and proteins followed by cells that causes the 
changes in MΦ phenotype and transport properties. This work as a whole has indicated 
that the chemical modification of alginate may provide a new avenue in development of 
biomaterials for artificial pancreas transplantation as well as several other medical 
applications. 
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CHAPTER 5 
 
INVESTIGATING THE SYNERGYSTIC EFFECTS OF A 
COMBINATORIAL ALGIANTE LIBRARY ON MACROPHAGE 
PHENOTYPE 
 
Understanding MΦ responses to biomaterials is crucial to the success of implanted 
medical devices, tissue constructs, and drug delivery vehicles. Cellular responses to materials 
may depend synergistically on multiple surface chemistries, due to the polyvalent nature of cell-
ligand interactions. Previous work in this lab examined the effect of chemically modified 
alginates on MΦ phenotype to find that different surface functionalities could sway MΦ 
phenotype in either direction. Using these findings, this research aims to understand the 
relationship between combined material surface chemistries and MΦ phenotype. Tumor necrosis 
factor-α (TNF-α) secretion, nitrite production, and arginase activity were measured and used to 
determine the ability of the materials to alter MΦ phenotype. Synergy was understood by 
calculating synergy values (actual/predicted) for urea and TNF-α, as well as TNF-α diffusion. 
Several materials appeared to improve M1 to M2 MΦ reprogramming capabilities, giving 
valuable insight into the complexity of surface chemistries needed for optimal incorporation and 
survival of implanted biomaterials.  
 
5.1 Introduction 
MΦs have been known to be functionally diverse cells with a multitude of roles in 
immunity,1 disease and wound healing,1–4 making them an appealing target in research areas like 
drug delivery,5,6 wound healing,4 and biomaterial implantation.7 In particular, they are crucial in 
the initiation, propagation and resolution stages of the foreign body response (FBR) to synthetic 
biomaterials.8–10  MΦs are important in all stages of this response due, in part, to their plasticity 
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and heterogeneous phenotypes. The phenotypes in which MΦs exist are best described as a 
complex scale bookended by classical and alternative activations.  
Classically activated, M1, MΦs are said to be pro-inflammatory and cytotoxic.11,12 As cells 
that mediate immune responses to bacterial, viral and fungal infections, they can be activated by 
microbial stimuli (lipopolysaccharides (LPS)) or interferon (IFN)-γ, which is released by 
activated lymphocytes.13–15 The inflammatory response that these stimulating factors initiate is 
followed by the release of important cytotoxic molecules like reactive nitrogen intermediates 
(RNIs) and tumor necrosis factor (TNF)-α that can have an impact on the presence of tumor 
cells.7,12,15 The functions of M1 MΦs also make them important in the inflammation stages of 
wound healing and the FBR, where they produce pro-inflammatory cytokines, phagocytose 
microorganisms near the injury, and recruit additional inflammatory cells to the site.7,9,16–18  
Alternatively activated, M2, MΦs are known to be pro-angiogenic, and can be activated by 
interleukin (IL)4 or IL13.19 The main functions of these cells include: maintaining homeostasis, 
tissue repair and remodeling, as well as promoting wound healing in the resolution stage of the 
FBR.7 They fulfill these roles with the release of IL10, vascular endothelial growth factor 
(VEGF), and transforming growth factor (TGF)-β.20 The entire spectrum of phenotypes that 
exists is imperative in one way or another,3,7 but an increased presence of either M1 or M2 MΦs 
may be useful for specific applications. For example, an earlier M2 MΦ presence rather than 
prolonged M1 presence may allow for proper wound closure while in cancer therapies an M1 
MΦ presence rather than pro-angiogenic, tumor associated M2 like MΦ, may lead to the 
elimination of cancerous cells.  
With the application of wound healing and successful implant incorporation, the significance 
of the plasticity of MΦs is made evident by examining the timeline of MΦ presence during the 
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FBR.7 MΦ phenotype is dynamic throughout the entirety of the FBR, and a balance of 
phenotypes is essential for timely progression from injury to proper healing.7 After implantation 
of a biomaterial, MΦs are classically activated by proteins that have adsorbed to the material 
surface.21–23 These MΦs release pro-inflammatory cytokines that continue to attract monocytes 
to the injury site leading to chronic inflammation.18 Attempting and failing phagocytosis of the 
large implant, causes the M1 MΦs to fuse into foreign body giant cells (FBGC).24 Chronic 
inflammation is only resolved with a presence of alternatively activated MΦs resulting from 
phagocytosis of dying cells around the implant, or stimulation by IL-4 or IL-13, typically from 
basophils.19,25,26 M2 MΦs seek to promote wound healing in the area of the implant.10 However, 
prolonged M2 MΦ activity can lead to the formation of an extensive fibrous capsule that may 
negatively impact the function of the implant.27 Finding a balance between chronic inflammation 
and continued wound healing remains an issue with many biomedical implants. Using the idea 
that material surface chemistries have an impact on MΦ phenotype, it may be hypothesized that 
a particular material could orchestrate appropriate progression through the FBR to avoid both 
chronic wound healing and complete fibrous encapsulation. 
Many techniques for MΦ reprogramming have been developed that focus on either the 
chemical or environmental stimuli MΦs are exposed to.13,14,28,29 Previous work in this lab has 
indicated that some chemically modified alginates may impact both MΦ phenotype and the 
diffusive properties of the material.8 Different modifications were found to influence MΦ 
phenotype in different ways. For example, some modifications decreased TNF-α production by 
M1 MΦs, which could make them useful for in decreasing the inflammatory response to a 
material. Other modifications appeared to amplify the presence of M2 MΦs by showing an 
increased arginase/iNOS ratio compared to the control. Some of the most promising materials 
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showed decreased TNF-α production and increased arginase/iNOS ratios for all activations of 
MΦs. Finally, some indicated that even a small amount of modification may be giving the 
materials some permselectivity capabilities, which could be important for applications in drug 
delivery and tissue engineering.  
Given the complexity of biological systems and the immune system in particular, the idea 
that the most effective material surface might be made up of several chemistries is reasonable.30 
However, this can make optimal biomaterial design criteria difficult to ascertain.30 Cellular 
responses to materials are typically directed by surface protein adsorption,21 and many biological 
interactions such as protein-ligand or protein-cell interactions, are typically polyvalent in 
nature.21,31 This suggests a need for a material with multiple surface chemistries to more closely 
imitate natural interactions, as multiple simultaneous interactions may have unique collective 
properties that vary from those displayed by each component individually.31 The synergistic 
effects of material properties have typically been studied using high-throughput combinatorial 
approaches.32 This logic and testing method have similarly been employed in synergistic drug 
delivery, where the aim is to achieve some synergistic therapeutic effect, reduction of dose or 
toxicity, and to delay or minimize drug resistance.33–36  
The focus of this work was to examine the synergistic effects of a few promising material 
surface chemistries described above. In order to more accurately describe the phenotype of MΦs 
in vitro, a newer nomenclature will be used throughout this paper that is based on the molecule 
used to activate the cells, for example M(LPS) and M(IL-4).11 By modifying alginate with one 
functional group that amplified M(IL-4) activation (ester or oxime) and one that indicated 
M(LPS) to M(IL-4) MΦ reprogramming (amide or nitro), the goal was to achieve an even 
greater M(IL-4) response from all MΦ phenotypes.8 This could be useful in the proper 
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integration of various biomaterials. Other materials examined here combine a surface modifier 
that had high permeability but low production of toxic cytokines (sulfonic acid or nitro) with one 
that had low permeability but high cytokine production (ketal or epoxide).8 An ideal combination 
of modifications would have low permeability and also cause low production of toxic cytokines. 
Understanding the synergistic effects of these materials may lead to the development of a diverse 
library of materials that could influence any desired MΦ phenotype.  
 
5.2 Materials and Methods 
Experiments were performed with a minimum of three replicates. Results were compared to 
controls of unmodified alginate as well as singly modified samples in previous work.8 All 
materials were purchased from Sigma (St. Louis, MO) and used as received, unless otherwise 
indicated. Fresh deionized (DI) water (Milli-Q Nanopure, Thermo Scientific, Waltham, MA) was 
used throughout this study.  
5.2.1 Materials. Surface modifiers,8 coupled to medium viscosity (~600-900 cps, ~250,000 MW) 
alginate (MP Biomedicals, Santa Ana, CA) were chosen based on the results of previous research 
in this lab (cite). This included: glycidamide; tert-butyl 4 aminobutanoate (VWR, Radnor, PA); 
malonamide (Fisher, Pittsburgh, PA); 1-amino-4-oxocyclohexane carboxylic acid ethylene ketal; 
2,4-dinitro-phenyl-hydoxylamine; 3-aminobenzamide oxime; and 3-amino-1-propane sulfonic 
acid (Fisher).  
5.2.2 Alginate modification. The seven different surface modifiers were combined based on 
purpose and coupled to the medium viscosity alginate using an 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, Oakwood Chemical, West Colombia, SC) and N-
hydroxysuccinimide (NHS, Thermo Scientific) (cite). These materials were synthesized as 
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previously described (cite) with 50 molar equivalents of surface modifier 1 and 50 molar 
equivalents of surface modifier 2 instead.  
5.2.3 Elemental analysis. In order to determine the percent modification of each material, 
elemental analysis was performed to obtain %C, %H and %N. Measurements were recorded in 
triplicate with an acetanilide calibration standard, combustion and reduction temperatures of 925 
°C and 640 °C, respectively, and a resulting accuracy of ± 0.3% for each element. All standards 
and reagents are from Perkin Elmer and/or Elementar America's Inc. The instrument used was a 
PE 2100 Series II combustion analyzer (Perkin Elmer Inc., Waltham, MA). 
5.2.4 Water Contact Angle (WCA). Samples were prepared by creating a positively charged 
surface on glass microscope slides with poly-L-lysine (PLL). This allowed for a thin, even 
coating of each modified alginate to be applied to slides by crosslinking with SrCl2 (SrCl2, Alfa 
Aesar, Haverhill, MA). These coated slides could then be inverted over a container of water. An 
air bubble (100μL) was deposited under the slide and imaged using a digital camera (Canon EOS 
Rebel T3i, Canon, Melville, NY). Five replicates were collected for each sample before the angle 
between the slide and the bubble was measured using ImageJ (NIH, Bethesda, MD) software. 
The final reported WCA is 180° minus the measured angle. 
5.2.5 Compression modulus. The compression modulus was measured for each sample using 
manual compression testing techniques. Modified alginate pegs were made to be approximately 
10x10x4 mm3 in size. These pegs were placed between two microscope slides and imaged after 
each of various sized weights were set on the top slide. The changing distance between the slides 
in each image was measured using ImageJ, and used to create stress-strain curves. Linear 
portions of these curves were used to determine the reported compression modulus for each 
sample. This was usually between 0 and ~60% strain using five replicates per sample. 
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5.2.6 Cell culture. RAW 264.7 cells (American Type Cell Collection, ATCC, Manassas, VA) 
were used as a model cell line for MΦs in these experiments. They were cultured in complete 
media (CM, Dulbecco’s modified Eagle’s medium (DMEM, Mediatech,Inc., Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS, Mediatech, Inc.), 100U/mL penicillin, and 100 
μg/mL streptomycin) at 37°C in 5% CO2. Every three to five days, the cells were passaged using 
a cell scraper to detach cells and subcultured between ~6.7 × 103 and 2.7 × 104 cells/cm2. 
5.2.7 Cell viability. In order to test the viability of RAW 264.7 cells in contact with the combined 
modified alginates, plates were seeded for MTT (methyl thiazolyldiphenyl tetrazolium), 
Research Products International Corp., Mt Prospect, IL) assays during passaging. For this, 24-
well plates (KSE Scientific, Durham, NC) were first coated with 0.05% PLL solutions using 200 
μL/well and incubating the plates at 37 °C for 1 h. Before seeding the cells into the plate, each 
well was washed twice with sterile phosphate buffered saline (PBS). The plates were seeded with 
125,000 cells/cm2 in 500 μL of CM per well and 25 ng/mL IL-4 (M(IL-4)) (eBioscience Inc., 
San Diego, CA) or 5 ug/mL LPS (M(LPS)) and allowed to adhere for 24 h. A control set of 
experiments using non-activated cells was included and referred to as naïve or M(0) cells. 
Alginate coatings were created by adding ~100 μL of modified alginate to each well, allowing it 
to coat the bottom, and removing any excess alginate. Next, 500 μL of 0.2 M SrCl2 were used per 
well to crosslink the coating. This solution was left in the wells for approximately 5 minutes 
before replacing it with clear CM. After 48 h the supernatant was removed and saved for further 
testing. 500 μL of clear CM were added back to each well along with 50 μL of a MTT (5 mg/mL 
in DI water). After a 2 h incubation at 37 °C, 425 μL of solution were removed from each well 
and replaced with 500 μL of dimethyl sulfoxide (DMSO).  The absorbance of each plate was 
read at 540 nm with a reference of 690 nm using a BioTek Synergy HT Multidetection 
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Microplate Reader (BioTek, Winooski, VT). Positive controls for each plate were cells with no 
alginate samples, and negative controls contained media, modified alginates and activators. 
Experiments were performed in quadruplicate and results are given as the mean value for each 
sample normalized to the positive control. 
5.2.8 TNF-α ELISA. Measurement of TNF-α, an M1 phenotype marker, was performed using 
commercially available enzyme linked immunosorbent assay (ELISA) kits (eBioscience, Inc., 
San Diego, CA) and performed as described by the manufacturer, using the supernatant collected 
during viability assays.  
5.2.9 Urea assay. After 48 h of incubation with the combined modified alginates, the supernatant 
was removed and saved for further testing. Cells were then washed with 400 μL of PBS, and the 
plates were placed on ice for 10 min with 100 μL of cell lysis buffer (150 μL protease inhibitor 
cocktail (Amresco, Solon, OH) and 15 μL Triton X-100 (Acros Organics) diluted to 15 mL with 
DI water) per well. 25 μL of this lysate were transferred from each well to a 96-well plate (Argos 
Technologies, Elgin, IL) along with 25 μL of a 10 mM MnCl2 (Fisher) and 50 mM Tris solution 
(Fisher). This plate was incubated for 10 minutes at 55 °C before 50 μL of 1 M arginine (pH 9.7) 
was added to each well and incubated at 37 °C for 20 h. Arginase activity, an M2 phenotype 
indicator, was measured through the conversion of arginine to urea. This was done by adding 
200 μL of a 1:2 ratio of solution 1 (1.2 g o-phthaldialdehyde (Alfa Aesar), 1 L H2O, and 500 μL 
HCl (Fisher) and solution 2 (0.6 g N-(naphthyl)ethylenediamine dihydrochloride (Acros 
Organics), 5 g boric acid (Fisher), 800 mL H2O, 111 mL sulfuric acid (Fisher), diluted to 1 L 
with H2O).37 The plate was read at 520 nm with a reference at 630 nm. 
5.2.10 Griess reagent assay. Nitrite production, which is also indicative of an M1 phenotype, 
was measured from the supernatant collected in the urea assay described above. A standard curve 
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was created using serial dilutions of 100 μM NaNO2 with volumes of 150 μL down the columns. 
To the remaining wells 150 μL of sample were added. To the entire plate, 130 μL of DI water 
and 20 μL of Griess reagent (Acros Organics) were added and allowed to incubated for up to 20 
minutes. The plate was read at 448 nm with a 690 nm reference. 
5.2.11 Staining for fluorescent imaging. RAW 264.7 cells were fluorescently labeled using a 
previously developed protocol.8 Briefly, cells were seeded at 100,000 cells/cm2 on clean, PLL 
coated glass coverslips in petri dishes, as M(LPS), M(IL4) or M(0) as described above. After 48 
h of incubation, the cells were stained for CD11c and CD206. These coverslips were imaged 
with an EVOS® FLoid ® Imaging Station (Life Technologies, Grand Island, NY) using the red 
channel (excitation/emission 586/646 nm), blue channel (390/446 nm) and the green channel 
(482/532 nm).  
5.2.12 TNF-α diffusion. To test the diffusive properties of these combined modified alginates, 
microparticles were made using an electrostatic droplet generation technique. Using the same 
equipment and techniques described in Bygd et al., microparticles with an average diameter of 
685.15 ± 14.20 μm were made with unmodified alginate. Amino polystyrene particles, 10 mg, 
(Spherotech Inc, Lake Forest, IL) were also labeled with 2 mg mouse IgG (Thermo Scientific) in 
PBS using 20 mg of EDC. These labeled polystyrene particles were encapsulated in the 
unmodified alginate particles during electrostatic droplet generation using procedures developed 
by Kulseng et al.38 Approximately 200 particles were incubated with 2mL of supernatant known 
to contain TNF-α. This supernatant was collected from M(LPS) RAW 264.7 cells cultured at 
~182,000 cells/cm2 after two days of incubation. After four days of incubation with the particles, 
the supernatant was removed and compared to the original TNF-α supernatant using ELISAs to 
determine how much had diffused into the particles.  
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5.2.13 Statistics and data analysis. Statistical analysis was performed using JMP® statistical 
software (Cary, NC). Statistical significance of the mean comparisons was determined by a two-
way ANOVA. Pair-wise comparisons were analyzed with Tukey’s honest significant difference 
test. Differences were considered statistically significant for p < 0.05. 
 
5.3 Results 
5.3.1 Modification and characterization. After the combined modification of alginate, the 
synthesized materials were characterized for their hydrophobicity, compression modulus and 
percent modification. The WCAs of the combined modified alginates fell in a range of 39.9°-
51.2° (Table 1), compared to the range of 49.7°-61.0° with the single modifications, and 54.1 ± 
2.0 (Table 1). This suggests the materials remained relatively hydrophilic. The compression 
modulus of the combined modified alginates ranged from 12.5-30.1 kPa (Table 5.1), which was 
similar to the range in compression modulus for the single modifications (18.8-25.0 kPa), and of 
unmodified alginate (25.3 ± 5.4, Table 5.1). Elemental analysis confirmed modification with %N 
values being greater for the modified alginates than unmodified (Table 5.2). 
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Table 5.1. Characterization of combined and single modified alginates. WCAs and compression 
moduli were measured. Errors associated with WCAs represent standard deviation between the 
five replicates measured. Compression moduli are given as the mean value ± standard deviation. 
(*) indicates p<0.05 compared with unmodified alginate.
Modification WCA (º) Compression modulus (kPa) 
sulfonic acid 59.2 ± 1.9* 18.8 ± 2.7* 
nitro 58.8 ± 1.0* 21.9 ± 3.1 
ketal 52.4 ± 0.9 22.2 ± 2.7 
epoxide 52.0 ± 1.1 22.8 ± 3.0 
ester 49.7 ± 1.0* 25.0 ± 3.7 
oxime 61.0 ± 1.1* 21.3 ± 2.9 
amide 57.7 ± 1.0* 22.9 ± 3.6 
sulfonic 
acid/ketal 49.5 ± 4.5 24.4 ± 3.4 
sulfonic 
acid/epoxide 43.7 ± 4.23* 18.3 ± 3.4* 
nitro/ketal 46.2 ± 3.5* 22.5 ± 3.3 
nitro/epoxide 39.9 ± 3.2* 28.2 ± 4.2 
ester/amide 51.2 ± 2.1 20.3 ± 3.3 
ester/nitro 47.0 ± 2.5* 30.1 ± 7.4 
oxime/amide 44.7 ± 2.0* 12.5 ± 1.8* 
oxime/nitro 45.1 ± 1.9* 17.4 ± 3.7* 
unmodified 
alginate 54.1 ± 2.0 25.3 ± 5.4 
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Table 5.2. Elemental analysis results for combined modifications and unmodified alginate. %C, 
%H, and %N are given as the mean value ± standard deviations.  
Modification %C %H %N 
sulfonic acid 32.43 ± 0.92 4.69 ± 0.29 1.68 ± 0.00* 
nitro 33.0 ± 0.40 4.39 ± 0.23 0.71 ± 0.03* 
ketal 28.70 ± 0.40* 3.96 ± 0.12 0.95 ± 0.05* 
epoxide 26.57 ± 0.26* 3.97 ± 0.17 1.69 ± 0.05* 
ester 31.45 ± 0.10* 4.53 ± 0.09 1.63 ± 0.01* 
oxime 29.19 ± 0.29* 4.16 ± 0.08 1.22 ± 0.03* 
amide 31.65 ± 0.21 4.56 ± 0.13 1.59 ± 0.06* 
sulfonic 
acid/ketal 22.6 ± 0.06 3.24 ± 0.06  2.31 ± 0.01 
sulfonic 
acid/epoxide 22.98 ± 0.14 3.32 ± 0.08 2.03 ± 0.03 
nitro/ketal 28.26 ± 0.05 3.82 ± 0.08 1.45 ± 0.05 
nitro/epoxide 29.62 ± 0.39 4.02 ± 0.06 1.37 ± 0.01 
ester/amide 23.58 ± 0.43 3.25 ± 0.04 1.93 ± 0.03 
ester/nitro 30.80 ± 0.19 3.94 ± 0.04 0.58 ± 0.1 
oxime/amide 23.52 ± 0.09 3.26 ± 0.03 1.94 ± 0.0 
oxime/nitro 29.62 ± 0.49 4.06 ± 0.12 1.43 ± 0.04 
unmodified 
alginate 32.73 ± 0.20 4.26 ± 0.13 0.04 ± 0.01 
 
5.3.2 Cell viability. Biomaterials must be cytocompatible for use as implantable materials. 
Cytotoxicity of the combined modified alginates was measured using MTT assays. The viability 
of the cells was expressed as a percentage of the positive control of cells cultured on PLL coated 
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tissue culture plastic. Cells exposed to all materials showed greater than 70% viability (Figure 
5.1). This suggests minimal cytotoxicity, especially for cells cultured under a hydrogel.  
 
Figure 5.1. Cell viability of M(LPS), M(IL-4), and M(0) RAW 264.7 MΦs encapsulated under 
modified and unmodified alginate layers. Data represents the mean value of four replications ± 
standard deviation. 
 
5.3.3 TNF-α ELISA. Production of the cytotoxic cytokine TNF-α by cells exposed to modified 
alginates was measured and reported in Figure 5.2A. Details of multiple comparisons for this 
data are given in Table 5.3-5.5. Values for single modifications of alginate are included in Figure 
5.2B for comparison. Most modifications of alginate were able to decrease the amount of TNF-α 
produced in comparison to unmodified alginate for all MΦ phenotypes. TNF-α production by 
M(IL-4) MΦs ranged from 0.61 to 0.82 ng with 1.1 ± 0.27 ng produced under unmodified 
alginate. M(0) MΦs produced a range of TNF-α that spanned 0.88 to 1.52 ng. TNF-α produced 
by M(LPS) cells spanned a higher range of 1.26 to 2.51 ng, and on a sample-to-sample basis, the 
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amount of cytokine produced was most often highest for M(LPS) MΦs. In the presence of 
unmodified alginate, M(0) cells and M(LPS) cells produced 1.97 ± 0.17 and 2.62 ± 0.17 ng of 
TNF-α, respectively. Sulfonic acid/ketal was the only modification that had statistically lower 
TNF-α production than unmodified alginate for all activations. Nitro/ketal, ester/amide, and 
oxime/amide had lower TNF-α production for M(LPS) and M(0) MΦs, while nitro/epoxide and 
oxime/nitro had lower production for M(LPS) and M(IL-4) cells. Ester/nitro decreased TNF-α 
production by M(IL-4) and M(0) cells, and sulfonic acid/epoxide only decreased TNF-α 
production for M(0) MΦs. 
 
 
 
Figure 5.2. TNF-α expressed by M(LPS), M(IL-4), and M(0) RAW 264.7 MΦs encapsulated 
under (A) combined modified, (B) single modified and unmodified alginate layers. Data 
represents the mean value for four replicates ± standard deviation.  (*) indicates p<0.05 
compared with unmodified alginate for the same activation by pairwise comparison. 
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Figure 5.2 continued 
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Table 5.3-5.5. Connecting letters reports for TNF-α produced by M(LPS), M(IL-4), and M(0) 
MΦs. Levels not connected by the same letter are significantly different (p<0.05). 
 
5.3. TNF-α (LPS)  
sulfonic acid/ketal   C D 
sulfonic 
acid/epoxide A B   
nitro/ketal   C D 
nitro/epoxide    D 
ester/amide  B C  
ester/nitro A    
oxime/amide  B C D 
oxime/nitro   C D 
unmodified 
alginate A    
 
5.4. TNF-α (IL-4)   
sulfonic acid/ketal  B 
sulfonic 
acid/epoxide A B 
nitro/ketal A B 
nitro/epoxide  B 
ester/amide A B 
ester/nitro  B 
oxime/amide A B 
oxime/nitro  B 
unmodified 
alginate A  
5.5. TNF-α (Naïve)    
sulfonic acid/ketal  B C 
sulfonic 
acid/epoxide   C 
nitro/ketal  B C 
nitro/epoxide A B  
ester/amide  B C 
ester/nitro  B C 
oxime/amide  B C 
oxime/nitro A B  
unmodified alginate A   
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5.3.4 Arginase/iNOS. Arginase activity was determined for encapsulated MΦs by exposing cell 
lysate to arginine and quantifying the urea produced. Nitrites are the stable form of NO and were 
quantified through a Griess reagent assay. Results from these assays are given as arginase:iNOS 
in Figure 5.3A, which corresponds to the amount of urea produced divided by the amount of 
nitrite in corresponding samples. Ratios for single modifications of alginate are included in 
Figure 5.3B for comparison. Absolute values for both urea and Griess assays are given in Figure 
5.4A and B. Details of multiple comparisons for this data are given in Table 5.6-5.11. Ratio 
values range from 3.75 mg/μmol with oxime/nitro to 11.0 mg/μmol with ester/amide for M(IL-4) 
MΦs. A value of 6.88 ± 3.05 mg/μmol was previously determined for M(IL-4) MΦs in the 
presence of unmodified alginate.8 M(LPS) MΦs exhibited a narrow range of 2.02-5.16 mg/μmol 
compared to 7.52 ± 1.76 mg/μmol for unmodified alginate. Finally, values for M(0) MΦs ranged 
from 0.98 mg/μmol with the ester/nitro modification to 3.71 mg/μmol with sulfonic acid/ketal. 
M(0) MΦs exhibited a arginase:iNOS ratio of 6.91 ± 2.13 mg/μmol with unmodified alginate. 
Higher values for these ratios indicate a stronger M2 phenotype presence, while low values 
suggest a M1 phenotype. Most values seem to indicate a stronger M1 presence when compared 
to unmodified alginate. Exceptions to this statement include nitro/ketal and ester/amide with 
M(IL-4) MΦs. 
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Figure 5.3. Arginase:iNOS ratios for all MΦ phenotypes encapsulated under (A) combined, (B) 
single and unmodified alginate layers. Error bars represent standard deviation. 
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Figure 5.4. Absolute values for urea (A) and nitrite (B) production for M(LPS), (IL-4) or M(0) 
MΦs encapsulated under modified and unmodified alginate layers. Data represent the mean 
value of four replicates for each sample ± standard deviation. (*) indicates p<0.05 compared with 
unmodified alginate for the same activation by pairwise comparison. 
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Table 5.6-5.8.  Connecting letters reports for urea production by each MΦ phenotype. Levels not 
connected by the same letter are significantly different (p<0.05). 
 
5.6. Urea (LPS)   
sulfonic 
acid/ketal A    
sulfonic 
acid/epoxide A B C  
nitro/ketal A B   
nitro/epoxide A    
ester/amide  B C D 
ester/nitro   C D 
oxime/amide A B C D 
oxime/nitro A B   
unmodified 
alginate    D 
 
5.7. Urea (IL-4)   
sulfonic 
acid/ketal  B C 
sulfonic 
acid/epoxide  B C 
nitro/ketal  B  
nitro/epoxide  B C 
ester/amide A   
ester/nitro  B C 
oxime/amide  B  
oxime/nitro  B C 
unmodified 
alginate   C 
5.8. Urea (Naïve)   
sulfonic acid/ketal A   
sulfonic 
acid/epoxide   C 
nitro/ketal   C 
nitro/epoxide  B C 
ester/amide  B C 
ester/nitro   C 
oxime/amide A B  
oxime/nitro   C 
unmodified 
alginate A B  
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Table 5.9-5.11.  Connecting letters reports for nitrite production by each MΦ phenotype. Levels 
not connected by the same letter are significantly different (p<0.05). 
 
5.9. Nitrite (LPS)   
sulfonic acid/ketal A B    
sulfonic 
acid/epoxide  B C   
nitro/ketal   C   
nitro/epoxide  B C   
ester/amide A     
ester/nitro  B    
oxime/amide  B    
oxime/nitro    D  
unmodified alginate     E 
 
5.10. Nitrite (IL-4)   
sulfonic acid/ketal   C   
sulfonic 
acid/epoxide   C   
nitro/ketal    D  
nitro/epoxide A     
ester/amide A     
ester/nitro  B    
oxime/amide A     
oxime/nitro  B C   
unmodified alginate     E 
5.11. Nitrite (Naïve) 
sulfonic acid/ketal A    
sulfonic 
acid/epoxide A B   
nitro/ketal A B   
nitro/epoxide   C  
ester/amide A    
ester/nitro   C  
oxime/amide   C  
oxime/nitro  B   
unmodified alginate    D 
 
5.3.5 Fluorescent imaging. Immunocytochemistry (ICC) fluorescent staining was used to 
identify the MΦ phenotypes resulting from culturing cells in the presence of modified and 
unmodified liposomes. CD11c, an LPS receptor, was used to identify M1 MΦs and a CD206, a 
mannose receptor, was used to indicate an M2 MΦ phenotype. DAPI was also used as a nuclei 
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stain. Representative images are shown in Figure 5.5 A and B. These images were used to 
qualitatively support the results found by measuring arginase activity, TNF-α secretion, and 
nitrite production. Staining images for MΦs cultured with single modifications of alginate are 
given in chapter 4. Control staining images of MΦs with activator alone are also included in 
chapter 4.  
Figure 5.5. A-C. . Immunocytochemistry fluorescent staining images. (A) nitro/epoxide and (B) 
ester/amide. Cells were stained with fluorescently labeled CD206 (red) and CD11c (green) 
markers as well as DAPI (blue). Scale bar is 50 μm. 
 
5.3.6 TNF-α diffusion. The amount of TNF-α able to diffuse into the particles was measured 
using an ELISA after 4 days of incubation (Figure 5.6A).8 Details of multiple comparisons for 
this data are given in Table 5.12. A wide range of values were calculated for percent loading. 
Nitro/ketal did not allow any diffusion of TNF-α, while nitro/epoxide allowed 87% loading. 
Percent loading values for single modifications of alginate are included in Figure 5.6B for 
comparison. 
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Figure 5.6.  Loading percentage of TNF-α into layered alginate particles containing mouse IgG 
labeled polystyrene particles. Error bars represent standard deviation. (*) indicates p<0.05 
compared with unmodified alginate by pairwise comparison. 
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Table 5.12.  Connecting letters reports for TNF-α diffusion through modified alginates. Levels 
not connected by the same letter are significantly different (p<0.05). 
TNF Diffusion  
sulfonic 
acid/ketal   C   
sulfonic 
acid/epoxide A     
nitro/ketal     E 
nitro/epoxide A     
ester/amide A     
ester/nitro    D  
oxime/amide  B    
oxime/nitro    D  
unmodified 
alginate  B    
 
5.3.7 Synergy. Normalizing the percent modifications of each combined alginate sample to that 
of the single modifications, we were able to determine weight fractions of each modification. 
Using the equation that was developed by Karande et al.:39  
𝑆𝑆 = 𝑀𝑀𝐴𝐴+𝐵𝐵
𝑋𝑋𝑀𝑀𝐴𝐴+(1−𝑋𝑋)𝑀𝑀𝐵𝐵          (1) 
we were able to determine synergy with respect to TNF-α production, urea production, and TNF-
α diffusion. These values are shown for each MΦ phenotype in Figure 5.7 A-D. For TNF-α 
production, synergy values were calculated to be in the range of 0.183-0.803 for M(LPS) MΦs, 
0.151-0.885 for M(0) cells, and a higher range of 0.463-0.889 for M(IL-4) MΦs. M(LPS) cells 
resulted in calculated synergy values ranging from 0.896 to 1.83 for urea production, a lower 
range of 0.146 to 0.662 for M(0) MΦs, and 0.636-3.65 for M(IL-4) MΦs. Synergy values for 
TNF-α diffusion were calculated in the range of 0 to 4.939.  
200 
 
 
  
 
Figure 5.7. Synergy values calculated for urea and TNF-α production by (A) M(LPS) (B) M(IL-
4) and (C) M(0) MΦs. (D) Synergy values for TNF-α diffusion through modified alginates. 
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Figure 5.7 continued 
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5.4 Discussion and conclusions 
 
Alginate is an appealing biomaterial for numerous wound healing and tissue engineering 
applications. It is a naturally occurring, relatively inexpensive polymer, it has low toxicity and 
good biocompatibility, and is easily gelled under mild conditions with divalent cations.40 The 
structure of alginate is similar to that of the extracellular matrix in living tissues, and it provides 
a relatively inert and moist microenvironment.40,41 However, the biocompatibility of alginate 
remains insufficiently understood. For example, in research by Elliot et al., alginate was used to 
encapsulate porcine islets in a clinical trial for diabetes treatment.42 While the trials were mildly 
successful in that there were surviving functional islets, the overall function of the implant was 
severely diminished by the presence of granulation tissue that developed in response to the 
alginate.42  Many aspects of the polymer have been studied in an attempt to improve upon the 
biocompatibility,43–56 and some work has been done to chemically modify alginate and study the 
impact this has on cell function.8,57–59 This research focuses on combining surface modifications 
to study the synergistic effects of chemical modification on cellular responses. By using 
materials that have been studied in the past, we have been able to compare predicted and actual 
values to examine synergy of the modifications.  
In this study, we aimed to find combined modifications that would improve the 
biocompatibility of alginate by reprogramming MΦs towards an M2-like phenotype. Based on 
the equation used to calculate synergy, values greater than one for arginase activity and less than 
one for TNF-α production would be desired. These values are most important for M(LPS) MΦs 
as this is the phenotype we are aiming to reprogram. M(LPS) MΦs tend to mediate the 
inflammatory stages of the foreign body response to biomaterials, which we are attempting to 
minimize. TNF-α production synergy values are less than one for all phenotypes studied. This 
203 
 
 
may be due, in part, to the fact the TNF-α, must diffuse through the alginate coating in order to 
be measured. As Figure 5.6 indicates, some of these combined modifications allow little to no 
TNF-α diffusion through the alginate. However, combining this information with the urea 
synergy values, we can determine which modifications may be favorably shifting MΦ phenotype 
towards an M2-like state. From the values presented in Figure 5.7, it can be determined that 
almost all of the modifications yield promising synergy values for M(LPS) MΦs. Sulfonic 
acid/ketal, nitro/epoxide, ester/amide, ester/nitro, oxime/amide and oxime/nitro all have TNF-α 
production synergy values below one and urea synergy values above one. Of these modifications 
nitro/epoxide and ester/amide also have promising synergy values for M(IL-4) MΦs. 
Interestingly, nitro/ketal also has the highest urea production synergy value for M(IL-4) cells. 
With respect to the M(0) MΦ synergy values, all TNF-α production values are below one, but the 
urea production values are as well. In some cases, the urea synergy values are even lower than 
the TNF-α production values. 
By including the TNF-α diffusion study, this work also examined the changes in diffusive 
properties of alginate due to combined surface modifications. Ideally, combined modifications 
would result in a lower mass transport of TNF-α than in the case of single modifications. This 
would be indicated by synergy values less than one. Modifications sulfonic acid/ketal, 
nitro/ketal, and oxime/nitro all had values below one. The other modifications had relatively high 
synergy values, suggesting that they are not permselective towards TNF-α, which could 
potentially be harmful for applications of islet encapsulation as in Elliot et al.42 In that example, 
tissue development surrounding the implant cut off blood supply to the encapsulated islet 
preventing them from functioning properly. In this case, with increased TNF-α , the toxic 
cytokine would be able to reach the islets and impact their ability to regulate blood sugar. 
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However, the two modifications with the highest synergy values, are nitro/epoxide and 
ester/amide. These are the two materials that gave the best results as far as TNF-α production and 
urea production. This then supports the idea that nitro/epoxide and ester/amide may better 
enhance M(LPS) to M(IL-4) MΦ reprogramming than the individual modifications.  
Although this study is not conclusive, it provides valuable insight into the impact of 
multiple surface modifications on MΦ phenotype. This library is also not large enough to offer 
much in the way of justified reasoning for the synergistic effects of the combined modifications. 
However, it provided evidence that maximum MΦ reprogramming may require a multitude of 
stimuli, and further supported the findings that simply altering the surface chemistry of a 
biomaterial may have a significant impact on its biocompatibility.  
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CHAPTER 6 
 
IN VITRO MACROPHAGE REPROGRAMMING BY MODIFIED 
LIPOSOMES FOR CONTROLLED DRUG DELIVERY 
 
Liposomes are one of the most widely investigated drug delivery systems. They are 
known for their low immunogenicity, good biocompatibility, cell specificity and drug protection. 
Due to several physiochemical properties such as size and charge, liposomes naturally target the 
phagocytic capabilities of MΦs.  In the tumor microenvironment, MΦs strongly influence growth 
and progression, making them an ideal target for drug delivery. Using the natural capability of 
liposomes to target MΦs, and the knowledge that material properties are capable of altering 
cellular responses, this work aims to alter MΦ phenotype with arginine-like surface modified 
DOPE:DOPC liposomes. These liposomes were incubated with interleukin-4 (IL-4) or 
lipopolysaccharide (LPS) stimulated MΦs and naïve RAW 264.7 MΦs. MΦ phenotype was 
determined by measuring arginase activity, tumor necrosis factor (TNF)-α secretion, and nitrite 
production. With significant variations in the molecular profiles of each activated cell type, these 
findings suggest that MΦ responses could be altered with small variations in surface 
functionalities of liposomes. 
 
6.1 Introduction 
Liposomes were first described and proposed as drug delivery systems in 1965.1,2 Since 
then, many variations of liposomes have been designed and optimized for a multitude of 
applications.3,4 There are several known benefits to the use of liposomes as a drug delivery 
vehicle. They allow for stable loading of hydrophilic and hydrophobic molecules,3,5 longer 
intravascular circulation time,6 and passive targeting of tumors by the enhanced permeability and 
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retention effect.7,8 Tumors have increased permeability of the blood vessels due to the rapid and 
defective angiogenesis.7 A tumor site is also characterized by poor lymphatic drainage, which 
allows liposomes to accumulate and release any encapsulated drug in the vicinity of the tumor 
cells.7 Due to their accumulation in the interstitial area surrounding capillaries in the tumor 
environment, liposomes are naturally taken up and cleared by tumor-associated macrophages 
(TAMs).9,10 Some nanoparticle delivery systems are designed to avoid recognition and uptake in 
order to increase circulation time.11 A more novel approach targets MΦs by harnessing their 
inherent phagocytic capabilities and aims to redirect their phenotype to improve the effectiveness 
of liposome drug delivery systems.  
MΦs are functionally heterogeneous cells that exist in a spectrum of phenotypes with 
proinflammatory (M1) MΦs playing a significant role in inflammation, while proangiogenic 
(M2) MΦs are primarily involved in wound healing and tissue repair.12–17 M1 MΦs are activated 
by LPS, which is found on the outer membrane of gram negative bacteria, or proinflammatory 
factors like interferon (IFN)-γ.18–20 They produce cytokines like IL-12 and IL-23 that are key 
mediators of inflammation, as well as TNF-α and reactive nitrogen intermediates.15,17,21 M2 MΦs 
are stimulated by IL-4, glucocorticoids or transforming growth factor (TGF)-β to secrete IL-10 
and increase arginase activity.22–24 In order to more accurately describe the phenotype of MΦs in 
vitro, a newer nomenclature will be used throughout this paper that is based on the molecule 
used to activate the cells, for example M(LPS) and M(IL-4).25  
In tumor microenvironments, MΦs typically exhibit a M2-like phenotype causing them to 
impact tumor growth, angiogenesis and metastasis.26,27 It is this essential role in tumor 
development that implicates them as an effective target in cancer therapeutics. One approach that 
has been gaining popularity seeks to redirect these immunosuppressive TAMs toward the 
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proimmunogenic phenotype of MΦ. The focus of these works have typically been the use of 
proinflammatory cytokines, such as IL-12 and INF-γ.28,29 While these approaches have been 
successful at reversing protumoral cytokine profiles in vitro and abating tumor growth in vivo, 
systemic protein delivery is generally difficult. With short half-lives and relative toxicity at high 
doses, effective levels may not be achievable.30 These limitations have led to the investigation of 
materials surface modifications that alter cellular responses.12–14,31–35 Using material surface 
properties to induce MΦ reprogramming in combination with delivery of chemotherapeutics may 
improve the outcome of liposome based cancer treatment options.  
Arginine is metabolized in cells by either inducible nitric oxide synthase (iNOS) or 
arginase.21,36 These processes result in the production of citrulline and NO or ornithine and urea, 
respectively.21,37,38 These products as well as several intermediates have been linked to 
inflammation related diseases, and can have opposing effects on wound healing.21,39 Based on 
this concept, an arginine-like material library was used to surface modify DOPE:DOPC 
liposomes. Arginine like functional groups have guanidine structures, and arginine rich peptides 
have been found useful for intracellular delivery because their guanidine functionality allows 
them to interact with the phosphate groups in cell membranes. Research has also shown that 
arginine-like modifications can inhibit MMP activity, which is increased during the foreign body 
and chronic wound responses.39  
Using the FDA list of approved liposomal-based carriers,4 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were 
found to be a commonly used pair in the development of liposome-based vaccines. DOPE has a 
primary amine group on the hydrophilic head, allowing for modification with small molecule 
modifiers containing carboxylic acid groups through carbodiimide chemistry. DOPC has been 
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used on multiple occasions to study lipid flip-flop, where it was found that increasing DOPC 
content increases the rate of certain peptide-induced variations of flip-flop.40,41 Positive lipid 
head groups have also been shown to aid in fusion with the negatively charged cell 
membrane,42,43 and result in adverse cell viability.9 We believe that zwitterionic lipids in 
combination with modified DOPE will influence macrophage phenotype, which has the potential 
to not only deliver drugs but alter cellular responses in the tumor microenvironment.  
   
6.2 Materials and Methods 
Fourteen arginine-like modifiers were coupled to liposomes in order to examine their 
effect on MΦ activation. Experiments were performed with a minimum of three replicates. 
Results were compared to controls of unmodified (UM) liposomes. All materials were purchased 
from Sigma (St. Louis, MO) and used as received, unless otherwise indicated. Fresh deionized 
(DI) water (Milli-Q Nanopure, Thermo Scientific, Waltham, MA) and sterile 1X phosphate 
buffered saline (PBS, diluted from 10X solution (Fisher, Pittsburgh, PA), to 0.1 M, pH 7.4) were 
used throughout this study. 
6.2.1 Materials. Liposomes were fabricated from DOPC and DOPE (Avanti Polor Lipids, Inc., 
Alabaster, AL). Arginine-like modifiers (Figure 6.1) that were coupled to DOPE in the 
liposomes were: 2-amino-3-guanidinopropionic acid (Matrix Scientific, Elgin, SC), 3-
guanidinopropionic acid, nitroarginine, creatine (Acros Organics), carnitine, citrulline, 5-
hydoxylysine, acetylglutamine, N-carbamyl-alpha-aminoisobutyric acid, acetyl-carnitine, 2,4-
diaminobutyric acid, acetylornithine, albizzin, arginine (Amresco, Solon, OH).  
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Figure 6.1. The chemical structures of molecules used in the modification of DOPE:DOPC 
liposomes. The alphabetical designations listed here are used as labels in the following figures 
for convenience. 
 
6.2.2 Liposome modification. To synthesize DOPE:DOPC liposomes, 25mg/mL solutions of 
each lipid in chloroform were added to a round-bottom flask in a 2:1 ratio, with excess 
chloroform. After sufficient mixing, the chloroform was removed via rotory evaporation. 
Liposomes were first formed by suspending the resulting lipid film in 1X PBS. The round-
bottom flask was vortexed and sonicated for ~15 minutes until any residual lipids were removed 
from the glass and a cloudy solution was formed. The modification of these liposomes has been 
described previously.12,13 Briefly, 2 mL of 1X PBS (pH 7.4), 2 mg of modifier, 0.2 mL of 5% 
w/v DOPE:DOPC liposomes, and 20 mg of 1-ethyl-3(-3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) were vortexed and incubated overnight at room temperature (rt). The 
liposomes were dialyzed for 24 h in H2O and lyophilized (Labconco, Kansas City, MO, 4.5L) 
before reconstituting at 1% w/v in pH 7.4 PBS. The modifiers in Figure 6.1 were conjugated to 
the primary amine on DOPE through the carboxylic acid group. These liposomes were then 
extruded with an Avanti® Mini-Extruder (Avanti Polor Lipids, Inc.) and 100 nm polycarbonate 
membranes. 
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6.2.3 Zeta potential and dynamic light scattering (DLS). To avoid the influence of ions in the 
water on the results, 100 μL of 1% w/v of modified or unmodified liposomes were diluted in 5 
mL of pH 7 Milli-Q DI water and extruded 5 times. Zeta potential and liposome size were 
measured with a Zetasizer Nano Z (Malvern).  
6.2.4 Cell culture. RAW 264.7 MΦs were cultured at 37°C with 5% CO2 in complete medium 
(CM), consisting of 10% fetal bovine serum, 100 U/L penicillin, and 100 µg/L streptomycin in 
Dulbecco’s modified Eagle’s medium (DMEM). Cells were passaged every three to five days 
and subcultured between ~6.7 × 103 and 2.7 × 104 cells/cm2. 
6.2.5 Cell viability. During passaging RAW 264.7 cells were seeded in a 24-well plate at 1.25 x 
105 cells/cm2 in 500 µL of CM per well and activated with either 5 µg/mL LPS (M(LPS)) or 25 
ng/mL IL-4 (M(IL-4)) (eBioscience Inc., San Diego, CA). A control set of experiments was not 
activated (M(0)). The supernatant was removed and replaced with fresh CM and 50 µL of 
0.0625% modified liposomes after a 24 h incubation. Cells without particles served as positive 
controls (PC) while particles and IL-4 or LPS in the absence of cells served as negative controls 
(NC). After an additional 24 h, the media was collected and stored for future testing. To each 
well, 500 μL of clear CM and 50 μL of MTT solution (5 mg/mL in DI water) were added and the 
plates were incubated at 37 °C and 5% CO2 for 2 h. From each well, 425 μL of solution were 
them removed and the formazan crystals were dissolved with 500 μL of dimethyl sulfoxide 
(DMSO, Fisher).  The absorbance of each plate was read at 540 nm with a reference of 690 nm 
using a BioTek Synergy HT Multidetection Microplate Reader (BioTek, Winooski, VT). 
6.2.6 TNF-α ELISA. Measurement of TNF-α in the M(LPS), M(IL-4) or M(0) supernatant was 
performed using commercially available enzyme linked immunosorbent assay (ELISA) kits 
(eBioscience, Inc.) and performed as described by the manufacturer. 
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6.2.7 Urea assay. After 24 h of incubation with liposomes as described above, the supernatant 
was collected and the cells were rinsed with 500 μL of PBS. The plates were then placed on ice 
for 10 min with 100 μL of cell lysis buffer (150 μL protease inhibitor cocktail (Amresco) and 15 
μL Triton X-100 (Acros Organics) diluted to 15 mL with DI water) per well. The lysate, 25 μL, 
was transferred from each well to a 96-well plate (Argos Technologies, Elgin, IL) along with 25 
μL of a 10 mM MnCl2 (Fisher) and 50mM Tris solution (Fisher). The plate was incubated for 10 
minutes at 55 °C before 50 μL of 1 M arginine (pH 9.7) was added to each well and incubated at 
37 °C for 20 h. The urea concentration in the lysate was determined the by adding 200 μL of a 
1:2 ratio of solution 1 (1.2 g o-phthaldialdehyde (Alfa Aesar), 1 L H2O, and 500 μL HCl 
(Fisher)) and solution 2 (0.6 g N-(naphthyl)ethylenediamine dihydrochloride (Acros Organics), 5 
g boric acid (Fisher), 889 mL H2O, and 111 mL sulfuric acid (Fisher)).44 The plate was read at 
520 nm with a reference at 630 nm using a plate reader. 
6.2.8 Griess reagent assay. Nitrite production was measured from the supernatant collected in 
the urea assay described above. A standard curve was created through serial dilutions of 100 μM 
NaNO2. To each well of a 96-well plate 150 μL of sample or standard, 130 μL of DI water, and 
20 μL of Griess reagent (Acros Organics) were added and allowed to incubate for up to 20 
minutes. The plate was read at 448 nm with a 690 nm reference with a plate reader. 
6.2.9 Staining for fluorescent imaging. RAW 264.7 cells were fluorescently labeled using a 
protocol that has been described previously.45 Briefly, cells were seeded at 100,000 cells/cm2 on 
clean glass coverslips in 35 mm2 petri dishes. The cells were activated as described above, with 
non-activated cells still serving as a control. After 24 h incubation, the supernatant was replaced 
with fresh CM and 200 μL 0.0625% modified liposomes. The cells were fluorescently stained 
with DAPI and antibodies for CD11c and CD206 48 h after initial seeding. These coverslips 
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were imaged with an EVOS® FLoid ® Imaging Station (Life Technologies, Grand Island, NY) 
using the red channel (excitation/emission 586/646 nm), blue channel (390/446 nm) and the 
green channel (482/532 nm). 
6.2.10 Statistics and data analysis. Statistical analysis was performed using JMP® statistical 
software (Cary, NC). Statistical significance of the mean comparisons was determined by a two-
way ANOVA. Pair-wise comparisons were analyzed with Tukey’s honest significant difference 
test. Differences were considered statistically significant for p < 0.05. 
 
6.3 Results 
6.3.1 Modification and characterization. After the modification and extrusion of DOPE:DOPC 
liposomes, the zeta potential and size were measured. All zeta potentials were negative and 
measured in the range of -8.9 to -33.9 mV (Figure 6.2A). Unmodified DOPE:DOPC has a zeta 
potential of -16.8 ± 0.83, which is in line with previously published results.46 Figure 6.2B shows 
the liposomes were 83.5 to 108.8 nm in diameter, which fall in the range of the 100 nm filters 
used to extrude them. Previous reports have suggested that small (~85nm), negatively charged 
liposomes result in optimal internalization by MΦs.9,47,48 Details of multiple comparisons for this 
data are in Tables 6.1 and 6.2. 
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Figure 6.2. Material characterization of DOPE:DOPE liposomes. (A) Zeta potential and (B) size. 
(*) indicates p<0.05 compared with unmodified liposomes by pairwise comparison. 
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Tables 6.1 and 6.2. Connecting letters reports for zeta potential and liposome size. Levels not 
connected by the same letter are significantly different (p<0.05). 
 
6.1. Zeta 
Potential 
 
A   C D    
B A       
C A       
D A       
E  B      
F      F  
G     E   
H    D E   
I       G 
J   C D    
K  B C     
L   C D E   
M   C D E   
N   C D    
UM   C D E   
 
6.2. Liposome 
Diameter 
 
A A B C 
B A B C 
C A B C 
D   C 
E  B C 
F  B C 
G A B C 
H A   
I A B  
J A B  
K A B  
L A B  
M A B C 
N A B  
UM A B C 
6.3.2 Cell viability. The DOPE:DOPC liposome configuration is commonly used and should not 
have any impact on cell viability.4,49 However, the modified materials must be cytocompatible. 
Cytotoxicity of the modified liposomes was measured using an MTT assay, and the viability of 
cells exposed to these materials was normalized to M(LPS), M(IL-4), or M(0) cells in the 
absence of liposomes. In the presence of all materials, RAW 264.7 MΦs exhibited upwards of 
70% viability suggesting minimal cytotoxicity. Only E liposomes showed a lower viability of 65-
70% for all activations (Figure 6.3).  
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Figure 6.3. Cell viability of LPS activated, IL-4 activated, and naïve RAW 264.7 MΦs incubated 
with modified and unmodified liposomes. Error bars represent standard deviation. 
 
6.3.3 TNF-α Secretion. Levels of TNF-α production were measured for all activations of MΦs in 
the presence of each modified liposome sample (Figure 6.4). Details of multiple comparisons for 
this data are given in Tables 6.3-6.5. Several modifications of liposomes were able to 
significantly increase the amount of TNF-α produced in comparison to unmodified liposomes for 
M(IL-4) and M(0) macrophages. Modifications A, C, and H increased production of TNF-α in 
M(IL-4) cells. A – F, H, J, and K modifications caused an increase in TNF-α production in M(0) 
cells. In an opposite trend, modification K decreased TNF-α production in M(LPS) cells, and 
modification I did the same for M(0) cells. TNF-α production in response to modified liposomes 
by M(LPS) cells ranged from 2.3 to 4.0 ng/mL with 3.2 ± 0.26 ng/mL produced when exposed to 
unmodified liposomes. M(0) cells produced 0.6 ± 0.023 ng/mL when exposed to unmodified 
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liposomes, and a range of TNF-α that spanned 0.36 to 3.1 ng/mL in response to modified 
liposomes. TNF-α produced by M(IL-4) cells spanned a smaller range of 0.29 to 0.95 ng/mL, 
with 0.43 ± 0.051 ng/mL produced after incubation with unmodified liposomes. Values for 
activated cells without materials were 5.0 ± 0.35 ng/mL, 0.58 ± 0.066 ng/mL, and 0.39 ± 0.016 
ng/mL for M(LPS), M(IL-4), and M(0), respectively. On a sample-to-sample basis, the amount 
of cytokine produced was always highest for M(LPS) cells, and the most promising 
modifications (A, C and H) caused M(IL-4) and M(0) macrophages to produce levels of TNF-α 
closer to the level of M(LPS) cells. 
 
Figure 6.4. Production of the cytotoxic cytokine TNF-α by M(LPS), M(IL-4), and M(0) RAW 
264.7 MΦs incubated with modified and unmodified liposomes. Data represents the mean value 
of four replicates for each sample ± standard deviation. (*) indicates p<0.05 compared with 
unmodified liposomes for the same activation by pairwise comparison.  
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Tables 6.3-6.5. Connecting letters reports for TNF-α production by each MΦ phenotype. Levels 
not connected by the same letter are significantly different (p<0.05). 
 
6.3. TNF-α (LPS)   
A A   
B A   
C A   
D A   
E A   
F A   
G A   
H A   
I A   
J A   
K  B  
L A   
M A   
N A   
UM A   
PC   C 
 
 
 
 
 
 
 
 
 
6.4. TNF-α (IL-4)   
A  B     
B   C D E  
C A      
D   C D E  
E   C D E F 
F   C D   
G      F 
H  B     
I    D E F 
J   C D E F 
K   C D   
L    D E F 
M   C D E  
N     E F 
UM   C D E F 
PC  B C    
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6.5. TNF-α (Naïve)   
A   C       
B     E     
C A         
D      F G   
E      F G   
F    D      
G       G H  
H  B        
I         I 
J     E     
K     E F    
L      F G H  
M       G H  
N       G H  
UM        H  
PC         I 
 
6.3.4 Arginase/iNOS. Arginase activity is increased during the wound healing response, and is 
therefore a common marker for M2 MΦs. The activity of this enzyme can be measured by 
exposing cell lysate to arginine and measuring the amount of urea produced. Griess reagent 
assays were used to quantify nitrites, the stable form of NO. The production of NO results from 
RNIs by increased levels of inducible nitric oxide synthase (iNOS), which is more prominent in 
an M1 phenotype. In order to report the results from these assays, the amount of urea was 
divided by the amount of nitrite in corresponding samples. By dividing these two values, the data 
illustrates the extent of polarization towards an M2 phenotype (high values) or towards an M1 
phenotype (low values). This data is given as arginase:iNOS in Figure 6.5. Absolute values for 
urea and nitrite production are provided in Figure 6.6A and B with details of multiple 
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comparisons given in Tables 6.6-6.11. Values for arginase/iNOS ratios range from 162 mg/μmol 
with modification C to 690 mg/μmol with modification F for M(IL-4) macrophages, and 
unmodified liposomes resulted in a ratio of 320 ± 37.4 mg/μmol. Low ratio values result from 
modifications B, C, I, and J, while higher values were observed for modifications D, E, F, G, L, 
and M from M(IL-4) macrophages. The positive control for M(IL-4) is 238 ± 49.9 mg/μmol. 
M(LPS) macrophages exhibited a lower and narrower range of 28 mg/μmol with modification H 
to 115 mg/μmol with modification G. All ratio values were approximately the same as that for 
unmodified liposomes and for the positive control (73.5 ± 11.0 and 56.2 ± 8.92 mg/μmol, 
respectively), with modifications G being slightly higher and modification H being slightly 
lower. Finally, a restricted range of 2.49 - 42.5 mg/μmol was calculated for M(0) macrophages. 
The positive control for M(0) was 25.9 ± 3.27 mg/μmol, and when incubated with unmodified 
liposomes, 4.33 ± 1.33 mg/μmol was measured for M(0) macrophages.  
 
Figure 6.5. Arginase:iNOS ratios for all MΦ phenotypes exposed to modified and unmodified 
liposomes and stimulation with LPS or IL-4. Naïve cells are also shown. Data represent the mean 
value of four replicates for each sample ± standard deviation. 
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Figure 6.6. Absolute values for urea (A) and nitrite (B) production for LPS, IL-4 or naïve MΦs 
in the presence of modified and unmodified liposomes. Data represent the mean value of four 
replicates for each sample ± standard deviation. (*) indicates p<0.05 compared with unmodified 
liposomes for the same activation by pairwise comparison. 
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Tables 6.6-6.8.  Connecting letters reports for urea production by each MΦ phenotype. Levels 
not connected by the same letter are significantly different (p<0.05). 
6.6. Urea (LPS)  
A  B 
B  B 
C  B 
D  B 
E  B 
F  B 
G A  
H  B 
I  B 
J  B 
K  B 
L A B 
M  B 
N  B 
UM  B 
PC  B 
 
6.7. Urea (IL-4)   
A   C D 
B    D 
C    D 
D A B C  
E    D 
F   C D 
G A    
H A    
I    D 
J    D 
K    D 
L A B   
M A B C  
N  B C D 
UM    D 
PC    D 
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6.8. Urea (Naïve)   
A  B C D E F 
B A B     
C A B C D   
D A      
E  B C D E  
F      F 
G     E F 
H A B C    
I      F 
J    D E F 
K   C D E F 
L   C D E F 
M      F 
N   C D E F 
UM     E F 
PC      F 
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Table 6.9-6.11. Connecting letters reports for nitrite production by each MΦ phenotype. Levels 
not connected by the same letter are significantly different (p<0.05). 
 
6.9. Nitrite 
(LPS) 
  
A    D E F  
B      F G 
C      F G 
D  B C D    
E      F G 
F      F G 
G   C D E F  
H  B      
I  B C D    
J  B C     
K       G 
L  B C D E   
M     E F G 
N  B C D E   
UM  B C D    
PC A       
 
6.10. Nitrite 
(IL-4) 
  
A   C D     
B A        
C A B       
D        H 
E  B C      
F   C D E    
G       G H 
H   C D     
I    D E F G  
J    D E F   
K     E F G H 
L     E F G H 
M     E F G H 
N     E F G H 
UM      F G H 
PC A        
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6.11. Nitrite 
(Naïve) 
 
A      F  
B     E F  
C  B      
D   C     
E A       
F    D E F  
G      F  
H   C D    
I   C D E   
J   C D E   
K   C D E   
L   C D    
M   C D    
N   C D E   
Unmodified   C     
PC       G 
 
6.3.5 Fluorescent imaging. Immunocytochemistry (ICC) fluorescent staining was used to 
identify the MΦ phenotypes resulting from culturing cells in the presence of modified and 
unmodified liposomes. A CD11c marker was used to identify M1 MΦs and a CD206 marker was 
used to indicate an M2 MΦ phenotype. DAPI was also used as a nuclei stain. Representative 
images are shown in Figure 6.7. These images were used to qualitatively support the results 
found by measuring arginase activity, TNF-α secretion, and nitrite production.  
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Figure 6.7. Fluorescent staining images of M(LPS), M(IL-4), and M(0) MΦs incubated with 
each of the modified and unmodified liposome samples. (A) Modification C and (B) 
Modification H. Scale bar is 50 µm. 
 
6.4 Discussion 
 Liposomes naturally target cells of the mononuclear phagocytic system, MΦs in 
particular.9–11,47 This is largely due to their intrinsic involvement in innate immunity where they 
serve to engulf and destroy invading microorganisms as well as other foreign objects.9,21 It is also 
known that inflammation is a component of the tumor microenvironment and a hallmark of 
cancer.50,51 Due to their pivotal role in inflammation, MΦs are thus an important target for drug 
delivery to treat cancer and other diseases.9 As liposomes are a well established, clinically 
relevant drug delivery system and MΦs are key to the survival of tumors, using one to target the 
other is logical. As a result of other research suggesting that surface chemistries of various 
materials have the ability to alter MΦ phenotype,12–14 this research focused on using modified 
liposomes for MΦ reprogramming to improve the efficacy of liposomal drug delivery systems in 
cancer. 
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 An extensive study by Epstein-Barash et al. examined the effect of size and charge of 
liposomes on the internalization and bioactivity in a variety of cell types including RAW 264.7 
MΦs.47 As previously mentioned, it was found that small, negatively charged liposomes were 
optimal for internalization by cells in the mononuclear phagocytic system, and some lipids 
preferentially recognized MΦs.9,47 It was also found that positively charged liposomes induced 
cytokine activation and toxicity.47,48 This may be different than expected as cationic liposomes 
are typically associated with efficient cellular delivery of drug cargoes due to the electrostatic 
interaction between positively charged liposomes and negatively charged cell membrane.9 
However, further investigation has shown that some cationic liposomes can induce apoptosis 
through a variety of mitochondrial pathways. For this reason, the negative charge of the 
liposomes used in this work may have increased benefits for MΦ targeting and internalization. 
 The results of this work indicate that multiple modifications of liposomes influence MΦ 
reprogramming towards an M1 phenotype. Modifications A, C, and H exhibited increased 
production of TNF-α by M(IL-4) and M(0) MΦs. Modifications B, D, E, F, and K increased 
TNF-α production by M(0) MΦs only. Of these materials, A, B, C, E, F, and H modifications 
also had increased nitrite production by M(IL-4) MΦs, but only modifications C and E showed 
an increase from M(0) MΦs. While a decrease in urea production was expected for these 
modification based on TNF-α and nitrite results, there were no significant changes in urea 
production by M(IL-4) MΦs, and modification G showed an increase for M(LPS) cells. M(0) 
MΦs, however, did show a significant decrease in urea production after incubation with all of the 
modified alginates when compared to unmodified liposomes. This combined with increased 
nitrite production, generally caused lower arginase/iNOS ratios for all modifications with M(0) 
MΦs. Ratios for M(LPS) MΦs were relatively even across the board. Modification B, C, E, I, 
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and J appear to have lower ratios than for unmodified liposomes incubated with M(IL-4) 
activated MΦs.  
Taken together, the data provided can be used to determine modifications that may 
improve the efficiency of liposomal drug delivery systems for cancer therapy by MΦ 
reprogramming. These modifications could influence MΦ phenotype by pushing M2 or naïve 
cells in the M1 direction. Modifications A, C, and H cause M(IL-4) MΦs to produce the most 
TNF-α, and also increase nitrite production. C is especially promising because it also appears to 
have a lower arginase:iNOS ratio than of unmodified liposomes. Modifications C and E cause 
M(0) cells to have a TNF-αhigh, nitritehigh, urealow molecular secretion profiles, with lowered 
arginase:iNOS ratios. Modification H also causes extremely high amounts of TNF-α production 
by M(0) MΦs and decreased arginase:iNOS ratios. For this reason, modifications C and H were 
chosen for an in vivo study where they will be loaded with doxorubicin and used to treat three 
different types of cancer.   
 
6.5 Conclusion 
In this research, it was found that surface modification of liposomes can significantly 
alter MΦ phenotype in comparison to unmodified DOPE:DOPC liposomes. The fact that all 
materials used were similar in size and zeta potential, served to validate that the findings were 
mainly the result of the surface functionality. As a whole, this work suggests that modification of 
liposomes may offer an improvement to an already clinically relevant drug delivery system. This 
was done by targeting MΦs, which are significant players in the tumor microenvironment, to 
redirect their phenotype and elicit an anti-cancer response. In order to determine the impact of 
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these findings on cancer therapies, a continued study of the most promising modifications (C and 
H) must be conducted in vivo.  
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CHAPTER 7 
 
ON GOING WORK: IN VIVO MACROPHAGE REPROGRAMMING AND 
DRUG DELIVERY WITH MODIFIED LIPOSOMES 
 
7.1 Introduction 
Liposomal doxorubicin exists in several forms as an FDA approved chemotherapeutic.1,2 
The mechanisms of action for doxorubicin involves the nucleic acids of dividing cells.2 
Doxorubicin prevents replication and transcription in rapidly growing cancer cells by inhibiting 
DNA and RNA synthesis in two ways. One, it inserts itself between base pairs of DNA strands, 
and two, it inhibits the enzyme topoisomerase II, which aids in the relaxation of super-coiled 
DNA.2 Doxorubicin also forms iron-mediated free radicals, which can cause oxidative damage to 
DNA, proteins, and cell membrane lipids.2 These mechanisms make doxorubicin one the most 
effective anticancer drugs ever developed that can be used to treat more types of cancer than any 
other chemotherapeutic.2 However, like any other chemotherapeutic, doxorubicin exhibits side 
effects, like irreversible congestive heart failure, that restrict its usefulness.2,3 It is the 
combination of its effectiveness against a wide range of cancer types and its dose limiting 
toxicities that make it appealing for liposomal encapsulation. 
DuanoXome, Myocet and Doxil are three formulations of liposomal doxorubicin that 
have been developed and used to treat cancer.2 Doxil is the most successful of these products on 
the market,2 with annual global sales around $500M.4  It was developed based on three 
requirements that must be met in order to achieve therapeutically applicable delivery of 
liposomes: extended circulation time, stable drug loading for delivery of sufficient drug levels, 
and extravasation of the liposomes into the diseased tissue.2,3,5 Doxil addresses these issues by 
using components like phospholipids with high melting temperatures, cholesterol and PEGylated 
lipopolymers.2 These liposomes are small in size (<100 nm) and can be loaded using a pH or 
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ammonium ion gradient.2 By focusing on these aspects, Doxil has been able to reduce dose 
limiting toxicities and diminish the occurrence of congestive heart failure.2,3 Despite the overall 
success of Doxil, palmar plantar erythrodysthesia, mucositis, and complement activation-related 
pseudo-allergy are some side effects that may result from treatment with Doxil, leaving room for 
improvement upon this already effective chemotherapeutic. 
With benefits such as biocompatibility, cell specificity and drug protection, liposomal 
drug delivery systems are one of the most widely studied phagocyte-targeted therapies.6,7 
Liposomes passively target tumor microenvironments due to the enhanced permeability and 
retention effect and are naturally taken up by M2-like tumor associated macrophages (TAMs) 
because of their physiochemical properties.6,8–10 TAMs are prevalent in established tumors and 
are associated with different stages of tumor development and progression,7 which makes them 
an appealing target for cancer therapies. For this reason, cancer cell lines that are known to 
produce TAMs, such as B16 melanoma, Lewis lung carcinoma (LLC) and EL4 lymphoma, have 
been chosen for this work. An opposing phenotype of macrophages is that of a proinflammatory, 
M1, nature that produce cytotoxic molecules like tumor necrosis factor (TNF)-α and reactive 
nitrogen intermediates.11,12 Reprogramming of TAMs into proinflammatory macrophages has 
been shown to be effective at preventing growth and reducing tumor size.13 Using surface 
functionalized liposomes to accomplish reprogramming in addition to treatment with a 
chemotherapeutics in vivo is the main focus of this work.  
In order to confirm that macrophage involvement is necessary in tumorigenesis, 
liposomal clondronate was used as a control to deplete macrophages.7,8 Clodronate belongs to a 
family of drugs known as bisphosphonates, which are currently used to treat inflammatory 
diseases like osteoporosis and rheumatoid arthritis by preventing bone metastases and bone 
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resorption.7,14 Liposomal clodronate has been shown to deplete macrophages as they are rapidly 
recognized and internalized by macrophage where intracellular drug accumulation causes cell 
death via apoptosis.7  
In this study, materials were chosen based on in vitro results suggesting these surface 
functionalities may be redirecting TAM-like macrophages towards a proinflammatory 
phenotype. The two modifications that were most effective in vitro, shown in chapter 6, were 
nitroarginine and aceylglutamine. While several versions of liposomal doxorubicin have been 
met with success in comparison to the free drug, there are still limiting side effects associated 
with this form of treatment.2 Further targeting of these macrophages to redirect them towards a 
proinflammatory phenotype, may improve the effectiveness of liposomal doxorubicin.  
 
7.2 Materials and Methods 
7.2.1 Liposome modification and loading. Liposomes were synthesized as in Chapter 6 using 
dioleoyl phosphatidylethanolamine (DOPE) and 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) in a ratio of 2:1. Using modifications C and H from Chapter 6 DOPE:DOPC liposomes 
were modified as previously described.15,16 Briefly, 2 mL of 1X PBS (pH 7.4), 2 mg of modifier, 
0.2 mL of 5% w/v DOPE:DOPC liposomes, and 20 mg of 1-ethyl-3(-3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) were vortexed and incubated overnight at room temperature 
(rt). The particles were dialyzed for 24 h in H2O and lyophilized (Labconco, Kansas City, MO, 
4.5L) before reconstituting at 1% w/v in chloroform. In a round bottom flask, 1 mL of this 
solution was mixed with 1 mL of 0.1% cholesterol in chloroform in order to stabilize the 
liposomes in vivo. The chloroform was removed by rotary evaporation. Liposomes that would 
remain empty were resuspended in pH 7.4 PBS and extruded 21 times with an Avanti® Mini-
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Extruder (Avanti Polor Lipids, Inc.) and 100 nm polycarbonate membranes. Liposomes to be 
loaded with doxorubicin were resuspended in 150mM citric acid (pH 4.0) and extruded before 
the pH was adjusted to ~7.4. This solution along with a solution of doxorubicin (10 mg/mL in 
pH 7.4 1X PBS) were incubated at 65°C for 10 minutes to equilibrate the temperatures before 
loading. Doxorubicin, 200 µL, was added to the liposome solution and incubated at 65°C for 45 
minutes. In order to remove the unloaded doxorubicin, the liposomes were centrifuged at 3,000 
rpm for 5 minutes. The supernatant was removed and replaced with sterile 1X PBS.  
7.2.2 Cell culture. B16 melanoma cells and EL4 mouse lymphoma cells were a generous gift 
from Dr. Wannemuehler’s lab. B16 and LLC cells were cultured at 37°C with 5% CO2 in 
complete medium (CM), consisting of 10% fetal bovine serum, 100 U/L penicillin, and 100 µg/L 
streptomycin in Dulbecco’s modified Eagle’s medium (DMEM). EL4 cells cultured at 37°C with 
5% CO2 in medium, consisting of 10% fetal bovine serum, 100 U/L penicillin, and 100 µg/L 
streptomycin in Roswell Park Memorial Institute medium (RPMI). B16 and LLC cells were 
passaged every three to five days through 0.025% trypsin-EDTA detachment and subcultured at 
~2.7 × 104 cells/cm2. EL4 cells were passaged every 4 days, fed every 2 days, and subcultured at 
~5.3 × 104 cells/cm2.  
7.2.3 Ethics Statement. The research protocol was approved by the local animal ethics 
committees at Iowa State University (Institutional Animal Care and Use Committee) prior to 
initiation of the study.  
7.2.4 Animals. 6-week-old female C57BL/6J mice were obtained from Jackson Laboratories (Bar 
Harbor, ME). The mice were maintained at the animal facilities in the College of Veterinary 
Medicine at Iowa State University, accredited by the American Association of Laboratory 
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Animal care, and were housed under standard conditions with a 12 h light/dark cycle. Both water 
and food were provided ad libitum. 
7.2.5 Tumor cell injections. Injections were performed in accordance with ISO 10993-6:2007. 
The mice were anesthetized via isoflurane inhalation at a concentration of 1-4% isoflurane/ 
balance O2 to minimize movement. Their backs were scrubbed with 70% isopropyl alcohol and 
the animals were injected with 200 µL of tumor cells in 1X sterile PBS. 5 × 106 EL4, 1 × 106 
LLC, or 2 × 105 B16 cells were injected per mouse. Tumors were monitored until they reached a 
size of 200-400 mm3. Volume was determined by measuring the length and width of the tumor 
and calculated using the equation ab2 × 0.4.13 
7.2.6 Sample injections. After the tumors reached the appropriate size, samples were injected 
intratumorally. 100 µL of 1X PBS, 0.1% doxorubicin (~6 mg/kg), ~5 mg/kg liposomal 
clodronate (FormuMax, Sunnyvale,CA), ~6 mg/kg doxorubicin and ~5 mg/kg liposomal 
clodronate, 0.5% loaded modified liposomes, or 0.5% unloaded modified liposomes were 
injected into each mouse. This marked Day 0 of treatment. There were four replicates for each 
sample and control for each of the three cancer cells lines. Two cohorts were studied.  
7.2.7 Imaging. ProSense-680, for imaging cathepsin activity, was synthesized as described by 
Weissleder et al.17 Briefly, 750 mg methoxyl polyethylene glycol succinimidyl N-
hydroxysuccinimide (NHS) (Nanocs, New York, NY) and 109.5 mg poly-L-lysine were reacted 
overnight in 30 mL of 0.1 M Na2CO3 at pH 8.5. The polymer graft was dialyzed against H2O and 
lyophilized. Then the polymer graft was dissolved at 8.4 mg/mL in 0.1 M NaHCO3 at pH 8.3 
and 11 mL were reacted with 8.84 mL of 0.1 mM of Cy5.5-NHS in DMSO (Lumiprobe, 
Hallandale Beach, FL) for 3 h at rt to form ProSense-680. Again, this product was dialyzed, 
lyophilized, and re-suspended in PBS at 5.3 mg/mL. The imaging agent ProSense-680 was 
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sterilized with a 0.22 mm filter and injected into the tail vein (0.15 mL, 32 mg/kg, 5.3 mg/mL) 
on days 0, 2, and 4 of treatment, 24 h prior to in vivo fluorescence imaging. On days 1, 3, and 5, 
in vivo fluorescence imaging was performed with a Kodak In Vivo Multispectral Imaging 
SystemFX Pro (Carestream Health, Rochester, NY). The animals were maintained under inhaled 
anesthesia using 1-4% isoflurane in 100% oxygen at a flow rate of 2.5 L/min. A binning of 2 x 2 
was used for imaging. Exposure time for each image was 2 min. Data were acquired using the 
manufacturer's proprietary software.  
7.2.8 Histology. After imaging on day 5, Mice were euthanized via CO2 asphyxiation and the 
tumors were excised. Two tissue sections from each cohort for each material were fixed in 10% 
formalin, embedded in paraffin, cut into 5 mm sections, and CD206/DAPI (4’,6- diamidino-2-
phenylindole), or F4-80/CD40/DAPI for histological analysis.  
7.2.9 Macrophage separation. The remaining two tissue samples from each cohort were 
combined and incubated for 30 minutes at 37°C in 5 mL of dissociation buffer (RPMI media, 
10% FBS, 200 U/mL collagenase type 1 (Gibco, Carlsbad, CA), 100 µg/mL DNase I 
(Calbiochem, Darmstadt, Germany)). The samples were vortexed every 10 minutes. The cells 
were then passed through a 70 µm strainer and 1 mL of the solution was passed over a 
30%/40%/70% Percoll (GE Healthcare, Uppsala, Sweden) gradient by centrifuging at 2,000 rpm 
for 25 minutes. Macrophages were collected at the 40%/70% interface and washed 2X with 
Hank’s balanced saline solution and resuspended at 1 × 108 cells/mL in sorting buffer (2 mM 
EDTA (ethylenediaminetetraacetic acid), 0.5% BSA (bovine serum albumin)). A volume of 100 
µL (1 × 107 cells) was incubated on ice for 15 minutes with 1µg of CD19 (115504, Biolegend, 
San Diego, CA) and CD5 antibodies (553019, BD Biosciences, San Jose, CA). The cells were 
washed with mojosort buffer before incubation with 10 µL of MojoSort™ streptavidin 
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nanobeads (76447, Biolegend) on ice for 15 minutes. The labeled cells were centrifuged to 
remove the unbound beads and resuspended in 3 mL of sorting buffer. To a 1.5 mL tube, 1 mL 
was transferred and placed in a magnet (Thermo Scientific, Waltham, MA) for 5 minutes before 
the supernatant was collected for negative selection. This process was repeated with CD11b 
antibody (101204, Biolegend) for positive selection, and cell collection continued until 
approximately 5 × 106 macrophages were retrieved. 
7.2.10 DNA quantification. The macrophages were seeded in a 24-well plate at 1.25 x 105 
cells/cm2 in 500 µL of CM per well. The supernatant was collected after 24 h of incubation for 
use in future assays by transferring the solution in each well to a 1.5 mL tube and centrifuging. 
The amount of DNA in each sample was quantified using a CyQuant kit (Life Technologies). 
The supernatant was replaced with 500 µL of a 55 mM sodium citrate, 30 mM EDTA, and 150 
mM NaCl solution. The tubes were sonicated for 20 minutes and stored at -80°C overnight. 
Samples were thawed and sonicated again for 10 minutes before 400 µL of an RNase solution 
(30 µL RNase (BP2539100, Fisher Bioreagents) (20 mg/mL) in 10 mL DI water) were added to 
each tube and incubated at room temperature for 1 h. The standard curve included DNA 
concentrations of 200, 150, 100, 67, 50, 25 and 5 ng/mL using the DNA standard provided in 
half DI water and half lysis solution (1 mL lysis buffer included in the kit, 100 µL dye included 
in the kit, and 9 mL DI water). 25µL of each sample along with 175 µL of lysis solution were 
placed in individual wells of a black, 96-well plate and at room temperature for 5 minutes in the 
dark before reading (excitation 480 nm, emission 520 nm). 
7.2.11 TNF-a ELISA. Measurement of TNF-α in the supernatant collected from the viability 
assays was performed using commercially available enzyme linked immunosorbent assay 
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(ELISA) kits (eBioscience, Inc., San Diego, CA) and performed as described by the 
manufacturer. 
7.2.12 Urea assay. Using different plates than those seeded for cell viability, supernatant was 
again collected after 24 h of incubation and the cells were rinsed with 500 μL of PBS. The plates 
were placed on ice for 10 min with 100 μL of cell lysis buffer (150 μL protease inhibitor cocktail 
(Amresco, Solon, OH) and 15 μL Triton X-100 (Acros Organics) diluted to 15 mL with DI 
water) per well. The lysate, 25 μL, was transferred from each well to a 96-well plate (Argos 
Technologies, Elgin, IL) along with 25 μL of a 10 mM MnCl2 (Fisher) and 50mM Tris solution 
(Fisher). The plate was incubated for 10 minutes at 55 °C before 50 μL of 1 M arginine (pH 9.7) 
was added to each well and incubated at 37 °C for 20 h. The urea concentration in the lysate was 
determined the by adding 200 μL of a 1:2 ratio of solution 1 (1.2 g o-phthaldialdehyde (Alfa 
Aesar), 1 L H2O, and 500 μL HCl (Fisher) and solution 2 (0.6 g N-(naphthyl)ethylenediamine 
dihydrochloride (Acros Organics), 5 g boric acid (Fisher), 800 mL H2O, 111 mL sulfuric acid 
(Fisher), diluted to 1 L with H2O).18 The plate was read at 520 nm with a reference at 630 nm 
using a plate reader. 
7.2.13 Griess reagent assay. Nitrite production was measured from the supernatant collected in 
the urea assay described above. A standard curve was created through serial dilutions of 100 μM 
NaNO2. To each well of a 96-well plate 150 μL of sample or standard, 130 μL of DI water, and 
20 μL of Griess reagent (Acros Organics) were added and allowed to incubate for up to 20 
minutes. The plate was read at 448 nm with a 690 nm reference with a plate reader. 
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CHAPTER 8 
 
IMPACT OF THIS WORK ON FUTURE PROJECTS 
 
8.1 In vivo study of islet encapsulation with modified alginates for diabetes treatment 
Chemically modified alginates have been reasonably successful at achieving macrophage 
reprogramming in vitro, as seen in chapters 4 and 5. Before expanding the library of 
modifications, it would be useful to investigate the impact of the current materials on 
macrophage phenotype and implant success in vivo. Discrepancies often exists between in vitro 
and in vivo studies of the same materials, validating the need for in vivo studies.1 The chemically 
modified alginates investigated in chapters 4 and 5 have been developed with the aim of 
understanding how surface functionalities can influence macrophage phenotype.2 With the 
ultimate application of islet encapsulation, a desired outcome would involve the reprogramming 
of proinflammatory macrophages that infiltrate the implant site towards a wound healing 
phenotype. This would aid in the incorporation of the artificial pancreas by resolving 
inflammation and inducing angiogenesis, which is necessary for islet survival, as well as glucose 
and insulin exchange.  
 
8.2 Modified liposomes to specifically target tumor associated macrophages for improved 
delivery 
 
Due to the success of the modified liposomes at influencing macrophage phenotype in 
vitro in chapter 6, promising modifications of liposomes are being investigated in vivo (chapter 
7).  These liposomes are being injected intratumorally but are also passively targeting tumor cells 
by taking advantage of the enhanced permeability and retention (EPR) effect.3,4 While this 
approach has been found the be extremely effective and is a widely used strategy,3,5 it can be met 
with several limitations. This targeting method depends on the diffusion of drugs, which 
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depending on the nature of the drug, does not always readily happen.3 There is also a lack of 
control associated with passive targeting that can lead to multiple-drug resistance.3 Finally, some 
tumors do not display the EPR effect.3 For these reasons, further investigation of modified 
liposomes for drug delivery may require additional active targeting approaches. This could be 
accomplished by attaching a ligand to the surface of the liposomes that can bind to a receptor 
that is overexpressed by tumor cells or vasculature, but not by normal cells.4,6 Some ligands of 
interest include antibodies or other receptors specific to molecules that are over expressed in 
cancer cells, cell penetrating peptides, or lectins.4–7 There are advantages and disadvantages to 
each of these targeting strategies, but the approach of active targeting has yet to be optimized. It 
is plausible that a combination of ligands may be needed to see a vast improvement in the 
precision of drug delivery. 
 
8.3 In vitro and in vivo studies of the influence of modified liposomes on the phenotype of 
cancer associated fibroblasts 
 
While tumor associated macrophages (TAMs) play a significant role in tumorigenesis by 
promoting angiogenesis, matrix remodeling and suppressing adaptive immunity,8 cancer 
associated fibroblasts (CAFs) have also been found to be vital for tumor progression and 
metastasis.9,10 CAFs are key components of the tumor stroma that regulate tumor growth and in 
progression in many of the same ways as TAMs. They promote angiogenesis and remodel the 
extracellular matrix, in addition they serve to recruit inflammatory immune cells.10  Several 
studies have examined how CAF-targeted cancer therapies improve the efficacy of 
chemotherapy.10–12 Their findings suggest that targeting CAFs leads to reduced the recruitment 
of tumor promoting immune cells and improving a systemic anti-cancer immune response.10–12 
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Studying the impact of the modified liposomes used in chapters 6 and 7 on CAFs both in vtiro 
and in vivo may provide valuable insight into the effectiveness of these materials.  
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